Enzyme-responsive hydrogel delivery systems
Enzyme-responsive hydrogel systems using TEV protease-cleavable peptides address the challenges of spatial and temporal control in therapeutic delivery by enabling precise, site-specific release of therapeutic agents through enzymatic triggers.
Patent Information
- Application Number
- PCT/AU2026/050462
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-08
- Filing Date
- 2026-05-08
- Publication Date
- 2026-11-12
AI Technical Summary
Current hydrogel delivery systems face challenges in achieving spatial and temporal control of therapeutic cargo release, particularly due to passive diffusion and reliance on endogenous stimuli that are not universally applicable across different tissue types and patient populations.
Development of enzyme-responsive hydrogel systems using tobacco etch virus (TEV) protease-cleavable peptides that self-assemble into hydrogels, allowing controlled release of therapeutic agents through specific enzymatic triggers.
The system provides precise, site-specific, and controllable delivery of therapeutic agents by enzymatic cleavage, overcoming limitations of passive diffusion and heterogeneity in endogenous stimuli.
Smart Images

Figure IMGF000064_0001 
Figure IMGF000067_0001 
Figure IMGF000023_0001_TABLE
Abstract
Description
10065921651Enzyme-responsive hydrogel delivery systemsCross-reference to related applications
[0001] This application claims the benefit of priority from Australian provisional application no. 2025901759, filed on 8 May 2025, the contents of which are incorporated herein by reference in their entirety.Field of the invention
[0002] The present invention relates to compounds capable of self assembly to form hydrogels and methods of using the same. The present invention also related to proteases that are capable of cleaving the compounds and hydrogel formed therefrom, and methods of using the same.Background of the invention
[0003] Biochemical systems capable of delivering or supporting the expression of proteins hold significant promise as a therapeutic modality, especially for conditions caused by protein dysfunction or dysregulation. Although direct soluble protein delivery has emerged as a plausible therapy with applications in neurodegeneration and islet transplantation, properties such as short half-life and susceptibility to in vivo proteolysis hinder broad efficacy.
[0004] Current local delivery approaches across the blood-brain barrier rely on poorly controlled mechanisms such as passive diffusion, necessitating the development of new local delivery approaches with improved control and release mechanisms. Key focal points for the development of these technologies are (i) spatial control, to ensure the cargo material is delivered only to the target site and (ii) temporal control, to ensure the release of cargo material only occurs at the target time point.
[0005] In attempts to tackle spatial control, hydrogels have emerged as a scalable and tunable system to delivering therapeutic agents, using (i) encapsulation through secondary interactions or (ii) covalent conjugation. Assimilation of a therapy in a hydrogel system provides protection from the host immune response and improves delivery specificity the target site.10065921652
[0006] Among hydrogel systems, self-assembling peptide (SAP) hydrogels, composed of short peptide sequences that spontaneously assemble into nanofibrillar networks, stand out due to their unique properties and functional versatility. Properties of SAPs can be controlled based on sequence, length and terminal functional groups, providing an opportunity to manipulate properties such as viscoelasticity, morphology, and biostability.
[0007] However, stable SAPs are intrinsically limited by their passive diffusion release profile into the adjacent tissue space. Although these systems perform well at sustained protection and passive release of their cargo, their release profiles are difficult to control.
[0008] In attempts to temporally control hydrogel release profiles, endogenous stimulus-responsive materials have been developed whose cargo is released by triggers such as (i) physicochemical alterations caused by properties of the tissue space (eg pH and temperature) or (ii) local endogenous enzyme expression. These materials take advantage of target site-specific physiology and gene expression profiles and facilitate semi-site-specific hydrogel degradation followed by cargo release - for example, phosphorylation of unmodified peptide hydrogelators by protein tyrosine kinase, activated in T cells after organ transplantation, can improve delivery of immunosuppressive agents to transplant sites.
[0009] Compared to passive diffusion, the response of SAPs to local physicochemical and enzymatic characteristics of the delivery site endows controllable, site-specific, delivery of therapeutic cargo to a tissue site. However, target cell type heterogeneity related to metabolism and protein expression, as well as heterogeneity of patient populations, limits the development of broad-use stimulus-responsive systems. The reliance of these systems on endogenous stimuli also prevents coordination with other therapeutic or developmental considerations.
[0010] There is a need for new and / or improved delivery systems and components thereof.
[0011] Reference to any prior art in the specification is not an acknowledgment or suggestion that this prior art forms part of the common general knowledge in any jurisdiction or that this prior art could reasonably be expected to be understood,10065921653regarded as relevant, and / or combined with other pieces of prior art by a skilled person in the art.Summary of the invention
[0012] In one aspect, the present disclosure provides a compound capable of selfassembly comprising, consisting essentially of or consists of a tobacco etch virus (TEV) protease cleavable peptide and a moiety that facilitates or promotes self-assembly.
[0013] In some embodiments, the only amino acids present in the compound are those of the TEV protease cleavable peptide and equal to, or less than, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 additional amino acid(s) N and / or C terminal to the TEV protease cleavable peptide.
[0014] In one embodiment, the TEV protease cleavable peptide is from 7 to 20, 7 to 19, 7 to 18, 7 to 17, 7 to 16, 7 to 15, 7 to 14, 7 to 13, 7 to 12, 7 to 11, 7 to 10, 7 to 9, or 7 to 8 amino acids in length.
[0015] In one embodiment, the TEV protease cleavable peptide is about 7, about 8, about 9, about 10, about 11, about 12, about 13, about 14, about 15, about 16, about 17, about 18, about 19 or about 20 amino acids in length.
[0016] In one embodiment, the TEV protease cleavable peptide is 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 amino acids in length.
[0017] In some embodiments, the TEV protease cleavable peptide is cleavable by any TEV protease described herein, including those comprising the amino acid sequences shown in Table 1.
[0018] In some embodiments, the TEV protease cleavable peptide comprises, consists essentially of or consists of EX1LYX2QX3 (SEQ ID NO: 1), wherein Xi, X2and X3 are any amino acid, preferably any naturally occurring amino acid. Preferably Xi is asparagine (N). Preferably, X2 is any large or medium hydrophobic amino acid.Preferably, X3 is any small hydrophobic or polar amino acid.
[0019] In one embodiment, the only amino acids present in the compound is EX1LYX2QX3 (SEQ ID NO: 1), wherein Xi, X2and X3 are any amino acid, preferably any naturally occurring amino acid. Preferably Xi is asparagine (N). Preferably, X2 is any10065921654large or medium hydrophobic amino acid. Preferably, X3 is any small hydrophobic or polar amino acid.
[0020] In one embodiment, the only amino acids present in the compound is EX1LYX2QX3X4 (SEQ ID NO: 2), wherein Xi, X2, X3, and X4 are any amino acid, preferably any naturally occurring amino acid. Preferably Xi is asparagine (N).Preferably, X2 is any large or medium hydrophobic amino acid. Preferably, X3 is any small hydrophobic or polar amino acid. Preferably, X4 is any large basic amino acid (e.g. lysine (K), arginine (R) or histidine (H)).
[0021] In some embodiments, the TEV protease cleavable peptide comprises, consists essentially of or consists of ENLYFQX (SEQ ID NO: 3) wherein X is any amino acid, preferably any naturally occurring amino acid. Typically, X is serine (S) or glycine (G).
[0022] In one embodiment, the compound comprises a TEV protease cleavable peptide of ENLYFQS (SEQ ID NO: 4) or ENLYFQG (SEQ ID NO: 5) with an additional amino acid at the C-terminus. Typically, the additional amino acid is a lysine (K), an arginine (R) or a histidine (H). Preferably, the additional amino acid is a lysine (K). The compound therefore may comprise the amino acid sequence ENLYFQSK (SEQ ID NO: 6) or ENLYFQGK (SEQ ID NO: 7).
[0023] In one embodiment, the only amino acids present in the compound is ENLYFQX1X2 (SEQ ID NO: 38), wherein Xi and X2 are any amino acid, preferably any naturally occurring amino acid. Preferably Xi is S or G. Preferably, X2 is K.
[0024] In any embodiment, the TEV protease cleavable peptide is not degradable by biological and metabolic activity of cells and tissues.
[0025] In any embodiment, the compound is not significantly degradable by biological and metabolic activity of cells and tissues.
[0026] In any embodiment, the compound is not significantly degradable by biological and metabolic activity of cells and tissues over the period of time required for treatment of a disease or condition.
[0027] In one embodiment, the compound is not a polymer.10065921655
[0028] In one embodiment, the compound is capable of self-assembly in an aqueous environment (e.g. cell culture media). Preferably, the compound is capable of selfassembly in an aqueous environment at a wide range of pH.
[0029] In one embodiment, the wide range of pH is from about pH 6 to about pH 10, preferably pH 6 to pH 10.
[0030] In one embodiment, the moiety that facilitates or promotes self-assembly initiates self-assembly.
[0031] In one embodiment, the moiety that facilitates or promotes self-assembly does so by hydrophobic-hydrophilic interactions. Preferably, the moiety is an amphiphile. Where the moiety is an amphiphile it may contain a hydrophilic portion and a lipophilic portion. The hydrophilic portion may be a peptide. The lipophilic portion may be an aliphatic chain, which is either saturated or unsaturated. The aliphatic chain may be palmitoyl, myristoyl, stearoyl, lauroyl, octanoyl or decanoyl. Preferably, the aliphatic chain is palmitoyl.
[0032] In one embodiment, the compound comprises, consists essentially of or consists of a palmitoyl group linked to a TEV protease cleavable peptide linked to an amide group. Preferably, the TEV protease cleavable peptide is any one described herein. More preferably, the compound comprises, consists essentially of or consists of palmitoyl-AAAGGGENLYFQSK-amide (SEQ ID NO: 33). In one embodiment, the structure of palmitoyl-AAAGGGENLYFQSK-amide (SEQ ID NO: 33) is as shown in Figure 1a.
[0033] In one embodiment, the moiety that facilitates or promotes self-assembly does so by TT-TT stacking. Preferably, the moiety comprises an aromatic TT system. More preferably, the moiety is fluorenylmethoxycarbonyl (Fmoc).
[0034] In one embodiment, the compound comprises, consists essentially of or consists of an Fmoc group linked to a TEV protease cleavable peptide. Preferably, the TEV protease cleavable peptide is any one described herein. More preferably, the compound comprises, consists essentially of or consists of Fmoc-ENLYFQSK (SEQ ID NO: 34). In one embodiment, the structure of Fmoc-ENLYFQSK is as shown in Figure 1b (SEQ ID NO: 34).10065921656
[0035] In any embodiment, the compound is capable of forming a hydrogel.Preferably the hydrogel is one as described herein. Preferably the hydrogel has one or more properties as described herein.
[0036] In another aspect, the present disclosure provides a composition comprising, consisting essentially of or consisting of compounds of the present disclosure as described herein.
[0037] In another aspect, the present disclosure provides a hydrogel comprising, consisting essentially of or consisting of compounds of the present disclosure as described herein.
[0038] In one embodiment, about 0.02%, about 0.05%, about 0.1%, about 0.125%, about 0.15%, about 0.2%, about 0.3%, about 0.4%, about 0.5%, about 0.6%, about 0.75%, about 1%, about 1.25%, about 1.5%, about 1.75%, about 1.8%, about 1.85%, about 1.9%, about 1.95%, about 2%, about 2.2%, about 2.5% or about 3% w / w of all compounds capable of self-assembly in the hydrogel or composition are compounds of the present disclosure as described herein. In one embodiment, 0.02%, 0.05%, 0.1%, 0.125%, 0.15%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.75%, 1%, 1.25%, 1.5%, 1.75%, 1.8%, 1.85%, 1.9%, 1.95%, 2%, 2.2%, 2.5% or 3% w / w of all compounds capable of self-assembly in the hydrogel or composition are compounds of the present disclosure as described herein.
[0039] In one embodiment, the hydrogel or composition comprises about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 75%, about 80%, about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99% or 100% w / w of compounds of the present disclosure as described herein. In one embodiment, the hydrogel or composition comprises 10%, 20%, 30%, 40%, 50%, 60%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% w / w of compounds of the present disclosure as described herein.
[0040] In one embodiment, the hydrogel or composition comprises about 0.2, about 1, about 2.5, about 5, about 7.5, about 10, about 12.5, about 15, about 16, about 17, about 18, about 19 about 20, about 25 or about 30 mg / mL-1of compounds of the present disclosure as described herein. In one embodiment, the hydrogel or10065921657composition comprises 0.2, 1, 2.5, 5, 7.5, 10, 12.5, 15, 16, 17, 18, 19, 20, 25 or 30 mg / mL'1of compounds of the present disclosure as described herein.
[0041] In one embodiment, the hydrogel or composition comprises compounds of the present disclosure as described herein and one or more further compounds capable of self-assembly. Preferably, the one or more further compounds capable of self-assembly are not cleavable by a TEV protease, or not cleavable by a TEV protease as described herein.
[0042] In one embodiment, the hydrogel or composition further comprises one or more active agents, preferably wherein the one or more active agents are as described herein. The one or more active agents are releasable upon cleavage of the TEV protease cleavable peptide by a TEV protease.
[0043] The one or more active agents may be physically enclosed in and / or physically bonded to the hydrogel, or loaded into the hydrogel.
[0044] In any embodiment the hydrogel or composition further comprises one or more pharmaceutically acceptable excipients.
[0045] The hydrogel or composition of the present disclosure may have one or more of the following properties:• is injectable;• is cytocompatible with native tissue at physiological conditions;• is biocompatible with native tissue at physiological conditions;• shows viscoelastic behaviour with a storage modulus (G’) greater than the loss modulus (G”) at y (0.1%), f (0.1-100 Hz) independent of frequency;• decreases in viscosity under shear strain (ie shear-thinning behaviour);• shows a sol-gel transformation at the oscillatory strain from 100 to 0.1%;• formed (e.g. comprises, consists essentially of or consists of) of nanofi brillar structures or nano-cylindrical micelles;10065921658responsive to a TEV protease via cleavage of the TEV protease cleavable peptide; and• does not significantly affect cell viability. Typically, the cell is a primary astrocyte or cortical neuron (or both primary astrocytes and cortical neurons) or SH-SY5Y cell line. Cell viability may be determined using any assay or method described herein (e.g. a cytotoxicity assay such as a CellTiter-Blue® Cell Viability, and live and dead assay), including the Examples.
[0046] In another aspect, the present disclosure provides a process for producing a hydrogel, the process comprising the steps of adding water to a compound according to any one of the herein disclosed embodiments, thereby forming a hydrogel.
[0047] In some embodiments, the process further comprises the step of adding a basic solution and / or an acidic solution.
[0048] In some embodiments, the process further comprises the step of adding a physiological buffer.
[0049] In some embodiments, the process further comprises the step of adjusting the pH to about 7.4.
[0050] In some embodiments, adjusting the pH comprises addition of a base and / or an acid.
[0051] In some embodiments, the base is NaOH.
[0052] In some embodiments, the acid is HCI.
[0053] In some embodiments, the process further comprises mixing the solution to dissolve the compound. Preferably, the mixing is performed by sonication.
[0054] In another aspect, the present disclosure provides a polypeptide comprising, consisting essentially of or consisting of an amino acid sequence of any one of SEQ ID NO: 8 to 21 , 52 or 53, or an amino acid sequence having at least 80%, 81 %, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to an amino acid sequence of any one of SEQ ID NO: 8 to 21 , 52 or 53.10065921659
[0055] Preferably, the polypeptide does not comprise an N-terminal sequence encoding any one or more or all of (a) start codon methionine, (b) one or more flexible linkers, (c) an N-terminal Hise tag, and (d) and a thrombin cleavage site, (e.g. without including a sequence that comprises or consists of MGSSHHHHHHSSGLVPRGS (SEQ ID NO: 35) or MGSSHHHHHHSSGLVPRGSHM (SEQ ID NO: 36)) for example as shown in SEQ ID NO: 8, 10, 12, 14, 16, 18, 20 and / or 52.
[0056] In another aspect, the present disclosure provides a protease comprising, consisting essentially of or consisting of an amino acid sequence of any one of SEQ ID NO: 8 to 21 , 52 or 53, or an amino acid sequence having at least 80%, 81 %, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to an amino acid sequence of any one of SEQ ID NO: 8 to 21 , 52 or 53.
[0057] Preferably, the protease does not comprise an N-terminal sequence encoding any one or more or all of (a) start codon methionine, (b) one or more flexible linkers, (c) an N-terminal Hise tag, and (d) and a thrombin cleavage site, (e.g. without including a sequence that comprises or consists of MGSSHHHHHHSSGLVPRGS (SEQ ID NO: 35) or MGSSHHHHHHSSGLVPRGSHM (SEQ ID NO: 36)) for example as shown in SEQ ID NO: 8, 10, 12, 14, 16, 18, 20, and / or 52.
[0058] In one embodiment, the present disclosure provides a protease comprising, consisting essentially of or consisting of an amino acid sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to an amino acid sequence of any one of SEQ ID NO: 8 to 21, 52 or 53, wherein the variation is one or more additions, substitutions (e.g. conservative substitutions) or deletions, and those additions, substitutions (e.g. conservative substitutions) or deletions are not at residue positions 46, 81 , 139, 146, 148, 149, 151, 167, 168, 169, 170, 171, 172, 174, 176, 178, 209, 211, 214, 215, 216, 217, 218, 219 and 220, or residue positions equivalent to 46, 81, 139, 146, 148, 149, 151, 167, 168, 169, 170, 171, 172, 174, 176, 178, 209, 211, 214, 215, 216, 217, 218, 219 and 220, wherein the numbering is accordance with SEQ ID NO: 29 or SEQ ID NO: 29 where position 219 is S. Preferably, any protease with one or more variations to an amino acid sequence of any one of SEQ ID NO: 8 to 21, 52 or 53 exhibits 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% activity compared to a protease that is identical in amino acid100659216510sequence to any one of SEQ ID NO: 8 to 21 , 52 or 53. The activity may be any one described herein and typically as measured by a method of anyone as described herein.
[0059] As used herein an amino acid residue at the position equivalent to position in SEQ ID NO: 29 can be determined by any means known to a person skilled in the art. For example, an alignment of one or more sequences with an amino acid sequence of SEQ ID NO: 29 would allow a person skilled in the art to determine the amino acid at the position equivalent to position in SEQ ID NO: 29. A person skilled in the art can compare the three-dimensional structure of a polypeptide with the three dimensional structure of a polypeptide having the amino acid sequence of SEQ ID NO: 29 and determine the amino acid residue that is at an equivalent position to that in SEQ ID NO: 29.
[0060] In any embodiment, the protease is capable of expression yields of equal to, or greater than, 20 mg / L, equal to, or greater than, 25 mg / L, equal to, or greater than, 30 mg / L, equal to, or greater than, 35 mg / L, equal to, or greater than, 40 mg / L, equal to, or greater than, 45 mg / L, equal to, or greater than, 50 mg / L, equal to, or greater than, 55 mg / L, equal to, or greater than, 60 mg / L, equal to, or greater than, 65 mg / L, equal to, or greater than, 70 mg / L, equal to, or greater than, 75 mg / L, equal to, or greater than, 80 mg / L, equal to, or greater than, 85 mg / L, equal to, or greater than, 90 mg / L, equal to, or greater than, 95 mg / L, equal to, or greater than, 100 mg / L, equal to, or greater than, 105 mg / L, equal to, or greater than, 110 mg / L, equal to, or greater than, 115 mg / L, equal to, or greater than, 120 mg / L, equal to, or greater than, 125 mg / L, equal to, or greater than, 130 mg / L, equal to, or greater than, 135 mg / L, equal to, or greater than, 140 mg / L, equal to, or greater than, 145 mg / L, equal to, or greater than, 150 mg / L, equal to, or greater than, 155 mg / L, equal to, or greater than, 160 mg / L, equal to, or greater than, 165 mg / L, equal to, or greater than, 170 mg / L, equal to, or greater than, 175 mg / L, equal to, or greater than, 180 mg / L, equal to, or greater than, 185 mg / L, or greater than, 190 mg / L, preferably wherein the expression is under standard conditions, such as those described herein including the Examples (including Example 3); and / orexhibits a stability level that is greater than TEVp2M, preferably wherein the stability level is measured by ellipticity at a temperature of equal to or greater than any one or more of the following temperatures: 20°C, 22°C, 24°C, 26°C, 28°C, 30°C, 32°C, 34°C, 36°C, 38°C, 40°C, 42°C, 44°C, 46°C, 48°C, 50°C, 52°C, 54°C, 56°C, 58°C, 60°C, 62°C, 64°C, 66°C, 68°C, 70°C, 72°C, 74°C, 76°C, 78°C and 80°C. Typically, the100659216511stability level is measured using a method as described herein, including the Examples (including Example 3).
[0061] Typically, the expression yields is mg of purified protein per L of culture, for example 20 mg / L, is 20 mg of purified protein per L of culture (e.g. IMAC-purified protein and where any tag, such as an MBP tad is not present, e.g. self-cleaved).
[0062] Typically, the stability level is determined by transition in curve that is produced when ellipticity of the sample is monitored at certain wavelengths (e.g. 222 nm) during ramping of temperature from 20 - 90 °C.
[0063] In another aspect, the present disclosure provides a protease capable of cleaving a peptide that comprises, consists essentially of or consists of ENLYFQX wherein X is any amino acid, preferably any naturally occurring amino acid, wherein the protease is:• capable of expression yields of equal to, or greater than, 20 mg / L, equal to, or greater than, 25 mg / L, equal to, or greater than, 30 mg / L, equal to, or greater than, 35 mg / L, equal to, or greater than, 40 mg / L, equal to, or greater than, 45 mg / L, equal to, or greater than, 50 mg / L, equal to, or greater than, 55 mg / L, equal to, or greater than, 60 mg / L, equal to, or greater than, 65 mg / L, equal to, or greater than, 70 mg / L, equal to, or greater than, 75 mg / L, equal to, or greater than, 80 mg / L, equal to, or greater than, 85 mg / L, equal to, or greater than, 90 mg / L, equal to, or greater than, 95 mg / L, equal to, or greater than, 100 mg / L, equal to, or greater than, 105 mg / L, equal to, or greater than, 110 mg / L, equal to, or greater than, 115 mg / L, equal to, or greater than, 120 mg / L, equal to, or greater than, 125 mg / L, equal to, or greater than, 130 mg / L, equal to, or greater than, 135 mg / L, equal to, or greater than, 140 mg / L, equal to, or greater than, 145 mg / L, equal to, or greater than, 150 mg / L, equal to, or greater than, 155 mg / L, equal to, or greater than, 160 mg / L, equal to, or greater than, 165 mg / L, equal to, or greater than, 170 mg / L, equal to, or greater than, 175 mg / L, equal to, or greater than, 180 mg / L, equal to, or greater than, 185 mg / L, or greater than, 190 mg / L, preferably wherein the expression is under standard conditions, such as those described herein including the Examples (including Example 3); and / or100659216512• exhibits a stability level that is greater than TEVp2M, preferably wherein the stability level is measured by ellipticity at a temperature of equal to or greater than any one or more of the following temperatures: 20°C, 22°C, 24°C, 26°C, 28°C, 30°C, 32°C, 34°C, 36°C, 38°C, 40°C, 42°C, 44°C, 46°C, 48°C, 50°C, 52°C, 54°C, 56°C, 58°C, 60°C, 62°C, 64°C, 66°C, 68°C, 70°C, 72°C, 74°C, 76°C, 78°C and 80°C. Typically, the stability level is measured using a method as described herein, including the Examples (including Example 3).
[0064] In any embodiment, the protease of the disclosure as described herein exhibits a stability level that is greater than TEVp2M, preferably wherein the stability level is measured by ellipticity at a temperature of equal to or greater than any one or more of the following temperatures: 20°C, 22°C, 24°C, 26°C, 28°C, 30°C, 32°C, 34°C, 36°C, 38°C, 40°C, 42°C, 44°C, 46°C, 48°C, 50°C, 52°C, 54°C, 56°C, 58°C, 60°C, 62°C, 64°C, 66°C, 68°C, 70°C, 72°C, 74°C, 76°C, 78°C and 80°C. Typically, the stability level is measured using a method as described herein, including the Examples (including Example 3).
[0065] Typically, the expression yields is mg of purified protein per L of culture, for example 20 mg / L, is 20 mg of purified protein per L of culture (e.g. IMAC-purified protein and where any tag, such as an MBP tad is not present, e.g. self-cleaved).
[0066] Typically, the stability level is determined by transition in curve that is produced when ellipticity of the sample is monitored at certain wavelengths (e.g. 222 nm) during ramping of temperature from 20 - 90 °C.
[0067] In any aspect or embodiment of the disclosure the polypeptide or protease is capable of cleaving a peptide that comprises, consists essentially of or consists of:- EX1LYX2QX3 (SEQ ID NO: 1), wherein Xi, X2and X3 are any amino acid, preferably any naturally occurring amino acid. Preferably Xi is asparagine (N). Preferably, X2 is any large or medium hydrophobic amino acid. Preferably, X3 is any small hydrophobic or polar amino acid;EX1LYX2QX3X4 (SEQ ID NO: 2), wherein Xi, X2, X3, and X4 are any amino acid, preferably any naturally occurring amino acid. Preferably Xi is asparagine (N). Preferably, X2 is any large or medium hydrophobic amino acid. Preferably, X3 is100659216513any small hydrophobic or polar amino acid. Preferably, X4 is any large basic amino acid.
[0068] In any aspect or embodiment of the disclosure the polypeptide or protease is capable of cleaving a peptide that comprises, consists essentially of or consists of:- ENLYFQX (SEQ ID NO: 3) wherein X is any amino acid, preferably any naturally occurring amino acid;- ENLYFQS (SEQ ID NO: 4);- ENLYFQG (SEQ ID NO: 5);- ENLYFQSK (SEQ ID NO: 6); and / or- ENLYFQGK (SEQ ID NO: 7).
[0069] In any aspect or embodiment of the disclosure the polypeptide or protease is capable of cleaving a compound of the disclosure.
[0070] In any embodiment, the protease of the disclosure may have negligible activity on mammalian proteomes.
[0071] In any embodiment, the protease does not significantly affect cell viability at concentrations of 1 mg / mL, 2 mg / mL, 3 mg / mL, 4 mg / mL, 5mg / ml, about 1mg / ml, about 2 mg / mL, about 3mg / mL, about 4mg / mL, about 5mg / ml, or from 1 mg / mL to 5mg / mL or about 1 mg / mL to about 5mg / mL. Typically the cell is an astrocyte or cortical neuron, preferably a primary astrocyte or neuron, or SH-SY5Y cell line. Cell viability may be determined using any assay or method described herein (e.g. a cytotoxicity assay such as CellTiter-Blue® Cell Viability assay), including the Examples.
[0072] In any embodiment, the protease may exhibit protease activity in the absence of reductant. For example, the protease activity of the protease in absence of reductant may be at least 75%, 80%, 85%, 90%, 95% or 100% of the protease activity of the protease when reductant is present. In one example, protease activity is measured using an assay or method as described herein, including the Examples.
[0073] In another aspect, the present disclosure provides a nucleic acid comprising, consisting essentially of, or consisting of a nucleotide sequence encoding a polypeptide100659216514or protease of the disclosure as described herein. In one embodiment, the nucleic acid comprises consists essentially of, or consists of a nucleotide sequence of SEQ ID NO: 22 to 28, or a nucleotide sequence of SEQ ID NO: 22 to 28 without an N-terminal sequence encoding any one or more or all of (a) start codon methionine, (b) one or more flexible linkers, (c) an N-terminal Hise tag, and (d) and a thrombin cleavage site (e.g. without including a sequence that encodes MGSSHHHHHHSSGLVPRGS (SEQ ID NO: 35) or MGSSHHHHHHSSGLVPRGSHM (SEQ ID NO: 36)). The nucleotide sequence may or may not include a stop codon, where the stop codon is TAA.
[0074] In another aspect, the present disclosure provides a vector comprising a nucleic acid of the disclosure as described herein.
[0075] In another aspect, the present disclosure provides a cell comprising a nucleic acid or vector of the disclosure as described herein.
[0076] The nucleic acid, vector or cell may be isolated, purified, partially purified and / or recombinant.
[0077] In another aspect, the present disclosure provides a method of releasing an active agent comprising contacting a hydrogel or composition comprising an active agent as described herein with a protease as described herein, thereby releasing the active agent.
[0078] In another aspect, the present disclosure provides a method of releasing an active agent in an individual, the method comprising:- administering a hydrogel or composition comprising an active agent as described herein to the individual; and subsequently- administering a protease as described herein to the individual,thereby releasing an active agent in the individual.
[0079] In another aspect, the present disclosure provides a method of delivering an active agent in an individual, the method comprising:administering a hydrogel or composition comprising an active agent as described herein to the individual; and subsequently100659216515administering a protease as described herein to the individual,thereby releasing an active agent in the individual.
[0080] In another aspect, the present disclosure provides a method of treating or preventing a disease or condition in an individual, the method comprising:- administering a hydrogel or composition comprising an active agent for treating or preventing the disease or condition to the individual; and subsequently- administering a protease as described herein to the individual,thereby treating or preventing the disease or condition in the individual.
[0081] The disease or condition may be any one described herein, including diseases or conditions caused by, or associated with, gene or protein dysfunction or dysregulation.
[0082] In aspect, the present disclosure further provides use of a hydrogel or composition as described herein, in the manufacture of a medicament for:- releasing an active agent in an individual, or- treating or preventing the disease or condition to the individual.
[0083] Further, the disclosure provides a hydrogel or composition as described herein, for use in treating or preventing the disease or condition in the individual.
[0084] In any aspect or embodiment, the protease is administered at a concentration of 2, 3 or 4 mg / ml or about 2, about 3, or about 4 mg / ml.
[0085] In any aspect or embodiment, administering a protease as described herein to the individual promotes or facilitates release of the active agent.
[0086] In another aspect, the present disclosure provides a kit comprising:a compound capable of self-assembly as described herein, or a composition comprising a compound capable of self-assembly as described herein; anda protease as described herein, or a composition comprising a protease as described herein.100659216516
[0087] In other embodiments there is provided a kit for use in a therapeutic or prophylactic application mentioned above, the kit including:a container holding compound capable of self-assembly as described herein, or a composition comprising a compound capable of self-assembly as described herein;a container holding a protease as described herein, or a composition comprising a protease as described herein;a label or package insert with instructions for use.
[0088] Preferably, the instructions describe the use of the kit and components thereof in a method or use as described herein.
[0089] In certain embodiments the kit may contain one or more further active principles or ingredients for treatment of a disease or condition.
[0090] As used herein, except where the context requires otherwise, the term "comprise" and variations of the term, such as "comprising", "comprises" and "comprised", are not intended to exclude further additives, components, integers or steps.
[0091] Further aspects of the present disclosure and further embodiments of the aspects described in the preceding paragraphs will become apparent from the following description, given by way of example and with reference to the accompanying drawings.Brief description of the drawings
[0092] Figure 1. Chemical structure of the TEVp-responsive SAPs and their assembling at physiological condition, a) Enzyme-responsive Micelles, b) Enzyme-responsive Gel.
[0093] Figure 2. ERG (enzyme-responsive gel) and ERM (enzyme-responsive micelle) can form distinct secondary structure at physiological pH alone and in combination with ECMLRG (ECM laminine resembling gel) and ECMRG (ECM resembling gel), a) prepared hydrogel from ERG and its combination with ECMLRG, as well as ECMRG and its combination with ERM1, and ERM5. FTIR and CD spectra of100659216517b, b’) ERG, ECMLRG, Co-assembly, Mix, c, c’) ERM1, ECMRG and ECMRG / ERM1, d, d’) ERM1, ECMRG and ECMRG / ERM1.
[0094] Figure 3. ERG and its combination with ECMLRG can form viscoelastic and injectable hydrogel. Adding ERM into ECMRG does not impact the viscoelastic and injectable properties of ECMRG. Mechanical properties of SAPs hydrogel under different frequencies and shear rates. Higher G’ than G” at different frequency rates (1-100 Hz) confirmed the viscoelastic behaviour of a) ECMLRG, ERG, Co-assembly, and Mix, and c) ECMRG, ECMRG / ERM1, ECMRG / ERM5. crossing over of the G” from G’ at a high shear rate (100%) and simultaneously backing over to the first state by lowering the shear rate (0.1%) confirms the injectability of b) ECMLRG, ERG, Co-assembly, and Mix, and d) ECMRG, ECMRG / ERM1, ECMRG / ERM5.
[0095] Figure 4. ERG and ERM can form distinct nanostructures at physiological pH alone and in combination with ECMLRG and ECMRG. TEM images of a) ECMLRG, b) ERG, c) Co-assembly, d) Mix, e) ECMRG, f,f’) ERM, and g) ECMRG / ERM after assembling. Incorporated ERM structures inside the ECMRG (yellow arrow).
[0096] Figure 5. ERG and ERM can form distinct nanostructures in wet condition alone and in combination with ECMLRG and ECMRG. AFM images of a) ECMLRG, b) ERG, c) Co-assembly, d) Mix, e) ECMRG, f) ERM at the concentration of 0.3 mg mL'1for hydrogels and 0.1 mg mL-1for nanostructures in wet condition, Magnification bar = 400 nm. Cryo-TEM images of g) ERG and h) ERM under cryogenic wet conditions. Magnification bar = 100 nm for small and 400 nm for big.
[0097] Figure 6. BioSAS-TEVp is a functional TEV protease variant with improved stability, (a) The structure of TEVpS219D (PDB 1LVM, residues 10-236), shown here, was used as the input to ProteinMPNN. The TEVp cleavage-product peptide (yellow sticks), the positions of residues that were held constant during the design process (black dots), and the positions that differ between the input structure and BioSAS-TEVp (light blue) are highlighted. N- and C- termini of the protein are omitted for clarity, (b) When expressed in E. coli, yields (mg of protein obtained from 1 L of autoinduction media) are significantly higher for BioSAS-TEVp compared with TEVp2M (n=3). (c) Representative melt-curves of TEVp2M and BioSAS-TEVp purified by size exclusion chromatography, measured as ellipticity at 208 nm. Lines represent100659216518the Boltzmann fit of the data, (d) Schematic of the fusion substrate used to assess TEVp activity, (e) Representative SDS-PAGE showing the cleavage of the fusion substrate by TEVp2M and BioSAS-TEVp after 24 hours.
[0098] Figure 7. Crystal structure of BioSAS-TEVp (C151A) and simulations, (a) Overlay of the crystal structures of BioSAS-TEVp (C151A) (chain A, blue) bound to peptide (yellow sticks) and the TEVpS219D-peptide complex (PDB 1LVM, chain A, white; peptide omitted for clarity), highlighting conserved structure. N- and C-termini are omitted for clarity, (b) Polder OMIT map (3 ct) and of the modelled peptide in the BioSAS-TEVp (C151 A) crystal structure, (c) Residues directly interacting with the peptide in the BioSAS-TEVp (C151 A) crystal structure are the same as those observed in the crystal structure of TEVpS219D (d) Initial structure (white sticks) and final frames (blue / teal sticks) from molecular dynamics (MD) simulations of BioSAS-TEVp in complex with the ERG peptide (Fmoc-ENLYFQSK (SEQ ID NO: 34)), showing that the protein-peptide complex is stable over triplicate 200 ns simulations. The distance between the sulfur of Cys151 and the reactive carbonyl carbon is shown for the input structure, (e) Histograms showing distances between the sulfur atom of Cys151 and the reactive carbonyl carbon for triplicate simulations of BioSAS-TEVp in complex with Fmoc-ENLYFQSK (SEQ ID NO: 34) and TEVp2M with the substrate peptide (GGGSMSENLYFQGSMG (SEQ ID NO: 37)). Mean distances are shown as dotted black line.
[0099] Figure 8. ERG and ERM respond to BioSAS-TEVp application even in the combination with ECMLRG, but ECMLRG and ECMRG remains unchanged, a) Representative chromatograms showing the elution characteristics of the reaction substrate product of ERG before and after conditioning with BioSAS-TEVp on HPLC. b) Representative chromatograms showing the mass of collected fractions from reaction products of ERG. c) Representative chromatograms showing the elution characteristics of the reaction substrate product of ERG, ECMLRG, and their combination before and after conditioning with BioSAS-TEVp on HPLC. d) Representative chromatograms showing the mass of collected fractions from reaction products of ECMLRG. e) Representative chromatograms showing the elution characteristics of the reaction substrate product of ECMRG before and after conditioning with BioSAS-TEVp on HPLC. f) Representative chromatograms showing the elution characteristics of the reaction substrate product of ERM before and after conditioning with BioSAS-TEVp on100659216519LCMS. g) Representative chromatograms showing the mass of collected fractions from reaction products of ERM before (top) and after (down) conditioning with BioSAS-TEVp.
[0100] Figure 9. Optimised condition for ERG-BioSAS-TEVp reaction is the ratio of 1:7.5-1.3.75 for 24 hours, a) HPLC analysis of TEVp-induced degradation of ERG by BioSAS-TEVp (1 mg mL-1) and several previously characterized variants after 24 hours incubation time. Stacked bar graph showing relative peptide cleavage percentage of each reaction mixture after 24 hours incubation, b) HPLC analysis of BioSAS-TEVp-induced degradation of ERG at various ratios of BioSAS-TEVp: ERG (1:60-1:0.75). c) HPLC analysis of BioSAS-TEVp (ratio of 1:3.75)-induced degradation of ERG at various timepoints. Data represents mean and SD of 3 technical replicates, d) HPLC analysis of TEVp-induced degradation of ERG, co- assembly, and mix hydrogels by adding on top (O) or vertexing (V) different concentration of BioSAS-TEVp (2-5 mg mL-1) with SAP hydrogels after 24 h incubation time. Stacked bar graph showing relative peptide cleavage percentage of each reaction mixture.
[0101] Figure 10. Application of BioSAS-TEVp causes nanostructural change in SAP systems containing ERG or ERM. BioSAXs scattering curve of all samples before (a) and after (a’) conditioning with BioSAS-TEVp for 24h. P(r) model overlaid based on BioSAXs scattering curve of b) BioSAS-TEVp, c) ERG , d) ERM , e) ECMRG, and f) ECMRG / ERM, and before and after BioSAS-TEVp conditioning.
[0102] Figure 11. Application of BioSAS-TEVp causes disassembling of assembled nanostructure in SAP systems containing ERG or ERM. TEM image of a) ECMLRG, b)ERG, c)Co-assembly, d) Mix, e)ERM, f) ECMRG / ERM before (small images) and after (big images) conditioning with BioSAS-TEVp Magnification bar = 500nm. g) Nanostructures diameter distribution (50 nanostructures) of each sample were calculated before (top)) and after (down)) BioSAS-TEVp treatment for 24 hours.
[0103] Figure 12. Confirming the disassembling of assembled nanostructure in SAP systems containing ERG or ERM in wet condition. AFM images of a)ECMLRG, b) ERG, c)Co-assembly, d) Mix, e) ECMRG, f) ERM on negative substrate and g) ERM on positive substrate after being treated with BioSAS-TEVp (4 mg mL-1) for 24 hours Magnification bar = 400nm. Cryo-TEM images of h) ERG and i) ERM after treating with BioSAS-TEVp (4 mg mL-1) for 24 hours. Magnification bar= 100nm100659216520
[0104] Figure 13. BioSAS-TEVp administration causes mechanical properties loss in samples including TEVp cleavable sequence. Rheological properties of SAP hydrogels before and after conditioning with BioSAS-TEVp. Storage modulus (G1) and loss modulus (G") are presented as a function of frequency
[0105] Figure 14. Nanostructural alteration causes release of the cargo in the environment, a) a schematic of the release chamber set up for simulating the environment with local administration of the enzyme. The release profile of FITC-Dextran from b) ECMLRG, c) ERG, d) Co-assembly, and e) Mix before and after BioSAS-TEVp administration over 28 days.
[0106] Figure 15. Developed SAP systems and BioSAS-TEVp are cytocompatible independently and as formulations, a) CellTiter-Blue® Cell Viability assay on a) SH-SY5 cells line and b) Primary astrocyte extracted from Swiss pups treated / conditioned with diluted SAP ± BioSAS-TEVp and different concentration of BioSAS-TEVp as well as TEVp2M. The untreated control group is set at 100% and other conditions show relative cell viability.
[0107] Figure 16. Cells remain their healthy morphology in contact with the developed SAP systems alone or in combination with BioSAS-TEVp. Primary astrocytes were subjected to a) DPBS, a’) BioSAS-TEVp, c) ECMRG in DPBS, c’) ECMRG with BioSAS-TEVp, d) ERG in DPBS, d’) ERG with BioSAS-TEVp, e) ERM in DPBS, e’) ERM with BioSAS-TEVp, then fixed and stained with astrocyte marker GFAP (green), and DAPI (blue), Scale bar = 100 pm. Primary cortical neurons were subjected to e) DPBS, e’) BioSAS-TEVp, f) ECMRG in DPBS, f’) ECMRG with BioSAS-TEVp, g) ERG in DPBS, g’) ERG with BioSAS-TEVp, h) ERM in DPBS, and h’) ERM with BioSAS-TEVp, then fixed and stained with neuronal marker p-tubulin (red), and DAPI (blue), Scale bar= 100 pm.
[0108] Figure 17. Cells can sense the SAP nanostructure and respond to them. Primary astrocytes were subjected to a) ECMRG in PBS, a’) ECMRG with BioSAS-TEVp, b) ERG in DPBS, a’) ERG with BioSAS-TEVp, c) ERM1 in DPBS, c’) ERM1 with BioSAS-TEVp, d) ERM5 in DPBS, d’) ERM5 with BioSAS-TEVp, then fixed and stained with neuronal marker p-tubulin (red), and DAPI (blue), Scale bar= 100 pm. Withe arrow: growing new dendrites, yellow arrow: ERM attached on the cells’ membrane.100659216521
[0109] Figure 18. Structural disassembling does not have negative impact in cell attachment in Mix sample. Primary astrocytes were cultured on top of a) GelMa (8%) in DPBS, a’) GelMa (8%) with BioSAS-TEVp, b) ECMLRG in DPBS, b’) ECMLRG with BioSAS-TEVp, c) ERG in DPBS, c’) ERG with BioSAS-TEVp, d) Co-assembly in DPBS, d’) Co-assembly with BioSAS-TEVp, e) Mix in DPBS, e’) Mix with BioSAS-TEVp, then fixed and stained with astrocyte marker GFAP (green), and DAPI (blue) after 3 days of incubation, Scale bar = 100 pm. Yellow arrows show the ECMLRG that washed away after media change.
[0110] Figure 19. Application of BioSAS-TEVp can activate the release of Viral vector released from SAP systems containing ERG or ERM. Immunofluorescence images after GFAP, DAPI and mCherry staining of Primary astrocyte subjected to a) DPBS as negative control, a’) BioSAS-TEVp, as well as supernatants from various SAP materials treated with DPBS (negative control) or BioSAS-TEVp. Control condition in which the cells were treated with the release AAV-mCherry from b,b’) ECMRG ± BioSAS-TEVp, and test conditions in which the cells were treated with the released AAV-mCherry from c,c’) ERG ± BioSAS-TEVp, d,d”) Mix ± BioSAS-TEVp, e,e’) ECMRG / ERM1 ± BioSAS-TEVp, and f,f’) ECMRG / ERM5 ± BioSAS-TEVp (left: DPBS treated I right: BioSAS-TEVp treated). Scale bar= 100 pm.
[0111] Figure 20. Application of BioSAS-TEVp can activate the release of Viral vector released from SAP systems containing ERG or ERM. Immunofluorescence images after B-tubul in, DAPI and GFP staining of Primary cortical neurons subjected to a) DPBS as negative control, a’) BioSAS-TEVp, as well as supernatants from various SAP materials treated with DPBS (negative control) or BioSAS-TEVp. Control condition in which the cells were treated with the release AAV-GFP from b,b’) ECMRG ± BioSAS-TEVp, and test conditions in which the cells were treated with the released AAV-GFP from c,c) ERG ± BioSAS-TEVp, d,d”) ECMRG / ERM1 ± BioSAS-TEVp, and e,e’) ECMRG / ERM5 ± BioSAS-TEVp (left: DPBS treated I right: BioSAS-TEVp treated). Scale bar= 100 pm.
[0112] Figure 21. By loading lower concentration of viral vector, the same rate of release can be achieved using BioSAS-TEVp. Immunofluorescence images after B-tubulin, DAPI, GFP staining for primary neural cells subjected to treatment with AAV-GFP and supernatant of ECMRG loaded with AAV-GFP with MOT a,a’)10A1, b,b’)10A2,100659216522c,c’)10A3, d,d’)10A4, before (top) and after (down) treatment with BioSAS-TEVp. Scale bar: 100 pm.
[0113] Figure 22. Applying BioSAS-TEVp does not have negative impact on the functionality of AAV. a) Flow cytometry scatter plot of neural cells treated with different concentration of AAV-GFP (MOT 0, 10A1, 10A2, 10A3, 10A4) in the presence of DPBS and BioSAS-TEVp. Number of transfected neural cells after treating with AAV-GFP that was added directly to the cells in the presence of b) DPBS, and c) BioSAS-TEVp.
[0114] Figure 23. BioSAS-TEVp can enhance the release of AAV-GFP from SAP systems including ERG and ERM and the released vectors successfully transfect the neural cells. Flow cytometry scatter plot of neural cells treated with released samples from a) ECMRG, a’) ECMRG + BioSAS-TEVp as negative control, b) ERG, b’) ERG + BioSAS-TEVp c) ECMRG / ERM1, c’) ECMRG / ERM1 + BioSAS-TEVp, d) ECMRG / ERM5, and d’) ECMRG / ERM5 + BioSAS-TEVp. e) mix, e’) mix + BioSAS-TEVp, f) quantification of GFP positive cells after treatment by the released AAV-GFP from SAP systems after treatment with DPBS or BioSAS-TEVp for 24 hr.
[0115] Figure 24. Application of BioSAS-TEVp can enhance the release of viral vector and reduction of inflammatory responses in vivo, a) a representative brain section showing the spatial control of Mix sample loaded with AAV-mCherry. b) a representative brain section showing the temporal control on the release of AAV-mCherry using BioSAS-TEVp. Four representative brain sections showing the distribution of the viral vectors in the brain without (c) and with (d) BioSAS-TEVp injection. Representative image of activated inflammatory cells (astrocyte (green) and microglia (yellow)) around the site of injection in brains with the injection of of e) mix loaded with mCherry, f) mix loaded with mCherry with BioSAS-TEVp administration 3 days post-injection.
[0116] Figure 25. Comparing the soluble expression of TEVp variants in E. coli.
[0117] Figure 26. (a) Hise-tagged BioSAS-TEVp elutes from a HiLoad 26 / 600 Superdex 200 pg column as a single clean peak, (b) SDS-PAGE gel loaded with Hise-tagged BioSAS-TEVp showing a single band at approximately 35 kDa, based on comparison to PageRuler™ Prestained Protein Ladder, 10 to 180 kDa (ThermoFisher Scientific).100659216523
[0118] Figure 27. Circular dichroism spectrum of BioSAS-TEVp immediately after size exclusion purification (left), (b) Circular dichroism spectrum of BioSAS-TEVp after a 80 °C freeze-thaw cycle at a concentration of 180 mg mL-1(right).
[0119] Figure 28. SDS-PAGE assay showing cleavage of target fusion with purified TEVp proteins in the presence and absence of DTT. Negative control is no-enzyme control.
[0120] Figure 29. Comparison of the peptide binding positions observed in the BioSAS-TEVp (C151A) crystal structure (purple and yellow sticks, chain A) and in the crystal structure of TEVpS219D (White cartoon, cyan sticks, PDB 1LVM, chain A).
[0121] Figure 30. Key protein-ligand interactions observed in the crystal structure of BioSAS-TEVp in complex with a TEVp substrate. Figure generated using PoseEdit.
[0122] Figure 31. Time series showing the distance between sulphur atom of the catalytic Cys151 and the reactive carbonyl carbon of substrate for each of the random seed molecular dynamics replicates. (Fmoc-ENLYFQSK peptide (SEQ ID NO: 34), subs= GGGSMSENLYFQGSMG (SEQ ID NO: 37))
[0123] Figure 32. Distribution of distance between sulphur atom of the catalytic Cys151 and the reactive carbonyl carbon of substrate for each of the MD simulation systems.
[0124] Figure 33. SDS-PAGE analysis showing soluble over-expression of BioSAS-TEVp and additional variants. The auto-cleavable construct (MBP-cs-His7-BioSAS-TEVp-core) displays complete self-cleavage (as evidenced by bands corresponding to cleaved MBP and TEVp core), consistent with truncated variants being active in overnight cleavage reactions.Sequence information
[0125] Sequences disclosed in this application are shown in Table 1 belowSEQ ID NO: Sequence name Sequence1 TEV cleavage site, EX1LYX2QX3wherein Xi, X2andX3 are any aminoacid, preferablyany naturally100659216524occurring aminoacid. Preferably Xiis asparagine (N).Preferably, X2 isany large ormediumhydrophobic aminoacid. Preferably,X3 is any smallhydrophobic orpolar amino acid.2 TEV cleavage site, EX1LYX2QX3X4wherein Xi, X2, X3,and X4 are anyamino acid,preferably anynaturally occurringamino acid.Preferably Xi isasparagine (N).Preferably, X2 isany large ormediumhydrophobic aminoacid. Preferably,X3 is any smallhydrophobic orpolar amino acid.Preferably, X4 isany large basicamino acid (e.g.lysine (K), arginine(R) or histidine(H)).3 TEV cleavage site, ENLYFQXwherein X is anyamino acid,preferably anynaturally occurringamino acid,preferably, X isserine (S) orglycine (G).4 TEV cleavage site ENLYFQS5 TEV cleavage site ENLYFQG6 TEV cleavage site ENLYFQSK7 TEV cleavage site ENLYFQGK33 Exemplary palmitoyl-AAAGGGENLYFQSK-amide palmitoyl peptideamphiphile10065921652534 Exemplary Fmoc Fmoc-ENLYFQSKpeptide38 Exemplary amino ENLYFQX1X2acids present inthe compoundwherein Xi and X2are any aminoacid, preferablyany naturallyoccurring aminoacid, preferably Xiis S or G,preferably, X2 is K.8 BIOSAS-TEVp MGSSHHHHHHSSGLVPRGSHMG ESLF K GPRDYTPICDNIVKLTLTSDGKSITLYGLQ(Underlined is N- terminal sequence: YGNYIITNRHLFRLNNGTLTIESKNGTYTI M = start codonADSKTLEVH LI EGKDLVI LKM PDSVPAAD GSS = flexiblelinker 1 TTLKFKKPVENEEVVLVSRDFSTPEPKCL HHHHHH = hexa- VSESSKITPDNDGTFWKHSIPTKDGECGhistadine tagSSG = flexible LPLVSTKDGTVVG LHSASN FN NTN FYFT linker 2AIPENFMELLNDESKRKWIKGWHLTSNS LVPRGS =Thrombin cleavage VEWGGHKVFMDKKEEPFQPVKEATQLM peptide (withNthrombin cleavingafter PR)The following “HM”are additionalresidues.Residuenumbering usedthroughout startsat G (#1) of“GES...”9 BIOSAS-TEVp GESLFKGPRDYTPICDNIVKLTLTSDGKSI without start TLYGLQYGNYIITNRHLFRLNNGTLTIESK codon, flexible NGTYTIADSKTLEVHLIEGKDLVILKMPDS linkers, Hise tag, VPAADTTLKFKKPVENEEVVLVSRDFSTP thrombin cleavage EPKCLVSESSKITPDNDGTFWKHSIPTKD site and additional GECGLPLVSTKDGTVVGLHSASNFNNTN amino acids FYFTAI PENFM ELLN DESKRKWI KGWH LT SNSVEWGGHKVFMDKKEEPFQPVKEAT QLMN10 AN-BioSAS-TEVp MGSSHHHHHHSSGLVPRGSHMPRDYTP (N-terminal ICDNIVKLTLTSDGKSITLYGLQYGNYIITN sequence, as per RHLFRLNNGTLTIESKNGTYTIADSKTLEV above, including H LI EGKDLVI LKM PDSVPAADTTLKFKKPVHise tag and EN EEVVLVSRDFSTPEPKCLVSESSKITP100659216526thrombin cleavage DNDGTFWKHSIPTKDGECGLPLVSTKDG site underlined) TVVG LHSASN FN NTN FYFTAI PEN FM ELL NDESKRKWIKGWHLTSNSVEWGGHKVF MDKKEEPFQPVKEATQLMN11 AN-BioSAS-TEVp PRDYTPICDNIVKLTLTSDGKSITLYGLQY without start GNYIITNRHLFRLNNGTLTIESKNGTYTIA codon, flexible DSKTLEVH LI EG KDLVI LKM PDSVPAADT linkers, Hise tag, TLKFKKPVENEEVVLVSRDFSTPEPKCLV thrombin cleavage SESSKITPDNDGTFWKHSIPTKDGECGL site and additional PLVSTKDGTVVGLHSASN FN NTN FYFTAI amino acids PENFMELLNDESKRKWIKGWHLTSNSVE WGGH KVFM DKKEEPFQPVKEATQLM N12 BioSAS-TEVp- MGSSHHHHHHSSGLVPRGSHMG ESLF K A219 GPRDYTPICDNIVKLTLTSDGKSITLYGLQ (N-terminal YGNYIITNRHLFRLNNGTLTIESKNGTYTI sequence, as per ADSKTLEVH LI EGKDLVI LKM PDSVPAAD above, including TTLKFKKPVENEEVVLVSRDFSTPEPKCL Hise tag and VSESSKITPDNDGTFWKHSIPTKDGECG thrombin cleavage LPLVSTKDGTVVG LHSASN FN NTN FYFT site underlined) AIPENFMELLNDESKRKWIKGWHLTSNS VEWGGHKVFM13 BioSAS-TEVp- GESLFKGPRDYTPICDNIVKLTLTSDGKSI A219 TLYGLQYGNYIITNRHLFRLNNGTLTIESK without start NGTYTIADSKTLEVHLIEGKDLVILKMPDS codon, flexible VPAADTTLKFKKPVENEEVVLVSRDFSTP linkers, Hise tag, EPKCLVSESSKITPDNDGTFWKHSIPTKD thrombin cleavage GECGLPLVSTKDGTVVGLHSASNFNNTN site and additional FYFTAI PENFM ELLN DESKRKWI KGWH LT amino acids SNSVEWGGHKVFM14 BioSAS-TEVp- MGSSHHHHHHSSGLVPRGSHMG ESLF K A220 GPRDYTPICDNIVKLTLTSDGKSITLYGLQ (N-terminal YGNYIITNRHLFRLNNGTLTIESKNGTYTI sequence, as per ADSKTLEVH LI EGKDLVI LKM PDSVPAAD above, including TTLKFKKPVENEEVVLVSRDFSTPEPKCL Hise tag and VSESSKITPDNDGTFWKHSIPTKDGECG thrombin cleavage LPLVSTKDGTVVG LHSASN FN NTN FYFT site underlined) AIPENFMELLNDESKRKWIKGWHLTSNS VEWGGHKVFMD15 BioSAS-TEVp- GESLFKGPRDYTPICDNIVKLTLTSDGKSI A220 TLYGLQYGNYIITNRHLFRLNNGTLTIESK without start NGTYTIADSKTLEVHLIEGKDLVILKMPDS codon, flexible VPAADTTLKFKKPVENEEVVLVSRDFSTP linkers, Hise tag, EPKCLVSESSKITPDNDGTFWKHSIPTKD thrombin cleavage GECGLPLVSTKDGTVVGLHSASNFNNTN site and additional FYFTAI PENFM ELLN DESKRKWI KGWH LT amino acids SNSVEWGGHKVFMD16 BioSAS-TEVp- MGSSHHHHHHSSGLVPRGSHMG ESLF K A221 GPRDYTPICDNIVKLTLTSDGKSITLYGLQ (N-terminal YGNYIITNRHLFRLNNGTLTIESKNGTYTI sequence, as per ADSKTLEVH LI EGKDLVI LKM PDSVPAADabove, including TTLKFKKPVENEEVVLVSRDFSTPEPKCL100659216527Hise tag and VSESSKITPDNDGTFWKHSIPTKDGECG thrombin cleavage LPLVSTKDGTVVG LHSASN FN NTN FYFT site underlined) AIPENFMELLNDESKRKWIKGWHLTSNS VEWGGHKVFMDK17 BioSAS-TEVp- GESLFKGPRDYTPICDNIVKLTLTSDGKSI A221 TLYGLQYGNYIITNRHLFRLNNGTLTIESK without start NGTYTIADSKTLEVHLIEGKDLVILKMPDS codon, flexible VPAADTTLKFKKPVENEEVVLVSRDFSTP linkers, Hise tag, EPKCLVSESSKITPDNDGTFWKHSIPTKD thrombin cleavage GECGLPLVSTKDGTVVGLHSASNFNNTN site and additional FYFTAI PENFM ELLN DESKRKWI KGWH LT amino acids SNSVEWGGHKVFMDK18 BioSAS-TEVp- MGSSHHHHHHSSGLVPRGSHMG ESLF K A222 GPRDYTPICDNIVKLTLTSDGKSITLYGLQ (N-terminal YGNYIITNRHLFRLNNGTLTIESKNGTYTI sequence, as per ADSKTLEVH LI EGKDLVI LKM PDSVPAAD above, including TTLKFKKPVENEEVVLVSRDFSTPEPKCL Hise tag and VSESSKITPDNDGTFWKHSIPTKDGECG thrombin cleavage LPLVSTKDGTVVG LHSASN FN NTN FYFT site underlined) AIPENFMELLNDESKRKWIKGWHLTSNS VEWGGHKVFMDKK19 BioSAS-TEVp- GESLFKGPRDYTPICDNIVKLTLTSDGKSI A222 TLYGLQYGNYIITNRHLFRLNNGTLTIESK without start codon, NGTYTIADSKTLEVHLIEGKDLVILKMPDS flexible linkers, Hise VPAADTTLKFKKPVENEEVVLVSRDFSTP tag, thrombin EPKCLVSESSKITPDNDGTFWKHSIPTKD cleavage site and GECGLPLVSTKDGTVVGLHSASNFNNTN additional amino FYFTAI PENFM ELLN DESKRKWI KGWH LT acids SN SVEWGGH KVFM DKK20 BioSAS-TEVp-core MGSSHHHHHHSSGLVPRGSH M PRDYTP (N-terminal ICDNIVKLTLTSDGKSITLYGLQYGNYIITN sequence, as per RHLFRLNNGTLTIESKNGTYTIADSKTLEV above, including H LI EGKDLVI LKM PDSVPAADTTLKFKKPV Hise tag and EN EEVVLVSRDFSTPEPKCLVSESSKITP thrombin cleavage DNDGTFWKHSIPTKDGECGLPLVSTKDG site underlined) TVVGLHSASNFNNTNFYFTAIPENFMELL NDESKRKWIKGWHLTSNSVEWGGHKVF MDK52 BioSAS-TEVp-core MGSSHHHHHHSSGLVPRGSPRDYTPIC (N-terminal DNIVKLTLTSDGKSITLYGLQYGNYIITNR sequence, as per HLFRLNNGTLTIESKNGTYTIADSKTLEVH above, including LI EG KDLVI LKM PDSVPAADTTLKFKKPVE Hise tag and NEEVVLVSRDFSTPEPKCLVSESSKITPD thrombin cleavage NDGTFWKHSIPTKDGECGLPLVSTKDGT site underlined) VVGLHSASNFNNTNFYFTAIPENFMELLN DESKRKWIKGWHLTSNSVEWGGHKVFM DK21 BioSAS-TEVp- HMPRDYTPICDNIVKLTLTSDGKSITLYGL core QYGNYIITNRHLFRLNNGTLTIESKNGTYT without start IADSKTLEVH LI EGKDLVI LKM PDSVPAADcodon, flexible TTLKFKKPVENEEVVLVSRDFSTPEPKCL100659216528linkers, Hise tag, VSESSKITPDNDGTFWKHSIPTKDGECG thrombin cleavage LPLVSTKDGTVVG LHSASN FN NTN FYFT site and additional AIPENFMELLNDESKRKWIKGWHLTSNS amino acids VEWGGHKVFMDK53 BioSAS-TEVp- PRDYTPICDNIVKLTLTSDGKSITLYGLQY core GNYIITNRHLFRLNNGTLTIESKNGTYTIA without start DSKTLEVH LI EG KDLVI LKM PDSVPAADT codon, flexible TLKFKKPVENEEVVLVSRDFSTPEPKCLV linkers, Hise tag, SESSKITPDNDGTFWKHSIPTKDGECGL thrombin cleavage PLVSTKDGTVVGLHSASN FN NTN FYFTAI site and additional PENFMELLNDESKRKWIKGWHLTSNSVE amino acids WGGHKVFMDK22 BIOSAS-TEVp ATGGGCAGCAGCCATCATCATCATCAT CACAGCAGCGGCCTGGTGCCGCGCGG CAGCCATATGGGAGAATCCCTGTTCAA AGGTCCTCGAGACTACACACCGATTTG CGATAACATCGTTAAGCTGACTTTAACG TCTGATGGGAAGAGCATTACACTGTAC GGTCTTCAATACGGAAACTATATCATAA CCAATCGCCACTTGTTCCGGCTGAATA ACGGGACGCTTACGATTGAGTCTAAGA ACGGTACGTACACTATTGCGGATAGCA AAACCTTAGAGGTGCATTTGATTGAGG GGAAAGACCTCGTAATCCTGAAAATGC CTGATTCTGTACCGGCTGCCGACACTA CACTGAAGTTTAAGAAACCTGTCGAGA ACGAAGAGGTTGTACTTGTTTCCCGGG ATTTCTCAACCCCGGAGCCGAAGTGTC TGGTTAGTGAGAGCTCAAAGATCACTC CGGATAACGATGGTACCTTTTGGAAAC ATTCGATCCCAACCAAGGATGGAGAGT GCGGTTTACCGTTAGTGTCCACGAAGG ACGGTACGGTGGTTGGTCTTCATTCAG CATCCAAI I I I AACAA I ACAAAC I I I IA CTTCACTGCCATTCCTGAGAATTTCATG GAACTCTTAAACGACGAGTCCAAGAGA AAGTGGATCAAGGGGTGGCACTTAACT TCCAACTCCGTGGAGTGGGGCGGACA TAAGG I l l i CATGGACAAGAAAGAGGA GCCGTTCCAACCGGTCAAGGAAGCGA CACAACTGATGAATTAA23 AN-BioSAS-TEVp ATGGGCAGCAGCCATCATCATCATCAT CACAGCAGCGGCCTGGTGCCGCGCGG CAGCCATATGCCTCGAGACTACACACC GATTTGCGATAACATCGTTAAGCTGACT TTAACGTCTGATGGGAAGAGCATTACA CTGTACGGTCTTCAATACGGAAACTATA TCATAACCAATCGCCACTTGTTCCGGC TGAATAACGGGACGCTTACGATTGAGT CTAAGAACGGTACGTACACTATTGCGGATAGCAAAACCTTAGAGGTGCATTTGAT100659216529TGAGGGGAAAGACCTCGTAATCCTGAA AATGCCTGATTCTGTACCGGCTGCCGA CACTACACTGAAGTTTAAGAAACCTGTC GAGAACGAAGAGGTTGTACTTGTTTCC CGGGATTTCTCAACCCCGGAGCCGAA GTGTCTGGTTAGTGAGAGCTCAAAGAT CACTCCGGATAACGATGGTACC I I I I G GAAACATTCGATCCCAACCAAGGATGG AGAGTGCGGTTTACCGTTAGTGTCCAC GAAGGACGGTACGGTGGTTGGTCTTCA TTCAGCATCCAA I l l i AACAATACAAAC I l l i ACTTCACTGCCATTCCTGAGAATT TCATGGAACTCTTAAACGACGAGTCCA AGAGAAAGTGGATCAAGGGGTGGCAC TTAACTTCCAACTCCGTGGAGTGGGGC GGACATAAGG I l l i CATGGACAAGAAA GAGGAGCCGTTCCAACCGGTCAAGGA AGCGACACAACTGATGAATTAA24 BioSAS-TEVp- ATGGGCAGCAGCCATCATCATCATCAT A219 CACAGCAGCGGCCTGGTGCCGCGCGG CAGCCATATGGGAGAATCCCTGTTCAA AGGTCCTCGAGACTACACACCGATTTG CGATAACATCGTTAAGCTGACTTTAACG TCTGATGGGAAGAGCATTACACTGTAC GGTCTTCAATACGGAAACTATATCATAA CCAATCGCCACTTGTTCCGGCTGAATA ACGGGACGCTTACGATTGAGTCTAAGA ACGGTACGTACACTATTGCGGATAGCA AAACCTTAGAGGTGCATTTGATTGAGG GGAAAGACCTCGTAATCCTGAAAATGC CTGATTCTGTACCGGCTGCCGACACTA CACTGAAGTTTAAGAAACCTGTCGAGA ACGAAGAGGTTGTACTTGTTTCCCGGG ATTTCTCAACCCCGGAGCCGAAGTGTC TGGTTAGTGAGAGCTCAAAGATCACTC CGGATAACGATGGTACCTTTTGGAAAC ATTCGATCCCAACCAAGGATGGAGAGT GCGGTTTACCGTTAGTGTCCACGAAGG ACGGTACGGTGGTTGGTCTTCATTCAG CATCCAAI I I I AACAA I ACAAAC I I I IA CTTCACTGCCATTCCTGAGAATTTCATG GAACTCTTAAACGACGAGTCCAAGAGA AAGTGGATCAAGGGGTGGCACTTAACT TCCAACTCCGTGGAGTGGGGCGGACA TAAGG I l l i CATGTAA25 BioSAS-TEVp- ATGGGCAGCAGCCATCATCATCATCAT A220 CACAGCAGCGGCCTGGTGCCGCGCGG CAGCCATATGGGAGAATCCCTGTTCAA AGGTCCTCGAGACTACACACCGATTTG CGATAACATCGTTAAGCTGACTTTAACGTCTGATGGGAAGAGCATTACACTGTAC100659216530GGTCTTCAATACGGAAACTATATCATAA CCAATCGCCACTTGTTCCGGCTGAATA ACGGGACGCTTACGATTGAGTCTAAGA ACGGTACGTACACTATTGCGGATAGCA AAACCTTAGAGGTGCATTTGATTGAGG GGAAAGACCTCGTAATCCTGAAAATGC CTGATTCTGTACCGGCTGCCGACACTA CACTGAAGTTTAAGAAACCTGTCGAGA ACGAAGAGGTTGTACTTGTTTCCCGGG ATTTCTCAACCCCGGAGCCGAAGTGTC TGGTTAGTGAGAGCTCAAAGATCACTC CGGATAACGATGGTACCTTTTGGAAAC ATTCGATCCCAACCAAGGATGGAGAGT GCGGTTTACCGTTAGTGTCCACGAAGG ACGGTACGGTGGTTGGTCTTCATTCAG CATCCAAI I I I AACAA I ACAAAC I I I I A CTTCACTGCCATTCCTGAGAATTTCATG GAACTCTTAAACGACGAGTCCAAGAGA AAGTGGATCAAGGGGTGGCACTTAACT TCCAACTCCGTGGAGTGGGGCGGACA TAAGG I l l i CATGGACTAA26 BioSAS-TEVp- ATGGGCAGCAGCCATCATCATCATCAT A221 CACAGCAGCGGCCTGGTGCCGCGCGG CAGCCATATGGGAGAATCCCTGTTCAA AGGTCCTCGAGACTACACACCGATTTG CGATAACATCGTTAAGCTGACTTTAACG TCTGATGGGAAGAGCATTACACTGTAC GGTCTTCAATACGGAAACTATATCATAA CCAATCGCCACTTGTTCCGGCTGAATA ACGGGACGCTTACGATTGAGTCTAAGA ACGGTACGTACACTATTGCGGATAGCA AAACCTTAGAGGTGCATTTGATTGAGG GGAAAGACCTCGTAATCCTGAAAATGC CTGATTCTGTACCGGCTGCCGACACTA CACTGAAGTTTAAGAAACCTGTCGAGA ACGAAGAGGTTGTACTTGTTTCCCGGG ATTTCTCAACCCCGGAGCCGAAGTGTC TGGTTAGTGAGAGCTCAAAGATCACTC CGGATAACGATGGTACCTTTTGGAAAC ATTCGATCCCAACCAAGGATGGAGAGT GCGGTTTACCGTTAGTGTCCACGAAGG ACGGTACGGTGGTTGGTCTTCATTCAG CATCCAAI I I I AACAA I ACAAAC I I I IA CTTCACTGCCATTCCTGAGAATTTCATG GAACTCTTAAACGACGAGTCCAAGAGA AAGTGGATCAAGGGGTGGCACTTAACT TCCAACTCCGTGGAGTGGGGCGGACA TAAGG I l l i CATGGACAAGTAA27 BioSAS-TEVp- ATGGGCAGCAGCCATCATCATCATCAT A222 CACAGCAGCGGCCTGGTGCCGCGCGGCAGCCATATGGGAGAATCCCTGTTCAA100659216531AGGTCCTCGAGACTACACACCGATTTG CGATAACATCGTTAAGCTGACTTTAACG TCTGATGGGAAGAGCATTACACTGTAC GGTCTTCAATACGGAAACTATATCATAA CCAATCGCCACTTGTTCCGGCTGAATA ACGGGACGCTTACGATTGAGTCTAAGA ACGGTACGTACACTATTGCGGATAGCA AAACCTTAGAGGTGCATTTGATTGAGG GGAAAGACCTCGTAATCCTGAAAATGC CTGATTCTGTACCGGCTGCCGACACTA CACTGAAGTTTAAGAAACCTGTCGAGA ACGAAGAGGTTGTACTTGTTTCCCGGG ATTTCTCAACCCCGGAGCCGAAGTGTC TGGTTAGTGAGAGCTCAAAGATCACTC CGGATAACGATGGTACCTTTTGGAAAC ATTCGATCCCAACCAAGGATGGAGAGT GCGGTTTACCGTTAGTGTCCACGAAGG ACGGTACGGTGGTTGGTCTTCATTCAG CATCCAAI I I I AACAA I ACAAAC I I I I A CTTCACTGCCATTCCTGAGAATTTCATG GAACTCTTAAACGACGAGTCCAAGAGA AAGTGGATCAAGGGGTGGCACTTAACT TCCAACTCCGTGGAGTGGGGCGGACA TAAGG I l l i CATGGACAAGAAATAA 28 BioSAS-TEVp- ATGGGCAGCAGCCATCATCATCATCAT core CACAGCAGCGGCCTGGTGCCGCGCGG CAGCCATATGCCTCGAGACTACACACC GATTTGCGATAACATCGTTAAGCTGACT TTAACGTCTGATGGGAAGAGCATTACA CTGTACGGTCTTCAATACGGAAACTATA TCATAACCAATCGCCACTTGTTCCGGC TGAATAACGGGACGCTTACGATTGAGT CTAAGAACGGTACGTACACTATTGCGG ATAGCAAAACCTTAGAGGTGCATTTGAT TGAGGGGAAAGACCTCGTAATCCTGAA AATGCCTGATTCTGTACCGGCTGCCGA CACTACACTGAAGTTTAAGAAACCTGTC GAGAACGAAGAGGTTGTACTTGTTTCC CGGGATTTCTCAACCCCGGAGCCGAA GTGTCTGGTTAGTGAGAGCTCAAAGAT CACTCCGGATAACGATGGTACC I I I I G GAAACATTCGATCCCAACCAAGGATGG AGAGTGCGGTTTACCGTTAGTGTCCAC GAAGGACGGTACGGTGGTTGGTCTTCA TTCAGCATCCAA I l l i AACAATACAAAC I l l i ACTTCACTGCCATTCCTGAGAATT TCATGGAACTCTTAAACGACGAGTCCA AGAGAAAGTGGATCAAGGGGTGGCAC TTAACTTCCAACTCCGTGGAGTGGGGCGGACATAAGG I l l i CATGGACAAGTAA10065921653229 Residues 2038- GESLFKGPRDYNPISSTICHLTNESDGHT 2258 of Uni Prof TSLYGIGFGPFIITNKHLFRRNNGTLLVQS P04517 LHGVFKVKNTTTLQQHLIDGRDMIIIRMPK (polyprotein), for DFPPFPQKLKFREPQREERICLVTTNFQT purposes herein KSMSSMVSDTSCTFPSSDGIFWKHWIQT residue G at the N- KDGQCGSPLVSTRDGFIVGIHSASNFTNT terminus is residue NNYFTSVPKNFMELLTNQEAQQWVSGW number 1 (same RLNADSVLWGGHKVFMDKPEEPFQPVK numbering as PDB EATQLMN1LVM). Thissequence containsS219D.30 BioSAS-TEVp MGSSHHHHHHSSGLVPRGSHMPRDYTP (C151A)-core ICDNIVKLTLTSDGKSITLYGLQYGNYIITN RHLFRLNNGTLTIESKNGTYTIADSKTLEV HLIEGKDLVILKMPDSVPAADTTLKFKKPVUnderlined EN EEVVLVSRDFSTPEPKCLVSESSKITP DNDGTFWKHSIPTKDGEAGLPLVSTKDGsequences denote TVVG LHSASN FN NTN FYFTAI PEN FM ELL additional tags NDESKRKWIKGWHLTSNSVEWGGHKVF MDKLEHHHHHH31 MBP-cs-His7- MKTEEGKLVIWINGDKGYNGLAEVGKKF BioSAS-TEVp-core EKDTGIKVTVEHPDKLEEKFPQVAATGD GPDIIFWAHDRFGGYAQSGLLAEITPDKAUnderlined FQDKLYPFTWDAVRYNGKLIAYPIAVEAL SLIYNKDLLPNPPKTWEEIPALDKELKAKsequences denote GKSALMFNLQEPYFTWPLIAADGGYAFKadditional tags YENGKYDIKDVGVDNAGAKAGLTFLVDLI KNKHMNADTDYSIAEAAFNKGETAMTIN GPWAWSNIDTSKVNYGVTVLPTFKGQPS KPFVGVLSAGINAASPNKELAKEFLENYL LTDEGLEAVNKDKPLGAVALKSYEEELAK DPRIAATMENAQKGEIMPNIPQMSAFWY AVRTAVINAASGRQTVDEALKDAQTNSS SNNNNNNNNNNLGIEGRGENLYFQGSS HHHHHHHSSGPRDYTPICDNIVKLTLTSD GKSITLYGLQYGNYIITNRHLFRLNNGTLT IESKNGTYTIADSKTLEVHLIEGKDLVILKM PDSVPAADTTLKFKKPVENEEVVLVSRD FSTPEPKCLVSESSKITPDNDGTFWKHSI PTKDGECGLPLVSTKDGTVVGLHSASNF N NTN FYFTAI PEN FM ELLN DESKRKWI KG WHLTSNSVEWGGHKVFMDK32 His7-MBP-BioSAS- MSSHHHHHHHSSGKTEEGKLVIWINGDK TEVp-core GYNGLAEVGKKFEKDTGIKVTVEHPDKL EEKFPQVAATGDGPDIIFWAHDRFGGYA QSGLLAEITPDKAFQDKLYPFTWDAVRY NGKLIAYPIAVEALSLIYNKDLLPNPPKTW EEIPALDKELKAKGKSALMFNLQEPYFTWPLI AADGGYAFKYENGKYDI KDVGVDNA100659216533Underlined GAKAGLTFLVDLIKNKHMNADTDYSIAEA AFNKGETAMTINGPWAWSNIDTSKVNYGsequences denoteVTVLPTFKGQPSKPFVGVLSAGI NAASPNadditional tags KELAKEFLENYLLTDEGLEAVNKDKPLGA VALKSYEEELAKDPRIAATMENAQKGEIM PN I PQMSAFWYAVRTAVI NAASGRQTVD EALKDAQTGSKGPPRDYTPICDNIVKLTL TSDGKSITLYGLQYGNYIITNRHLFRLNN GTLTIESKNGTYTIADSKTLEVHLIEGKDL VILKMPDSVPAADTTLKFKKPVENEEVVL VSRDFSTPEPKCLVSESSKITPDNDGTF WKHSIPTKDGECGLPLVSTKDGTVVGLH SASNFNNTNFYFTAIPENFMELLNDESKRKWIKGWHLTSNSVEWGGHKVFMDKDetailed description of the embodiments
[0126] The present inventor(s) have engineered several self-assembling peptide (SAP) hydrogel systems, including based on Fmoc and palmitoyl moieties, that facilitate stimulus-responsive release of active agents (e.g. nucleic acid based molecules such as viral vectors). These systems consist of SAP hydrogels that contain the target cleavage site of a TEV protease, and a stimulus protein that is a variant of the Tobacco Etch Virus protease. The variants described herein have increased stability and solubility compared to a commonly-used L56V / S219 / S135G variant of TEV protease (TEVp2M; Methods Mol Biol 2017:1586:221-230) protease, while being biocompatible and active. The inventor(s) show that these paired SAP-protease systems provide controllable, cytocompatible, release of adeno-associated viruses to primary astrocytes and cortical neurons compared to engineered systems that rely on passive diffusion mechanisms.
[0127] The inventors show that the engineered response components of the hydrogel and protease systems can safely facilitate the delivery of adeno-associated viruses in vitro and in vivo in a bioorthogonal, stimulus-responsive manner. These engineered hybrid hydrogel systems respond to applied external stimuli instead of relying on sitespecific physiology or gene expression profiles. As such, it represents a new class of bioorthogonal stimulus-responsive biomaterials, in which both the biomaterial and the stimulus are applied separately, to improve the delivery of imbibed therapeutics by enabling coordination with other therapeutic delivery timelines. Importantly, this approach represents a generalisable strategy for the development of readily injectable100659216534bioorthogonal nanomaterials for delivery of diverse therapeutics including proteins, small molecules, genetic molecules, and vectors in gene therapy in diverse tissues.
[0128] An advantage of embodiments of the present disclosure are the generation of improved, non-invasive, spatiotemporally controlled, methods for the delivery of proteins, small molecules, genetic molecules and vectors in gene therapy to difficult-to-access targets, particularly across the blood-brain barrier. Further, they have integrated the capacity, protective and spatial advantages of SAP hydrogels with enhanced temporal control through tissue-agnostic stimulus response to provide delivery for therapeutic cargo.Definitions
[0129] It will be understood that the invention disclosed and defined in this specification extends to all alternative combinations of two or more of the individual features mentioned or evident from the text or drawings. All of these different combinations constitute various alternative aspects of the invention.
[0130] The terms "about" and "approximately" shall generally mean an acceptable degree of error for the quantity measured given the nature or precision of the measurements. Typical, exemplary degrees of error are within 20 percent (%), preferably within 10%, and more preferably within 5% of a given value or range of values. Alternatively, and particularly in biological systems, the terms "about" and "approximately" may mean values that are within an order of magnitude, preferably within 5-fold and more preferably within 2-fold of a given value. Numerical quantities given herein are approximate unless stated otherwise, meaning that the term "about" or "approximately" can be inferred when not expressly stated.
[0131] Reference will now be made in detail to certain embodiments of the disclosure. While the invention will be described in conjunction with the embodiments, it will be understood that the intention is not to limit the invention to those embodiments. On the contrary, the disclosure is intended to cover all alternatives, modifications, and equivalents, which may be included within the scope of the present disclosure as defined by the claims.
[0132] One skilled in the art will recognize many methods and materials similar or equivalent to those described herein, which could be used in the practice of the present100659216535invention. The present disclosure is in no way limited to the methods and materials described. It will be understood that the invention disclosed and defined in this specification extends to all alternative combinations of two or more of the individual features mentioned or evident from the text or drawings. All of these different combinations constitute various alternative aspects of the invention.
[0133] All of the patents and publications referred to herein are incorporated by reference in their entirety.
[0134] For purposes of interpreting this specification, terms used in the singular will also include the plural and vice versa.
[0135] The general chemical terms used in the formulae herein have their usual meaning.
[0136] As used herein, the term "and / or" means "and", or "or", or both.
[0137] The term "(s)" following a noun contemplates the singular and plural form, or both.
[0138] It is intended that reference to a range of numbers disclosed herein (for example, 1 to 10) also incorporates reference to all rational numbers within that range (for example, 1 , 1.1 , 2, 3, 3.9, 4, 5, 6, 6.5, 7, 8, 9, and 10) and also any range of rational numbers within that range (for example, 2 to 8, 1.5 to 5.5, and 3.1 to 4.7) and, therefore, all sub-ranges of all ranges expressly disclosed herein are hereby expressly disclosed. These are only examples of what is specifically intended and all possible combinations of numerical values between the lowest value and the highest value enumerated are to be considered to be expressly stated in this application in a similar manner.
[0139] Various features of the invention are described with reference to a certain value, or range of values. These values are intended to relate to the results of the various appropriate measurement techniques, and therefore should be interpreted as including a margin of error inherent in any particular measurement technique. Some of the values referred to herein are denoted by the term “about” to at least in part account for this variability. The term “about”, when used to describe a value, may mean an amount within ±10%, ±5%, ±1% or ±0.1% of that value.100659216536Compounds capable of self-assembly
[0140] The present disclosure provides a compound capable of self-assembly comprising, consisting essentially of or consists of a tobacco etch virus (TEV) protease cleavable peptide and a moiety that facilitates or promotes self-assembly.
[0141] In some embodiments, the only amino acids present in the compound are those of the TEV protease cleavable peptide and equal to, or less than, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 additional amino acid(s) N and / or C terminal to the TEV protease cleavable peptide.
[0142] In one embodiment, the TEV protease cleavable peptide is from 7 to 20, 7 to 19, 7 to 18, 7 to 17, 7 to 16, 7 to 15, 7 to 14, 7 to 13, 7 to 12, 7 to 11, or 7 to 10, or 7 to 9, or 7 to 8 amino acids in length.
[0143] In one embodiment, the TEV protease cleavable peptide is about 7, about 8, about 9, about 10, about 11, about 12, about 13, about 14, about 15, about 16, about 17, about 18, about 19 or about 20 amino acids in length.
[0144] In one embodiment, the TEV protease cleavable peptide is 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 amino acids in length.
[0145] In some embodiments, the TEV protease cleavable peptide is cleavable by any TEV protease described herein, including those comprising the amino acid sequences shown in Table 1.
[0146] In some embodiments, the TEV protease cleavable peptide comprises, consists essentially of or consists of EX1LYX2QX3 (SEQ ID NO: 1), wherein Xi, X2and X3 are any amino acid, preferably any naturally occurring amino acid. Preferably Xi is asparagine (N). Preferably, X2 is any large or medium hydrophobic amino acid.Preferably, X3 is any small hydrophobic or polar amino acid.
[0147] In one embodiment, the only amino acids present in the compound is EX1LYX2QX3 (SEQ ID NO: 1), wherein Xi, X2and X3 are any amino acid, preferably any naturally occurring amino acid. Preferably Xi is asparagine (N). Preferably, X2 is any large or medium hydrophobic amino acid. Preferably, X3 is any small hydrophobic or polar amino acid.100659216537
[0148] In one embodiment, the only amino acids present in the compound is EX1LYX2QX3X4 (SEQ ID NO: 2), wherein Xi, X2, X3, and X4 are any amino acid, preferably any naturally occurring amino acid. Preferably Xi is asparagine (N).Preferably, X2 is any large or medium hydrophobic amino acid. Preferably, X3 is any small hydrophobic or polar amino acid. Preferably, X4 is any large basic amino acid (e.g. lysine (K), arginine (R) or histidine (H)).
[0149] In some embodiments, the TEV protease cleavable peptide comprises, consists essentially of or consists of ENLYFQX (SEQ ID NO: 3) wherein X is any amino acid, preferably any naturally occurring amino acid. Typically, X is serine (S) or glycine (G).
[0150] In one embodiment, the compound comprises a TEV protease cleavable peptide of ENLYFQS (SEQ ID NO: 4) or ENLYFQG (SEQ ID NO: 5) with an additional amino acid at the C-terminus. Typically, the additional amino acid is a lysine (K), an arginine (R) or a histidine (H). Preferably, the additional amino acid is a lysine (K). The compound therefore may comprise the amino acid sequence ENLYFQSK (SEQ ID NO: 6) or ENLYFQGK (SEQ ID NO: 7).
[0151] In one embodiment, the only amino acids present in the compound is ENLYFQX1X2 (SEQ ID NO: 38), wherein Xi and X2 are any amino acid, preferably any naturally occurring amino acid. Preferably Xi is S or G. Preferably, X2 is K.
[0152] In any embodiment, the TEV protease cleavable peptide is not degradable by biological and metabolic activity of cells and tissues.
[0153] In any embodiment, the compound is not degradable by biological and metabolic activity of cells and tissues.
[0154] In one embodiment, the compound is not a polymer.
[0155] In one embodiment, the compound is capable of self-assembly in an aqueous environment. Preferably, the compound is capable of self-assembly in an aqueous environment at a wide range of pH.
[0156] In some embodiment, the wide range of pH is from about pH 6 to about pH 10.100659216538
[0157] In one embodiment, the moiety that facilitates or promotes self-assembly initiates self-assembly.
[0158] In one embodiment, the moiety that facilitates or promotes self-assembly does so by hydrophobic-hydrophilic interactions. Preferably, the moiety is an amphiphile. Where the moiety is an amphiphile it may contain a hydrophilic portion and a lipophilic portion. The hydrophilic portion may be a peptide. The lipophilic portion may be an aliphatic chain, which is either saturated or unsaturated. The aliphatic chain may be palmitoyl, myristoyl, stearoyl, lauroyl, octanoyl or decanoyl. Preferably, the aliphatic chain is palmitoyl.
[0159] In one embodiment, the moiety that facilitates or promotes self-assembly does so by TT-TT stacking. Preferably, the moiety comprises an aromatic TT system. More preferably, the moiety is fluorenylmethoxycarbonyl (Fmoc).Active agents
[0160] Hydrogels of the disclosure may include one or more active agents that are therapeutic and / or prophylactic agents. The disclosure features methods of delivering or releasing a therapeutic and / or prophylactic agent to a mammalian cell or organ, optionally producing a polypeptide of interest in a mammalian cell, and treating a disease or disorder in a mammal in need thereof comprising administering to a mammal and / or contacting a mammalian cell with a hydrogel including an active agent (e.g. a therapeutic and / or prophylactic agent).
[0161] Therapeutic and / or prophylactic agents include biologically active substances and are alternately referred to as "active agents." A therapeutic and / or prophylactic agent may be a substance that, once delivered to a cell or organ, brings about a desirable change in the cell, organ, or other bodily tissue or system. Such agents may be useful in the treatment of one or more diseases, disorders, or conditions. In some embodiments, a therapeutic and / or prophylactic agent is a small molecule (drug) useful in the treatment of a particular disease, disorder, or condition. Examples of drugs useful in the hydrogel of the disclosure include, but are not limited to, antineoplastic agents (e.g., vincristine, doxorubicin, mitoxantrone, camptothecin, cisplatin, bleomycin, cyclophosphamide, methotrexate, and streptozotocin), antitumor agents (e.g., actinomycin D, vincristine, vinblastine, cystine arabinoside, anthracyclines, alkylative100659216539agents, platinum compounds, antimetabolites, and nucleoside analogs, such as methotrexate and purine and pyrimidine analogs), anti-infective agents, local anesthetics (e.g., dibucaine and chlorpromazine), beta-adrenergic blockers (e.g., propranolol, timolol, and labetolol), antihypertensive agents (e.g., clonidine and hydralazine), anti-depressants (e.g., imipramine, amitriptyline, and doxepim), anti-conversants (e.g., phenytoin), antihistamines (e.g., diphenhydramine, chlorphenirimine, and promethazine), antibiotic / antibacterial agents (e.g., gen-tamycin, ciprofloxacin, and cefoxitin), antifungal agents (e.g., miconazole, terconazole, econazole, isoconazole, butaconazole, clotrimazole, itraconazole, nystatin, naftifine, and amphotericin B), antiparasitic agents, hormones, hormone antagonists, immunomodulators, neurotransmitter antagonists, antiglaucoma agents, vitamins, narcotics, and imaging agents.
[0162] The present disclosure provides a hydrogel comprising one or more active agents, methods of making the hydrogel, and methods of delivering and / or administering the hydrogel (e.g., for the treatment of a disease or disorder).
[0163] In certain embodiments, the active agent or therapeutic agent is fully or partially encapsulated within, loaded in or imbibed into, the hydrogel. In further embodiments, the hydrogel may be loaded with one or more active agents, such as described herein, following gelation, eg by soaking, vortexing or mixing a hydrogel made according to the disclosure, with a solution comprising the one or more active agents.
[0164] In some embodiments, the active agent or therapeutic agent comprises a nucleic acid. In certain instances, the nucleic acid comprises an interfering RNA molecule such as, e.g., an siRNA, aiRNA, miRNA, or mixtures thereof. In certain other instances, the nucleic acid comprises single-stranded or double-stranded DNA, RNA, or a DNA / RNA hybrid such as, e.g., an antisense oligonucleotide, a ribozyme, a plasmid, an immunostimulatory oligonucleotide, or mixtures thereof.
[0165] In some embodiments, the active agent is a vector, for example a vector that comprises a nucleotide sequence encoding a therapeutic protein or polypeptide.Preferably, the nucleotide sequence encoding a therapeutic protein or polypeptide is operably linked to a promoter. The promoter typically allows expression of the100659216540therapeutic protein or polypeptide in a cell or organ of interest. The vector may be a viral vector, preferably an Adeno-associated virus (AAV) vector.
[0166] In other embodiments, the active agent or therapeutic agent comprises a peptide or polypeptide. In certain instances, the peptide or polypeptide comprises an antibody such as, e.g., a polyclonal antibody, a monoclonal antibody, an antibody fragment; a humanized antibody, a recombinant antibody, a recombinant human antibody, a Primatized™ antibody, or mixtures thereof. In certain other instances, the peptide or polypeptide comprises a cytokine, a growth factor, an apoptotic factor, a differentiation-inducing factor, a cell-surface receptor, a ligand, a hormone, a small molecule (e.g., small organic molecule or compound), or mixtures thereof.
[0167] In some embodiments, the active agent is a therapeutic agent, or a salt or derivative thereof. Therapeutic agent derivatives may be therapeutically active themselves or they may be prodrugs, which become active upon further modification. Thus, in one embodiment, a therapeutic agent derivative retains some or all of the therapeutic activity as compared to the unmodified agent, while in another embodiment, a therapeutic agent derivative is a prodrug that lacks therapeutic activity, but becomes active upon further modification.
[0168] In certain embodiments, the active agent may comprise one or more therapeutic proteins, polypeptides, or small organic molecules or compounds. Nonlimiting examples of such therapeutically effective agents or drugs include oncology drugs (e.g., chemotherapy drugs, hormonal therapeutic agents, immunotherapeutic agents, radiotherapeutic agents, etc.), lipid-lowering agents, anti-viral drugs, antiinflammatory compounds, antidepressants, stimulants, analgesics, antibiotics, birth control medication, antipyretics, vasodilators, anti-angiogenics, cytovascular agents, signal transduction inhibitors, cardiovascular drugs such as anti-arrhythmic agents, hormones, vasoconstrictors, and steroids.
[0169] Non-limiting examples of chemotherapy drugs include platinum-based drugs (e.g., oxaliplatin, cisplatin, carboplatin, spiroplatin, iproplatin, satraplatin, etc.), alkylating agents (e.g., cyclophosphamide, ifosfamide, chlorambucil, busulfan, melphalan, mechlorethamine, uramustine, thiotepa, nitrosoureas, etc.), anti-metabolites (e.g., 5-fluorouracil (5-Fll), azathioprine, methotrexate, leucovorin, capecitabine, cytarabine, floxuridine, fludarabine, gemcitabine, pemetrexed, raltitrexed, etc.), plant alkaloids (e.g.,100659216541vincristine, vinblastine, vinorelbine, vindesine, podophyllotoxin, paclitaxel (taxol), docetaxel, etc.), topoisomerase inhibitors (e.g., irinotecan (CPT-11; Camptosar), topotecan, amsacrine, etoposide (VP16), etoposide phosphate, teniposide, etc.), antitumor antibiotics (e.g., doxorubicin, adriamycin, daunorubicin, epirubicin, actinomycin, bleomycin, mitomycin, mitoxantrone, plicamycin, etc.), tyrosine kinase inhibitors (e.g., gefitinib (Iressa®), sunitinib (Sutent®; SU11248), erlotinib (Tarceva®; OSI-1774), lapatinib (GW572016; GW2016), canertinib (Cl 1033), semaxinib (SU5416), vatalanib (PTK787 / ZK222584), sorafenib (BAY 43-9006), imatinib (Gleevec®; STI571), dasatinib (BMS-354825), leflunomide (SLI101), vandetanib (Zactima™; ZD6474), etc.), pharmaceutically acceptable salts thereof, stereoisomers thereof, derivatives thereof, analogs thereof, and combinations thereof.
[0170] Examples of conventional hormonal therapeutic agents include, without limitation, steroids (e.g., dexamethasone), finasteride, aromatase inhibitors, tamoxifen, and goserelin as well as other gonadotropin-releasing hormone agonists (GnRH).
[0171] Examples of conventional immunotherapeutic agents include, but are not limited to, immunostimulants (e.g., Bacillus Calmette-Guerin (BCG), levamisole, interleukin-2, alpha-interferon, etc.), monoclonal antibodies (e.g., anti-CD20, anti-HER2, anti-CD52, anti-HLA-DR, and anti-VEGF monoclonal antibodies), immunotoxins (e.g., anti-CD33 monoclonal antibody-calicheamicin conjugate, anti-CD22 monoclonal antibody-pseudomonas exotoxin conjugate, etc.), and radioimmunotherapy (e.g., anti-CD20 monoclonal antibody conjugated to1111n,90Y, or131l etc.).
[0172] Examples of conventional radiotherapeutic agents include, but are not limited to, radionuclides suchas47Sc,64Cu,67Cu,37Sr,86Y,37Y,90Y,105Rh,111Ag,1111n,117mSn,149Pm,153Sm,166Ho,177Lu,186Re,188Re,211At, and212Bi, optionally conjugated to antibodies directed against tumor antigens.
[0173] Additional oncology drugs that may be used according to the disclosure include, but are not limited to, alkeran, allopurinol, altretamine, amifostine, anastrozole, araC, arsenic trioxide, bexarotene, biCNll, carmustine, CCNll, celecoxib, cladribine, cyclosporin A, cytosine arabinoside, cytoxan, dexrazoxane, DTIC, estramustine, exemestane, FK506, gemtuzumab-ozogamicin, hydrea, hydroxyurea, idarubicin, interferon, letrozole, leustatin, leuprolide, litertinoin, megastrol, L-PAM, mesna,100659216542methoxsalen, mithramycin, nitrogen mustard, pamidronate, Pegademase, pentostatin, porfimer sodium, prednisone, rituxan, streptozocin, STI-571, taxotere, temozolamide, VM-26, toremifene, tretinoin, ATRA, valrubicin, and velban. Other examples of oncology drugs that may be used according to the disclosure are ellipticin and ellipticin analogs or derivatives, epothilones, intracellular kinase inhibitors, and camptothecins.
[0174] Non-limiting examples of lipid-lowering agents for treating a lipid disease or disorder associated with elevated triglycerides, cholesterol, and / or glucose include statins, fibrates, ezetimibe, thiazolidinediones, niacin, beta-blockers, nitroglycerin, calcium antagonists, fish oil, and mixtures thereof.
[0175] Examples of anti-viral drugs include, but are not limited to, abacavir, aciclovir, acyclovir, adefovir, amantadine, amprenavir, arbidol, atazanavir, atripla, cidofovir, combivir, darunavir, delavirdine, didanosine, docosanol, edoxudine, efavirenz, emtricitabine, enfuvirtide, entecavir, entry inhibitors, famciclovir, fixed dose combinations, fomivirsen, fosamprenavir, foscarnet, fosfonet, fusion inhibitors, ganciclovir, ibacitabine, imunovir, idoxuridine, imiquimod, indinavir, inosine, integrase inhibitors, interferon type III (e.g., IFN-A molecules such as IFN-A1, IFN-A2, and IFN-A3), interferon type II (e.g., IFN-y), interferon type I (e.g., IFN-a such as PEGylated IFN-a, IFN-p, IFN-K, IFN-6, IFN-E, IFN-T, IFN-CO, and I FN- , interferon, lamivudine, lopinavir, loviride, MK-0518, maraviroc, moroxydine, nelfinavir, nevirapine, nexavir, nucleoside analogues, oseltamivir, penciclovir, peramivir, pleconaril, podophyllotoxin, protease inhibitors, reverse transcriptase inhibitors, ribavirin, rimantadine, ritonavir, saquinavir, stavudine, synergistic enhancers, tenofovir, tenofovir disoproxil, tipranavir, trifluridine, trizivir, tromantadine, truvada, valaciclovir, valganciclovir, vicriviroc, vidarabine, viramidine, zalcitabine, zanamivir, zidovudine, pharmaceutically acceptable salts thereof, stereoisomers thereof, derivatives thereof, analogs thereof, and mixtures thereof.
[0176] Additional drugs include zotarolimus, sirolimus, rapamycin, everolimus, biolimus, myolimus, novolimus, temsirolimus, deforolimus, merilimus, tacrolimus, pimecrolimus, ridaforolimus pharmaceutically acceptable salts thereof, stereoisomers thereof, derivatives thereof, analogs thereof, and mixtures thereof.100659216543Preparation of hydrogels
[0177] Preparation of hydrogels of the present invention may be divided into two stages: (1) self-assembly of the compound to form a secondary structure and aggregation to form nanofibers; (2) elongation, association, and entanglement of the nanofibers to form a three-dimensional network.
[0178] Self-assembly of the compounds described in the present disclosure may form a hydrogel through one or more of: modulating the amino acid sequence, changing the pH of the solution to induce gel formation, changing the chirality of the amino acids, increasing the number of aromatic residues to induce hydrogel formation through TT-TT stacking.
[0179] For example, the present disclosure provides a process for producing a hydrogel, the process comprising the steps of adding water to a compound according to any one of the herein disclosed embodiments, thereby forming a hydrogel.
[0180] In some embodiments, the process further comprises the step of adding a basic solution and / or an acidic solution.
[0181] In some embodiments, the process further comprises the step of adding a physiological buffer.
[0182] In some embodiments, the process further comprises the step of adjusting the pH to about 7.4.
[0183] In some embodiments, adjusting the pH comprises addition of a base and / or an acid.
[0184] In some embodiments, the base is NaOH.
[0185] In some embodiments, the acid is HCI.
[0186] In some embodiments, the process further comprises mixing the solution to dissolve the compound. Preferably, the mixing is performed by sonication.100659216544Characterization of mechanical properties of hydrogel
[0187] It will be appreciated that hydrogels loaded with an active agent, can be prepared using similar methods described herein to prepare a hydrogel per se (without the active agent), albeit that the active agent is included in the compound mixture prior to or at the time of gelation. In further embodiments, the hydrogel may be loaded with an active agent following gelation, eg by soaking a hydrogel made according to the disclosure, in a solution comprising the active agent. In alternative embodiments, the hydrogel may be loaded with an active agent by vortexing or mixing a hydrogel made according to the disclosure with a solution comprising one or more active agents.
[0188] In preferred embodiments, the active agent is not covalently linked to the compound capable of self assembly.
[0189] Methods for assessing the elasticity of a hydrogel are known in the art, including as described herein in Example 1. The term “elasticity” as used herein means a property as solid when applying force to an object, that is, a property of changing the form when applying force, but returning to the original form when removing force. This elasticity is represented by storage modulus (G': elastic modulus), and its unit is pascal (Pa).
[0190] Preferably, the elasticity of the hydrogels of the disclosure can be assessed or measured according to Young’s modulus, which is a mechanical property that measure the tensile or compressive stiffness of a solid material when a force is applied lengthwise. It quantifies the relationship between tensile / compressive stress o (force per unit area) and axial strain E (proportional deformation) in the linear elastic region of a material and is determined using the formula:E = O / E
[0191] A higher Young's modulus corresponds to greater (lengthwise) stiffness.
[0192] In a preferred embodiment, the hydrogels of the disclosure comprise a Young’s Modulus of from about 1,000 Pa to about 10,000 Pa.
[0193] As used herein, the term viscosity used herein means a property as liquid, that is, the quantity that describes a fluid's resistance to flow. This viscosity may be represented by loss modulus (G": viscous modulus) and its unit is pascal (Pa). It will be within the purview of the skilled person to assess the viscosity of a hydrogel obtained100659216545according to the disclosure to confirm that the hydrogel has sufficient viscosity to persist at the site of administration.
[0194] In certain embodiments, the injectable hydrogel of the disclosure may be extrudable to any length as it exhibits shear thinning behaviour under an applied force. In certain embodiments, the injectable hydrogel of the disclosure may be extrudable to at least a length of at least about 5 cm. In certain embodiments, the injectable hydrogel is extrudable to a length of from about 5 cm to about 30 cm or longer.
[0195] Preferably, the hydrogel of the disclosure may be extrudable through a cannular, a catheter, a flexible polymer catheter, a syringe without a needle, such as a syringe with a tip or nozzle, or a syringe with a needle of from about 0.1 mm to 2 mm, or from about 0.1 mm to about 1 mm, or from 0.1 mm to about 0.5 mm, or from 0.1 mm to about 0.4 mm, or from 0.1 mm to about 0.3 mm. Preferably, the hydrogel of the disclosure may be extrudable through a 25 gauge needle, for example that has an internal diameter of about 0.15-0.26 mm.
[0196] The hydrogels of the disclosure preferably comprise a homogenous structure and consistent physical characteristics throughout the gel to ensure reliable and reproducible drug release.
[0197] In further preferred embodiments, the hydrogels of the disclosure comprise a uniform microscale stiffness across the gel surface, and which can optionally be assessed using quantitative micro-elastography.
[0198] In preferred embodiments, the hydrogels of the disclosure provide sustained, consistent and prolonged degradation and release of the therapeutic agent contained therein, over a 6 hour period, over a 12 hour period, or over a 24 hour period, or over a 2 day period, or over a 3 day period, or over a 7 day period, or over a 14 day period, or over a 28 day period following application. Preferably, the peptide is not significantly degradable by biological and metabolic activity of cells and tissues over this period of time, e.g. over a 6 hour period, over a 12 hour period, or over a 24 hour period, or over a 2 day period, or over a 3 day period, or over a 7 day period, or over a 14 day period, or over a 28 day period.100659216546
[0199] In a preferred embodiment, a hydrogel of the disclosure has sufficient flow that it can be injected in and around a tissue site, and / or conform to the shape of the tissue site.
[0200] In certain embodiments, a hydrogel of the disclosure may remain acceptably intact and / or persist at the site of administration for a period of at least 4 days, at least 1 week, at least 2 weeks, at least 3 weeks, at least 1 month, at least 2 months, at least 3 months or more. Preferably, the hydrogels of the disclosure may persist in vivo for at least 1 month, preferably at least about 2 months.
[0201] In another aspect, the present disclosure provides a protease comprising, consisting essentially of or consisting of an amino acid sequence of any one of SEQ ID NO: 8 to 21 , 52 or 53, or an amino acid sequence having at least 80%, 81 %, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to an amino acid sequence of any one of SEQ ID NO: 8 to 21 , 52 or 53.
[0202] In one embodiment, the present disclosure provides a protease comprising, consisting essentially of or consisting of an amino acid sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to an amino acid sequence of any one of SEQ ID NO: 8 to 21, 52 or 53, wherein the variation is one or more additions, substitutions (e.g. conservative substitutions) or deletions, and those additions, substitutions (e.g. conservative substitutions) or deletions are not at residue positions 46, 81 , 139, 146, 148, 149, 151, 167, 168, 169, 170, 171, 172, 174, 176, 178, 209, 211, 214, 215, 216, 217, 218, 219 and 220, or residue positions equivalent to 46, 81, 139, 146, 148, 149, 151, 167, 168, 169, 170, 171, 172, 174, 176, 178, 209, 211, 214, 215, 216, 217, 218, 219 and 220, wherein the numbering is accordance with SEQ ID NO: 29 or SEQ ID NO: 29 where position 219 is S. Preferably, any protease with one or more variations to an amino acid sequence of any one of SEQ ID NO: 8 to 21, 52 or 53 exhibits 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% activity compared to a protease that is identical (e.g. 100% identical) in amino acid sequence to any one of SEQ ID NO: 8 to 21 , 52 or 53. The activity may be any one described herein and typically as measured by a method of anyone as described herein.100659216547
[0203] As used herein an amino acid residue at the position equivalent to position in SEQ ID NO: 29 can be determined by any means known to a person skilled in the art. For example, an alignment of one or more sequences with an amino acid sequence of SEQ ID NO: 29 would allow a person skilled in the art to determine the amino acid at the position equivalent to position in SEQ ID NO: 29. A person skilled in the art can compare the three-dimensional structure of a polypeptide with the three dimensional structure of a polypeptide having the amino acid sequence of SEQ ID NO: 29 and determine the amino acid residue that is at an equivalent position to that in SEQ ID NO: 29.
[0204] "Isolated," when used to describe the various polypeptides disclosed herein, means the polypeptide that has been identified and separated and / or recovered from a component of its natural environment. Contaminant components of its natural environment are materials that would typically interfere with diagnostic or therapeutic uses for the polypeptide, and may include enzymes, hormones, and other proteinaceous or non-proteinaceous solutes. In preferred embodiments, the polypeptide will be purified (1) to a degree sufficient to obtain at least 15 residues of N-terminal or internal amino acid sequence by use of a spinning cup sequenator, or (2) to homogeneity by SDS-PAGE under non-reducing or reducing conditions using Coomassie blue or, preferably, silver stain. Isolated protein includes polypeptide in situ within recombinant cells, since at least one component of the polypeptide natural environment will not be present. Ordinarily, however, isolated polypeptide will be prepared by at least one purification step.
[0205] A "fragment" is a portion of a polypeptide of the present disclosure that retains substantially similar functional activity or substantially the same biological function or activity as the polypeptide, which can be determined using assays described herein.
[0206] “Percent (%) amino acid sequence identity” or “percent (%) identical” with respect to a polypeptide sequence, i.e. a polypeptide of the disclosure defined herein, is defined as the percentage of amino acid residues in a candidate sequence that are identical with the amino acid residues in the specific polypeptide of the disclosure, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, and not considering any conservative substitutions as part of the sequence identity.100659216548
[0207] Those skilled in the art can determine appropriate parameters for measuring alignment, including any algorithms (non-limiting examples described below) needed to achieve maximal alignment over the full-length of the sequences being compared. When amino acid sequences are aligned, the percent amino acid sequence identity of a given amino acid sequence A to, with, or against a given amino acid sequence B (which can alternatively be phrased as a given amino acid sequence A that has or comprises a certain percent amino acid sequence identity to, with, or against a given amino acid sequence B) can be calculated as: percent amino acid sequence identity = X / Y100, where X is the number of amino acid residues scored as identical matches by the sequence alignment program's or algorithm's alignment of A and B and Y is the total number of amino acid residues in B. If the length of amino acid sequence A is not equal to the length of amino acid sequence B, the percent amino acid sequence identity of A to B will not equal the percent amino acid sequence identity of B to A.
[0208] In calculating percent identity, typically exact matches are counted. The determination of percent identity between two sequences can be accomplished using a mathematical algorithm. A nonlimiting example of a mathematical algorithm utilized for the comparison of two sequences is the algorithm of Karlin and Altschul (1990) Proc. Natl. Acad. Sci. USA 87:2264, modified as in Karlin and Altschul (1993) Proc. Natl. Acad. Sci. USA 90:5873-5877. Such an algorithm is incorporated into the BLASTN and BLASTX programs of Altschul et al. (1990) J. Mol. Biol. 215:403. To obtain gapped alignments for comparison purposes, Gapped BLAST (in BLAST 2.0) can be utilized as described in Altschul et al. (1997) Nucleic Acids Res. 25:3389. Alternatively, PSI-Blast can be used to perform an iterated search that detects distant relationships between molecules. See Altschul et al. (1997) supra. When utilizing BLAST, Gapped BLAST, and PSI-Blast programs, the default parameters of the respective programs (e.g., BLASTX and BLASTN) can be used. Alignment may also be performed manually by inspection. Another non- limiting example of a mathematical algorithm utilized for the comparison of sequences is the ClustalW algorithm (Higgins etal. (1994) Nucleic Acids Res. 22:4673-4680). ClustalW compares sequences and aligns the entirety of the amino acid or DNA sequence, and thus can provide data about the sequence conservation of the entire amino acid sequence. The ClustalW algorithm is used in several commercially available DNA / amino acid analysis software packages, such as the ALIGNX module of the Vector NTI Program Suite (Invitrogen Corporation, Carlsbad, CA). After alignment of amino acid sequences with ClustalW, the percent amino acid100659216549identity can be assessed. A non-limiting examples of a software program useful for analysis of ClustalW alignments is GENEDOC™ or JalView (http: / / www.jalview.org / ). GENEDOC™ allows assessment of amino acid (or DNA) similarity and identity between multiple proteins. Another non- limiting example of a mathematical algorithm utilized for the comparison of sequences is the algorithm of Myers and Miller (1988) CABIOS 4:11-17. Such an algorithm is incorporated into the ALIGN program (version 2.0), which is part of the GCG Wisconsin Genetics Software Package, Version 10 (available from Accelrys, Inc., 9685 Scranton Rd., San Diego, CA, USA). When utilizing the ALIGN program for comparing amino acid sequences, a PAM 120 weight residue table, a gap length penalty of 12, and a gap penalty of 4 can be used.
[0209] The polypeptide desirably comprises an amino end and a carboxyl end. The polypeptide can comprise D-amino acids, L-amino acids or a mixture of D- and L-amino acids. The D-form of the amino acids, however, is particularly preferred since a polypeptide comprised of D-amino acids is expected to have a greater retention of its biological activity in vivo.
[0210] The polypeptide can be prepared by any of a number of conventional techniques. The polypeptide can be isolated or purified from a naturally occurring source or from a recombinant source. Recombinant production is preferred. For instance, in the case of recombinant polypeptides, a DNA fragment encoding a desired peptide can be subcloned into an appropriate vector using well-known molecular genetic techniques (see, e.g., Maniatis et al., Molecular Cloning: A Laboratory Manual, 2nd ed. (Cold Spring Harbor Laboratory, 1982); Sambrook et al., Molecular Cloning A Laboratory Manual, 2nd ed. (Cold Spring Harbor Laboratory, 1989). The fragment can be transcribed and the polypeptide subsequently translated in vitro. Commercially available kits also can be employed (e.g., such as manufactured by Clontech, Palo Alto, Calif.; Amersham Pharmacia Biotech Inc., Piscataway, N.J.; InVitrogen, Carlsbad, Calif., and the like). The polymerase chain reaction optionally can be employed in the manipulation of nucleic acids.
[0211] The term "conservative substitution" as used herein, refers to the replacement of an amino acid present in the native sequence in the peptide with a naturally or non-naturally occurring amino acid or a peptidomimetic having similar steric properties. Where the side-chain of the native amino acid to be replaced is either polar or hydrophobic, the conservative substitution should be with a naturally occurring amino100659216550acid, a non- naturally occurring amino acid or with a peptidomimetic moiety which is also polar or hydrophobic (in addition to having the same steric properties as the sidechain of the replaced amino acid).
[0212] Conservative amino acid substitution tables providing functionally similar amino acids are well known to one of ordinary skill in the art. The following six groups are examples of amino acids that may be considered to be conservative substitutions for one another:1) Alanine (A), Serine (S), Threonine (T);2) Aspartic acid (D), Glutamic acid (E);3) Asparagine (N), Glutamine (Q);4) Arginine (R), Lysine (K);5) Isoleucine (I), Leucine (L), Methionine (M), Valine (V); and6) Phenylalanine (F), Tyrosine (Y), Tryptophan (W).
[0213] As naturally occurring amino acids are typically grouped according to their properties, conservative substitutions by naturally occurring amino acids can be determined bearing in mind the fact that replacement of charged amino acids by sterically similar non-charged amino acids are considered as conservative substitutions. For producing conservative substitutions by non-naturally occurring amino acids it is also possible to use amino acid analogs (synthetic amino acids) well known in the art. A peptidomimetic of the naturally occurring amino acid is well documented in the literature known to the skilled person and non-natural or unnatural amino acids are described further below. When affecting conservative substitutions the substituting amino acid should have the same or a similar functional group in the side chain as the original amino acid.
[0214] The phrase "non-conservative substitution" or a “non-conservative residue” as used herein refers to replacement of the amino acid as present in the parent sequence by another naturally or non-naturally occurring amino acid, having different electrochemical and / or steric properties. Thus, the side chain of the substituting amino acid can be significantly larger (or smaller) than the side chain of the native amino acid100659216551being substituted and / or can have functional groups with significantly different electronic properties than the amino acid being substituted. Examples of non-conservative substitutions of this type include the substitution of phenylalanine or cycohexylmethyl glycine for alanine, isoleucine for glycine, or -NH-CH[(-CH2)5-COOH]-CO- for aspartic acid. Non-conservative substitution includes any mutation that is not considered conservative.
[0215] A non-conservative amino acid substitution can result from changes in: (a) the structure of the amino acid backbone in the area of the substitution; (b) the charge or hydrophobicity of the amino acid; or (c) the bulk of an amino acid side chain.Substitutions generally expected to produce the greatest changes in protein properties are those in which: (a) a hydrophilic residue is substituted for (or by) a hydrophobic residue; (b) a proline is substituted for (or by) any other residue; (c) a residue having a bulky side chain, e.g., phenylalanine, is substituted for (or by) one not having a side chain, e.g., glycine; or (d) a residue having an electropositive side chain, e.g., lysyl, arginyl, or histadyl, is substituted for (or by) an electronegative residue, e.g., glutamyl or aspartyl.
[0216] Alterations of the native amino acid sequence to produce mutant polypeptides, such as by insertion, deletion and / or substitution, can be done by a variety of means known to those skilled in the art. For instance, site-specific mutations can be introduced by ligating into an expression vector a synthesized oligonucleotide comprising the modified site. Alternately, oligonucleotide-directed site-specific mutagenesis procedures can be used, such as disclosed in Walder et al., Gene 42: 133 (1986); Bauer et al., Gene 37: 73 (1985); Craik, Biotechniques, 12-19 (January 1995); and U.S. Pat. Nos. 4,518,584 and 4,737,462. A preferred means for introducing mutations is the QuikChange Site-Directed Mutagenesis Kit (Stratagene, LaJolla, Calif.).
[0217] Any appropriate expression vector (e.g., as described in Pouwels et al., Cloning Vectors: A Laboratory Manual (Elsevier, N.Y.: 1985)) and corresponding suitable host can be employed for production of recombinant polypeptides. Expression hosts include, but are not limited to, bacterial species within the genera Escherichia, Bacillus, Pseudomonas, Salmonella, mammalian or insect host cell systems including baculovirus systems (e.g., as described by Luckow et al., Bio / Technology 6: 47 (1988)), and established cell lines such as the COS-7, C127, 3T3, CHO, HeLa, and BHK cell lines, and the like. The skilled person is aware that the choice of expression host has100659216552ramifications for the type of polypeptide produced. For instance, the glycosylation of polypeptides produced in yeast or mammalian cells (e.g., COS-7 cells) will differ from that of polypeptides produced in bacterial cells, such as Escherichia coli.
[0218] Alternately, a compound, protease, polypeptide or peptide of the disclosure can be synthesized using standard peptide synthesizing techniques well-known to those of ordinary skill in the art (e.g., as summarized in Bodanszky, Principles of Peptide Synthesis (Springer-Verlag, Heidelberg: 1984)). In particular, a compound, protease, polypeptide or peptide can be synthesized using the procedure of solid-phase synthesis (see, e.g., Merrifield, J. Am. Chem. Soc. 85: 2149-54 (1963); Barany et al., Int. J.Peptide Protein Res. 30: 705-739 (1987); and U.S. Pat. No. 5,424,398). If desired, this can be done using an automated peptide synthesizer. Removal of the t-butyloxycarbonyl (t-BOC) or 9-fluorenylmethyloxycarbonyl (Fmoc) amino acid blocking groups and separation of the polypeptide from the resin can be accomplished by, for example, acid treatment at reduced temperature. The polypeptide-containing mixture can then be extracted, for instance, with dimethyl ether, to remove non-peptidic organic compounds, and the synthesized polypeptide can be extracted from the resin powder (e.g., with about 25% w / v acetic acid). Following the synthesis, further purification (e.g., using high performance liquid chromatography (HPLC)) optionally can be done in order to eliminate any incomplete polypeptides or free amino acids. Amino acid and / or HPLC analysis can be performed on the synthesized a compound, protease, polypeptide or peptide to validate its identity. For other applications according to the disclosure, it may be preferable to produce the protease, polypeptide or peptide as part of a larger fusion protein, such as by the methods described herein or other genetic means, or as part of a larger conjugate, such as through physical or chemical conjugation, as known to those of ordinary skill in the art and described herein.
[0219] Modifications contemplated herein include, but are not limited to, modification to side chains, incorporating of unnatural amino acids and / or their derivatives during polypeptide synthesis and the use of crosslinkers and other methods which impose conformational constraints on the polypeptides of the disclosure. Any modification, including post-translational modification, that reduces the capacity of the molecule to form a dimer is contemplated herein. An example includes modification incorporated by click chemistry as known in the art. Exemplary modifications include PEGylation and glycosylation.100659216553
[0220] Examples of side chain modifications contemplated by the present disclosure include modifications of amino groups such as by reductive alkylation by reaction with an aldehyde followed by reduction with NaBH4; amidination with methylacetimidate; acylation with acetic anhydride; carbamoylation of amino groups with cyanate; trinitrobenzylation of amino groups with 2, 4, 6-trinitrobenzene sulphonic acid (TNBS); acylation of amino groups with succinic anhydride and tetrahydrophthalic anhydride; and pyridoxylation of lysine with pyridoxal-5-phosphate followed by reduction with NaBH4.
[0221] The guanidine group of arginine residues may be modified by the formation of heterocyclic condensation products with reagents such as 2,3-butanedione, phenylglyoxal and glyoxal.
[0222] The carboxyl group may be modified by carbodiimide activation via O-acylisourea formation followed by subsequent derivatisation, for example, to a corresponding amide.
[0223] Sulphydryl groups may be modified by methods such as carboxymethylation with iodoacetic acid or iodoacetamide; performic acid oxidation to cysteic acid; formation of a mixed disulphides with other thiol compounds; reaction with maleimide, maleic anhydride or other substituted maleimide; formation of mercurial derivatives using 4-chloromercuribenzoate, 4-chloromercuriphenylsulphonic acid, phenylmercury chloride, 2-chloromercuri-4-nitrophenol and other mercurials; carbamoylation with cyanate at alkaline pH.
[0224] Tryptophan residues may be modified by, for example, oxidation with N-bromosuccinimide or alkylation of the indole ring with 2-hydroxy-5-nitrobenzyl bromide or sulphenyl halides. Tyrosine residues on the other hand, may be altered by nitration with tetranitromethane to form a 3-nitrotyrosine derivative.
[0225] Modification of the imidazole ring of a histidine residue may be accomplished by alkylation with iodoacetic acid derivatives or N-carboethoxylation with diethylpyrocarbonate.
[0226] Examples of incorporating unnatural amino acids and derivatives during protein synthesis include, but are not limited to, use of norleucine, 4-amino butyric acid, 4-amino-3-hydroxy-5-phenylpentanoic acid, 6-aminohexanoic acid, t-butylglycine,100659216554norvaline, phenylglycine, ornithine, sarcosine, 4-amino-3-hydroxy-6-methylheptanoic acid, 2-thienyl alanine and / or D-isomers of amino acids.Nucleic acids
[0227] Nucleic acid molecules that encode a polypeptide or protease of the disclosure are also within the scope of the disclosure.
[0228] The nucleic acids are useful, for example, in making the polypeptide or protease of the present disclosure. They may be administered to cells in culture or in vivo and may include a secretory signal that directs or facilitates secretion of the protease of the disclosure from the cell. Also within the scope of the disclosure are expression vectors and host cells that contain or include nucleic acids of the disclosure (described further below). While the nucleic acids of the disclosure may be referred to as “isolated,” by definition, the polypeptides of the disclosure are not wild-type polypeptides and, as such, would not be encoded by naturally occurring nucleic acids. Thus, while the polypeptides, proteases and nucleic acids of the present disclosure may be “purified,” “substantially purified,” “isolated,” “recombinant” or “synthetic” they need not be so in order to be distinguished from naturally occurring materials.
[0229] The terms “nucleic acid molecule” and “polynucleotide” are used interchangeably herein and refer to a polymeric form of nucleotides of any length, either deoxyribonucleotides or ribonucleotides, or analogs thereof. Non-limiting examples of polynucleotides include a gene, a gene fragment, messenger RNA (mRNA), cDNA, recombinant polynucleotides, plasmids, vectors, isolated DNA of any sequence, isolated RNA of any sequence, nucleic acid probes, and primers. A polynucleotide of the disclosure may be provided in isolated or purified form. A nucleic acid sequence which “encodes” a selected polypeptide is a nucleic acid molecule which is transcribed (in the case of DNA) and translated (in the case of mRNA) into a polypeptide in vivo when placed under the control of appropriate regulatory sequences. The boundaries of the coding sequence are determined by a start codon at the 5' (amino) terminus and a translation stop codon at the 3' (carboxy) terminus. For the purposes of the disclosure, such nucleic acid sequences can include, but are not limited to, cDNA from viral, prokaryotic or eukaryotic mRNA, genomic sequences from viral or prokaryotic DNA or RNA, and even synthetic DNA sequences. A transcription termination sequence may be located 3' to the coding sequence.100659216555
[0230] Polynucleotides of the disclosure can be synthesised according to methods well known in the art, as described by way of example in Sambrook et al (1989, Molecular Cloning — a laboratory manual; Cold Spring Harbor Press).
[0231] The polynucleotide molecules of the present disclosure may be provided in the form of an expression cassette which includes control sequences operably linked to the inserted sequence, thus allowing for expression of the polypeptide of the disclosure in vivo in a targeted subject. These expression cassettes, in turn, are typically provided within vectors (e.g., plasmids or recombinant viral vectors).
[0232] Expression vectors are routinely constructed in the art of molecular biology and may for example involve the use of plasmid DNA and appropriate initiators, promoters, enhancers and other elements, such as for example polyadenylation signals which may be necessary, and which are positioned in the correct orientation, in order to allow for expression of a polypeptide or protease of the disclosure. Other suitable vectors would be apparent to persons skilled in the art. By way of further example in this regard the inventors refer to Sambrook et al.
[0233] Thus, a polypeptide or protease of the disclosure may be provided by delivering such a vector to a cell and allowing transcription from the vector to occur. Preferably, a polynucleotide of the disclosure or for use in a vector is operably linked to a control sequence which is capable of providing for the expression of the coding sequence by the host cell, i.e. the vector is an expression vector.
[0234] “Operably linked” refers to an arrangement of elements wherein the components so described are configured so as to perform their usual function. Thus, a given regulatory sequence, such as a promoter, operably linked to a nucleic acid sequence is capable of effecting the expression of that sequence when the proper enzymes are present. The promoter need not be contiguous with the sequence, so long as it functions to direct the expression thereof. Thus, for example, intervening untranslated yet transcribed sequences can be present between the promoter sequence and the nucleic acid sequence and the promoter sequence can still be considered “operably linked” to the coding sequence.
[0235] A number of expression systems have been described in the art, each of which typically consists of a vector containing a gene or nucleotide sequence of interest100659216556operably linked to expression control sequences. These control sequences include transcriptional promoter sequences and transcriptional start and termination sequences. The vectors of the disclosure may be for example, plasmid, virus or phage vectors provided with an origin of replication, optionally a promoter for the expression of the said polynucleotide and optionally a regulator of the promoter. A “plasmid” is a vector in the form of an extra-chromosomal genetic element. The vectors may contain one or more selectable marker genes, for example an ampicillin resistance gene in the case of a bacterial plasmid or a resistance gene for a fungal vector. Vectors may be used in vitro, for example for the production of DNA or RNA or used to transfect or transform a host cell, for example, a mammalian host cell. The vectors may also be adapted to be used in vivo, for example to allow in vivo expression of the polypeptide.
[0236] A “promoter” is a nucleotide sequence which initiates and regulates transcription of a polypeptide-encoding polynucleotide. Promoters can include inducible promoters (where expression of a polynucleotide sequence operably linked to the promoter is induced by an analyte, cofactor, regulatory protein, etc.), repressible promoters (where expression of a polynucleotide sequence operably linked to the promoter is repressed by an analyte, cofactor, regulatory protein, etc.), and constitutive promoters. It is intended that the term “promoter” or “control element” includes full-length promoter regions and functional (e.g., controls transcription or translation) segments of these regions.
[0237] A polynucleotide, expression cassette or vector according to the present disclosure may additionally comprise a signal peptide sequence. The signal peptide sequence is generally inserted in operable linkage with the promoter such that the signal peptide is expressed and facilitates secretion of a polypeptide encoded by coding sequence also in operable linkage with the promoter.
[0238] Typically a signal peptide sequence encodes a peptide of 10 to 30 amino acids for example 15 to 20 amino acids. Often the amino acids are predominantly hydrophobic. In a typical situation, a signal peptide targets a growing polypeptide chain bearing the signal peptide to the endoplasmic reticulum of the expressing cell. The signal peptide is cleaved off in the endoplasmic reticulum, allowing for secretion of the polypeptide via the Golgi apparatus. Thus, a peptide of the disclosure may be provided to an individual by expression from cells within the individual, and secretion from those cells.100659216557Methods of treatment
[0239] In another aspect, the present disclosure provides a method of releasing an active agent comprising contacting a hydrogel or composition comprising an active agent as described herein with a protease as described herein, thereby releasing the active agent.
[0240] In another aspect, the present disclosure provides a method of releasing an active agent in an individual, the method comprising:- administering a hydrogel or composition comprising an active agent as described herein to the individual; and subsequently- administering a protease as described herein to the individual,thereby releasing an active agent in the individual.
[0241] In another aspect, the present disclosure provides a method of delivering an active agent in an individual, the method comprising:- administering a hydrogel or composition comprising an active agent as described herein to the individual; and subsequently- administering a protease as described herein to the individual,thereby releasing an active agent in the individual.
[0242] In another aspect, the present disclosure provides a method of treating or preventing a disease or condition in an individual, the method comprising:- administering a hydrogel or composition comprising an active agent for treating or preventing the disease or condition to the individual; and subsequently - administering a protease as described herein to the individual,thereby treating or preventing the disease or condition in the individual.
[0243] In aspect, the present disclosure further provides use of a hydrogel or composition as described herein, in the manufacture of a medicament for:- releasing an active agent in an individual, or100659216558treating or preventing the disease or condition to the individual.
[0244] Further, the disclosure provides a hydrogel or composition as described herein, for use in treating or preventing the disease or condition in the individual.
[0245] The disease or condition may be any one described herein, including diseases or conditions caused by, or associated with, protein dysfunction or dysregulation.
[0246] Exemplary diseases or conditions include those of affecting one or more parts or cell types of the brain.
[0247] In some embodiments, the disease or condition may include one or more of brain injury, retinal diseases (including inherited retinal diseases), cancer, bacterial infection, or pain. For example:- brain tissue regeneration after brain injury through reprogramming reactive inflammatory cells (astrocyte and microglia) into active neural cells;- facilitating the delivery of viral vectors in the eye for the treatment of inherited retinal diseases;- filler for the tumor cavity after a craniotomy, as both a filler / scaffold for the surrounding cells to regenerate tissue, and as a delivery system for an anticancer drug;- filler and antibacterial agent delivery system for skin injuries. Due to the high content of water in the hydrogel structure, it can facilitate treatment and pain relief.
[0248] As used herein, the term “individual” or “subject” may be used interchangeably and shall be taken to mean any animal including humans, for example a mammal. Exemplary subjects include but are not limited to humans and non-human primates. For example, the subject is a human.
[0249] The words “treat” or “treatment” refer to therapeutic treatment wherein the object is to slow down (lessen) an undesired physiological change or disorder. For the purposes of this invention, beneficial or desired clinical results include, but are not limited to, alleviation of symptoms, diminishmentof extent of disease, stabilized (i.e., not worsening) state of disease, delay or slowing of disease progression, amelioration or palliation of the100659216559disease state, and remission (whether partial or total), whether detectable or undetectable. Treatment can also mean prolonging survival as compared to expected survival if not receiving treatment. Treatment may not necessarily result in the complete clearance of a disease or disorder but may reduce or minimise complications and side effects of infection and the progression of a disease or disorder.
[0250] By "therapeutically effective amount" is meant a dose that produces the effects for which it is administered. The exact dose will depend on the purpose of the treatment, and will be ascertainable by one skilled in the art using known techniques. As is known in the art and described above, adjustments for systemic versus localised delivery, age, body weight, general health, sex, diet, time of administration, drug interaction and the severity of the condition may be necessary, and will be ascertainable with routine experimentation by those skilled in the art.Kit
[0251] In another aspect, the present disclosure provides a kit comprising:- a compound capable of self-assembly as described herein, or a composition comprising a compound capable of self-assembly as described herein; and- a protease as described herein, or a composition comprising a protease as described herein.
[0252] In other embodiments there is provided a kit for use in a therapeutic or prophylactic application mentioned above, the kit including:- a container holding compound capable of self-assembly as described herein, or a composition comprising a compound capable of self-assembly as described herein;- a container holding a protease as described herein, or a composition comprising a protease as described herein;- a label or package insert with instructions for use.
[0253] Preferably, the instructions describe the use of the kit and components thereof in a method or use as described herein.100659216560
[0254] In certain embodiments the kit may contain one or more further active principles or ingredients for treatment of a disease or condition.
[0255] The kit or “article of manufacture” may comprise a container and a label or package insert on or associated with the container. Suitable containers include, for example, bottles, vials, syringes, blister pack, etc. The containers may be formed from a variety of materials such as glass or plastic. The container holds a therapeutic composition which is effective for treating the condition and may have a sterile access port (for example the container may be an intravenous solution bag or a vial having a stopper pierceable by a hypodermic injection needle). The label or package insert indicates that the therapeutic composition is used for treating the condition of choice. In one embodiment, the label or package insert includes instructions for use and indicates that the therapeutic or prophylactic composition can be used to treat a disease or condition described herein.
[0256] The kit may comprise (a) a therapeutic or prophylactic composition; and (b) a second container with a second active principle or ingredient contained therein. The kit in this embodiment of the disclosure may further comprise a package insert indicating the composition and other active principle can be used to treat a disorder or prevent a complication stemming from a disease or condition described herein. Alternatively, or additionally, the kit may further comprise a second (or third) container comprising a pharmaceutically-acceptable buffer, such as bacteriostatic water for injection (BWFI), phosphate-buffered saline, Ringer's solution and dextrose solution. It may further include other materials desirable from a commercial and user standpoint, including other buffers, diluents, filters, needles, and syringes.
[0257] In certain embodiments the therapeutic composition may be provided in the form of a device, disposable or reusable, including a receptacle for holding the therapeutic, prophylactic or pharmaceutical composition. In one embodiment, the device is a syringe. The device may hold 1-2 mL of the therapeutic composition. The therapeutic or prophylactic composition may be provided in the device in a state that is ready for use or in a state requiring mixing or addition of further components.100659216561Examples
[0258] The future success of gene therapy delivery technologies depends on the ability to engineer clinically plausible systems with improved control over the timing and location of delivery. While previously demonstrated SAP hydrogels protect fragile therapeutics and provide a standardised material from which they can passively diffuse to a target environment, previous efforts have been limited in temporal control or response elements.
[0259] The development of ERG (enzyme-responsive gel) and ERM (enzyme-responsive micelle) in this present disclosure demonstrates the potential for including response properties in these SAP frameworks, yielding responsive biomaterials with nanofibrillar and nanomicellar characteristics, respectively. The inventors have shown that by concurrently designing an exceptionally stable and functional variant of TEVp, BioSAS-TEVp, whose target cleavage site is embedded in ERG and ERM, it can be shown that bioorthogonal, biocompatible, stimulus-responsive systems have been developed through concomitant material and protein engineering. Most importantly, it has been shown that this system can be used in vitro and in vivo to deliver adeno-associated viruses in models of neural tissues.
[0260] The engineered systems described by the present disclosure in demonstrate bioorthogonal properties - they are systems in which both the delivery mechanism and stimulus can operate independently of the site of delivery. This offers surprising advantages including relevance to heterogeneous patient populations with differential gene expression profiles and versatility in target site applicability. Importantly, while proof-of-concept is demonstrated in astrocytes and the mouse brain, this approach represents a generalisable strategy for the development of readily injectable bioorthogonal nanomaterials for delivery of diverse therapeutics including proteins, small molecules and gene therapies in diverse tissues.Example 1 - Materials and MethodsPreparation of SAP hydrogels.
[0261] Fmoc-protected amino acids, hydroxybenzotriazole, O-benzotriazole-N,N,N’,N’- tetramethyl-uronium-hexafluoro-phosphate, Rink and Wang resins were100659216562purchased from GL Biochem (China). All other chemicals were purchased from Sigma-Aldrich.
[0262] ERM and ERG (detectable sequences of TEVp) and ECMRG (ECM resembling gel Fmoc-DIKVAVD (SEQ ID NO: 39), which is a control substrate for holding ERM that can resemble the extra cellular matrix), and ECMLRG (ECM laminine resembling gel Fmoc-DDIKVAV (SEQ ID NO: 40), which is a SAP hydrogel that provides the laminin functional epitopes for better cell attachment), were synthesised through manual solid-phase peptide synthesis for the first sequence optimizations. After assuring the sequence can form the desired nanostructures, all SAPs were custom made by GenScript (USA) in the form of freeze-dried powder with a purity of >98%.
[0263] SAP hydrogel preparation was performed with continuous vortexing of each sample.
[0264] The manual solid-phase method was conducted in a shaking plastic reactor vessel at a 0.2 mmol scale. Wang and Rink amide resins, as well as Fmoc- protected amino acids with the required side chain protecting groups, were purchased from GL Biochem (China). The peptide synthesis was conducted using stepwise deprotection of the N- terminal protecting group (Fmoc) by 20% piperidine in DMF followed by coupling of amino acids by adding Fmoc- protected amino acids (1 mmol) in Hydroxybenzotriazole (HOBt) (1 mmol), N, N-diisopropylethylamine (DI PEA) (1.5 mmol), and N, N'-Diisopropylcarbodiimide (DIC) (1.5 mmol), Dichloromethane (DCM) (5 mL). The peptides underwent the following cycle to reach a full sequence of the peptide.- Cleavage of the temporary protective group (Fmoc-group)- Washing step- Coupling to a protected amino acid- Washing stepIn each step, the deprotection and coupling procedures of the amino acids were tested through the Kaiser test, in which ninhydrin reacts with the free N-terminal of the amino acids and produces a blue colour. At the end of the synthesis, based on the desired nanostructure, the last Fmoc group was cleaved for ERM or remained uncleaved for ERG. For ERM, before the resin cleavage step, steps 1-4 were repeated to attach100659216563palmitic acid to the N-terminal of the sequence by using 1 -Pentadecanecarboxylic acid (palmitic acid) (1mmol), DIPEA (1 mmol) in DCM (5 mL) in coupling step. Then, resin and sidechain protecting groups were detached from the peptides by immersing them in the solution of trifluoroacetic acid (TFA) 95%, 2.5% distilled water, and 2.5% triethylsilane (TES). After 2 hours the solution was washed with diethyl ether and left in the rotary to evaporate the solvents.
[0265] To produce stable ERM peptide nanostructures with a positive charge under physiological conditions, 400pL MilliQ water (MQ) was added to the peptide powder (1, 2, 3, 4, 5, 10, 12.5, 15, and 20 mg) and sonicated for 20 minutes using a bath sonicator (DAI HAN Scientific (WUC-A03), 230 W, 50 Hz) at 80 °C. After sonication, the pH was adjusted to 7.4 by dropwise addition of 0.1 M NaOH. The desired concentration was achieved by adding PBS.
[0266] To produce a stable and self-supportive hydrogel from synthesized Fmoc-SAPs (ERG, ECMRG, and ECMLRG), 400pL MQ was added to each peptide powder, followed by 30 pL 0.5 M NaOH to dissolve the peptide. The pH was then adjusted to 7.4 by dropwise addition of 0.1 M HCI. Then, phosphate-buffered saline (PBS) was added to each peptide solution after gelation to dilute each to the desired concentration.
[0267] To confirm that adding ERM into another SAPs hydrogel does not have negative effect on the nanofiber’s formation and viscoelastic behaviour, ERM with two concentrations of 1, and 5 mg / ml were incorporated in the ECMRG as the control substrate. To do so, the ECMRG hydrogel was prepared with the same procedure, but the ERM solutions were added to the hydrogel instead of PBS to reach the desired concentration.
[0268] To confirm that adding ERG to the other types of Fmoc-SAP does not have negative impact on their self-assembling properties, ERG was mixed with ECMLRG before and after gelation.
[0269] For mixing before gelation (Co-assembly), the peptide powder of both ERG and ECMLRG with the ratio of 1:1 were mixed, then the same process of hydrogel preparation was conducted to reach a stable and self-supportive hydrogel.
[0270] For mixing after gelation (Mix), both hydrogel of ERG and ECMLRG were mixed through vortexing with a ratio of 1:1.100659216564Fourier Transform Infrared Spectroscopy
[0271] FTIR was conducted with an Alpha Platinum ATR FTIR (Bruker Optics) by placing 100 pL of the sample on a single reflection diamond. After collection of a background spectrum using MS, absorbance scans were collected in the 1550-1750 cm-1wavelength region.Circular Dichroism (CD)
[0272] CD experiments were performed using an Applied Photophysics Chirascan Spectrometer. ERG and ERM CD spectra were collected using a 10 mm quartz cuvette. Prepared hydrogels were diluted in MQ to 0.3 mg mL-1. A MQ baseline was collected prior to measurement of each sample. The circular dichroism spectrum of each hydrogel was measured in the wavelength of 180-260 nm, measuring every 1 nm.
[0273] BioSAS-TEVp CD spectra were collected using a 1 mm quartz cuvette.Purified protein samples were diluted to 1 mg mL-1in Mill i-Q® water. CD spectra were collected in duplicate from 200 nm to 250 nm, measuring every 0.5 nm.
[0274] BioSAS-TEVp and TEVp2M melt trajectories were collected using a 1 mm quartz cuvette. Purified protein samples were diluted to 1 mg mL-1in PBS buffer. Buffer-only blanks were performed with exactly matched dilutions prior to each experiment. Continuous CD melts were generated by recording at wavelengths of 208 nm and 222 nm from 25 °C to 94 °C at a rate of 1 °C min-1. A melt curve and melting temperature (Tm) was fit to each dataset in GraphPad Prism using a Boltzmann sigmoidal nonlinear regression according to the equation:rnO7Kl V — V i (Ymax-Ymin)I — Imin T rm-xRheology
[0276] Rheological analyses were performed using an Anton Paar MCR 702 TwinDrive with a cone plate configuration. To determine the rheological properties of each hydrogel, 250 pL of each hydrogel was placed on the centre of the sample holder. Each test was performed at 37° C with a shear strain of 0.1% and multiple frequency sweeps between 1-100 Hz.100659216565
[0277] To evaluate the shear thinning behaviour of each hydrogel, 250 pL of each hydrogel was placed on the centre of the sample holder. Each test applied continuous step-strain measurement, in which the applied oscillatory strain was changed from 0.1% to 100% after one minute at 1 Hz frequency. This cycle was repeated four times, with a 10 second decrease in the waiting time each cycle.Transmission Electron Microscopy
[0278] TEM was performed using a Thermo Scientific Talos L120C G2 (S)TEM with an operating voltage of 120 KV. Each sample was negatively stained prior to analysis by placing 4 pL of hydrogel on a copper grid coated with carbon support (EMSCFT300-Cll-25); after 1 minute of settling time, the sample was washed with a drop of MQ for five seconds and then stained by uranyl formate 1% (UF) for how long. After each step, excess solution was extracted using filter paper. Prepared samples were placed into the TEM for imaging using a Gatan 626 cryo-transfer TEM holder. At all times low dose procedures were followed, using an electron dose of 8-10 electrons / A2for imaging. Images were recorded using a CETA 4x4k CMOS camera with magnifications in the range of 40,000*-110,000*.Cryo-Transmission Electron Microscopy
[0279] Cryo-TEM was performed using a Thermo Scientific Talos L120C G2 (S)TEM with an operating voltage of 120 KV. Each sample was prepared by placing 4 pL of hydrogel on a 300-mesh copper grid with perforated carbon film (Lacey carbon film, ProSciTech, Australia). After 30 seconds of adsorption, each grid was blotted with VitrobotTM Filter Paper for 1-5 seconds. After blotting, each grid was transferred rapidly into liquid nitrogen-cooled ethane. The vitrified samples placed into the TEM for imaging using a Gatan 626 cryo-transfer TEM holder. At all times low dose procedures were followed, using an electron dose of 8-10 electrons / A2for imaging. Images were recorded using a CETA 4x4k CMOS camera with magnifications in the range of 40, 000*-110,000*.Atomic Force Microscopy
[0280] Atomic force microscopy was performed in wet conditions using an Asylum Research Cypher ES Environmental AFM, with a resolution of 0.6 A in the X and Y directions and 0.5 A in the Z direction. 120 pL of hydrogel, diluted with MilliQ water to1006592165660.3 mg mL'1was placed onto a clean silicon wafer coated with 0.1% poly-D-Lysine. The images were taken using tapping mode with BlueDrive. An AFM cantilever (Asylum Research BL-AC40TS with a spring constant of 0.09 N / m and a resonance frequency of 110 kHz) was placed on top of the sample. Tuning target amplitude was set as 1V prior to the imaging and setpoint was 500mV to 700mV for good performance based on the nano-microstructure size.Electrophoretic light scattering
[0281] Surface zeta potential was measured using a Zetasizer (Malvern, UK). ERG and ERM were diluted with MilliQ water to 1 mg mL-1 and 800 pL of them placed in a Malvern Folded Capillary Sample Cell DTS1070. Surface zeta potential was measured at 37 °C using ELS mode.Biological Small-Angle X-Ray Scattering
[0282] SAP samples were prepared 24 hours before measurements were taken by mixing PBS (negative control) and BioSAS-TEVp with SAP system and incubating them at 37 °C. For preparing the ECMRG / ERM sample, to be able to detect the ERM nanostructures alteration in the system after BioSAS-TEVp treatment, instead of using ERM with the concentration of 1 and 5 mg mL-1, ERM were mixed with ECMRG in the ratio of 1:1. Samples were run at the BioSAXS beamline at the Australian Synchrotron using the Coflow sample environment with water used as the laminar flow sheath. A 1.0 A beam was used with a total sample-to-detector distance of 3613 mm, giving a usable q range of 0.006 to 0.49 A’1. Each sample was scanned 19 times with 0.1 s exposure time. Background scattering was subtracted from each scan and the scans were then averaged. Data was then modelled using the P(r) inversion function in SASview.Variant design using ProteinMPNN
[0283] The standard TEVp residue numbering convention is used throughout this disclosure (that is, matching that of PDB 1LVM and 1LVB).
[0284] ProteinMPNN interface (Science 378, 49-56 (2022)) was carried out using the HuggingFace (Simon L. Durr. (2023). ProteinMPNN Gradio Webapp (v0.3). Zenodo). Default settings were used (temperature = 0.1, model = V_48_020). To generate BioSAS-TEVp, the crystal structure of catalytically active TEVpS219D bound to its100659216567peptide cleavage product (PDB 1LVM) was used as the input for ProteinMPNN. The first nine residues, which are outside the core chymotrypsin fold of TEVpS219D (as determined by visual inspection), were removed from the input structure. The PyMOL InterfaceResidues script (https: / / py^^^ was usedto identify residues at the interface between Chain A (TEVp) and Chain C (the peptide product) in 1LVM. These residues (residues 46, 81, 139, 146, 148, 149, 151, 167, 168, 169, 170, 171, 172, 174, 176, 178, 209, 211, 214, 215, 216, 217, 218, 219 and 220) were held constant, while the rest of the sequence was generated by ProteinMPNN. N-and C-terminal flanks originating from previously reported TEVp constructs (Protein Engineering, Design and Selection, 14, 12, 993-1000 (2001)) (GESLFKGPR (SEQ ID NO: 41) and EEPFQPVKEATQLMN (SEQ ID NO: 42), respectively) were added back onto the three top-ranking sequences.Constructs encoding proteinMPNN-qenerated sequences
[0285] The coding sequence of the proteinMPNN-generated sequences (including BioSAS-TEVp) were appended with an amino acid sequence encoding an N-terminal His6 tag and thrombin protease cleavage site (MGSSHHHHHHSSGLVPRGS (SEQ ID NO: 35)). The constructs was codon-optimized forexpression in E. coli, synthesized and cloned between Ndel and Xhol sites in pET-29b(+) vectors by Twist BioscienceSmall scale expression trials
[0286] The soluble expression of the proteinMPNN-generated sequences (including BioSAS-TEVp) in E. coli was compared with several other previously-reported TEVp sequences. To have a side-by-side comparison of how mutations within the TEVp structure contributed to solubility and expression levels, any solubility tags were removed from the engineered TEVp sequences and the proteins were expressed from the same pET-29b(+) vector. The sequences that were tested included TEVp S219D (TEVp), TEVSH, eTEV, SuperTEV_Lau, and SuperTEV_DogCatcher; all variants had solubility tags removed, were codon-optimized for expression in E. coli and were synthesized and cloned into pET-29b(+) vectors by Twist Bioscience.
[0287] Plasmids were transformed into chemically competent E. coli BL21(DE3) (NEB) using the recommended heat-shock protocol using LB Miller agar plates supplemented with 50 pg mL1kanamycin. A single transformant colony was picked and100659216568used to inoculate a seed culture in 10 mL LB media supplemented with 50 pg mL1kanamycin. The seed culture was incubated for 8-12 hours at 37 °C with shaking at 200 rpm and then diluted 1:100 to inoculate a 10 mL culture of simple autoinduction media (5 g L1Yeast Extract, 20 g L1Tryptone, 5 g L1NaCI, 6 g L1IX^HPCL. hhO, 3 g L1KH2PO4, 0.19 g L1MgCb, 6 g L1glycerol, 0.5 g L1glucose, 2 g L1d-lactose) supplemented with 50 mg mL-1kanamycin. Cell pellets from 0.5 mL aliquots were collected and lyzed using a 1 x mixture of BugBuster® Protein Extraction Reagent. The OD600 of the cultures were used to normalize the volumes of samples from the soluble and insoluble fractions prior to SDS-PAGE analysis.Large scale expression of BioSAS-TEVp
[0288] For large-scale expression of BioSAS-TEVp, a single transformant colony was picked and used to inoculate a seed culture in 10 mL LB media supplemented with 50 pg mL1kanamycin. The seed culture was incubated for 8-12 hours at 37 °C with shaking at 200 rpm and then diluted 1:100 to inoculate a 1 L culture of simple autoinduction media (5 g L1Yeast Extract, 20 g L1Tryptone, 5 g L1NaCI, 6 g L1Na2HPO4.7H2O, 3 g L1KH2PO4, 0.19 g L1MgCb, 6 g L1glycerol, 0.5 g L1glucose, 2 g L1d-lactose) supplemented with 50 mg mL1kanamycin in Thomson Ultra Yield Flasks30. This was incubated at 30°C for 24 hours with shaking at 250 rpm. Cell pellets were harvested by centrifugation at 5000 ref for 15 minutes at 20°C. Cell pellets were stored at -20 °C until purification.Preparation and expression of TEVp2M and other TEV protease variants
[0289] The His7-tagged L56V, S135G, S219V variant of TEV protease (TEVp2M) was expressed from the pDZ2087 plasmid (https: / / www.addgene.org / 92414 / sequences / ) (Methods Mol. Bio. 1586, p221-230 (2017) & Protein Science, 16, 11, p2360-2367 (2007)). This construct encodes the L56V, S135G, S219V variant of TEV protease (TEVp2M) as a fusion protein with an N-terminal maltose-binding protein (MBP) fusion. The N-terminal MBP and protease domain are linked by a TEV protease cleavage peptide, such that the MBP fusion partner is self-cleaved by the catalytic domain, leaving His7-TEVp2M. For the “SuperTEV” variant, the genes encoding the 10xHis-SuperTEV variant described by Lau (Purification 10xHix-SuperTEV, protocols. io, (2023)) was expressed from plasmid https: / / www.addgene.org / 193833 / . This variant combines substitutions identified from100659216569previous literature (T17S, L56V, N68D, I77V, S135G, I138T, S153N, T180A, S219V) with the aim of producing a soluble and active TEV protease variant. uTEV3 was expressed from plasmid https: / / www.addgene.org / 135464 / (Nature Methods, 17, 167-174 (2020)). For the TEV protease substrate used in in vitro assays, MPB-TEVcs-FKBP-EGFP, the sequence encoding the protein was obtained from previous work (J. Am. Chem. Soc., 146, 3, 2054-2061 (2024)REF), then synthetisedsynthesized and subcloned between Ndel and Xhol sites of pET29b(+) by Twist Bioscience. Proteins were expressed as noted above for BioSAS-TEVp (using appropriate antibiotics). Cell pellets were harvested by centrifugation at 5000 ref for 15 minutes at 20 °C. Cell pellets were stored at -20 °C until purification.Protein purification
[0290] All proteins were purified using immobilized metal affinity chromatography (IMAC) followed by size exclusion chromatography (SEC). Cell pellets were resuspended in 25 mL equilibration buffer (20 mM sodium phosphate, 500 mM NaCI, 20 mM imidazole, pH 7.4). Cells were lysed by sonication (2 x 5 min at 50% power), followed by addition of 0.5 pL Turbonuclease from Serratia marcescens (Sigma Aldrich) and centrifugation at 17400 ref for 75 min at 4 °C to remove cell debris. The supernatant was filtered through a 0.45 mM syringe filter prior to loading onto a 5 mL HisTrap HP (Cytiva) column pre-equilibrated with equilibration buffer at 2.5 mL min-1. Following loading, the column was washed with 20 column volumes of equilibration buffer, followed by elution of the target protein with five columns of IMAC elution buffer (20 mM sodium phosphate, 500 mM NaCI, 20 mM imidazole, pH 7.4). Eluate fractions were pooled and loaded onto a size exclusion column (HiLoad Superdex 26 / 600200 prep grade, GE Healthcare) pre-equilibrated with PBS buffer (8 g L-1NaCI, 0.2 g L-1KCI, 1.44 g L-1Na2HPO4, 0.24 g L'1KH2PO4). SDS-PAGE (SurePAGE™, Bis-Tris, 10'8, 4-12%, GenScript) was used to assess protein purity, following which protein concentration was determined using a NanoDrop OnecMicrovolume UV-Vis Spectrophotometer (ThermoFisher Scientific) using the predicted molar extinction coefficient from ProtParam (John M. Walker, The Proteomics Protocols Handbook, 2005).Expression yield calculation
[0291] For both TEVp2M and BioSAS-TEVp variants, a single transformant colony was picked and used to inoculate a seed culture in 10 mL LB media supplemented with100659216570100 g mL'1ampicillin or 50 pg mL-1, respectively. The seed cultures were incubated for 16 hours at 37 °C with shaking at 220 rpm and then diluted 1:500 to inoculate triplicate 10 mL cultures of the relevant expression medium for each (supra vide). Expression was carried out identically to large-scale expression for each construct (supra vide) with shaking at 220 rpm. Cell pellets were harvested by centrifugation at 5000 ref for 15 minutes at 20 °C. Cell pellets were stored at -20 °C until purification.
[0292] Cell pellets were resuspended in 500 pL of a 1 x mixture of BugBuster® Protein Extraction Reagent and IMAC equilibration buffer. Cell suspensions were incubated on a rotating mixer for 20 minutes at room temperature, followed by centrifugation at 16000 ref for 20 minutes at 4 °C to remove cell debris. Each supernatant was filtered through a 0.45 mM syringe filter and transferred to a fresh tube. Independently, each cell lysate was loaded onto freshly charged 1 mL HisTrap HP (Cytiva) pre-equilibrated with IMAC equilibration buffer, washed with 15 column volumes of equilibration buffer, followed by elution of the target protein with five columns of IMAC elution buffer. Each eluate was dialysed into PBS using SnakeSkin Dialysis Tubing, 10K MWCO, 35 mm dry I.D. (ThermoFisher Scientific), following which protein concentration and yield were determined using using a NanoDrop OnecMicrovolume UV-Vis Spectrophotometer (ThermoFisher Scientific) using the predicted molar extinction coefficient from ProtParam (John M. Walker, The Proteomics Protocols Handbook, 2005).Enzyme assays for assessment of fusion protein cleavage
[0293] Reactions were performed in TEV cleavage buffer (10 mM Tris pH 8.0, 50 mM NaCI, 1 mM EDTA) at a reaction volume of 300 pL using a fusion protein substrate containing the cleavage site for the TEV protease: MPB-TEVcs-FKBP-EGFP, which was expressed and purified by IMAC and SEC into TEV cleavage buffer as described elsewhere (J. Am. Chem. Soc., 146, 3, 2054-2061 (2024)). The final concentration of each technical replicate was 12 pM substrate fusion protein, 4 pM protease, with or without 2 pM dithiothreitol depending on the condition of interest. Specifically, to 270 pL of 1.11 x substrate fusion protein was added 30 pL of 10 x protease and mixed by repeated pipette mixing. Negative controls contained PBS in place of protease with all other reaction components technically identical. Reactions were incubated at 22 °C and at timepoints of 0 h and 24 h, 10 pL aliquots were quenched in 10 pL of 2 x Laemmli100659216571loading buffer, snap frozen in liquid nitrogen and subsequently stored at -80 °C until analysis. SDS-PAGE (SurePAGE™, Bis-Tris, 10 x 8, 4-12%, GenScript) was used to assess fusion protein cleavage.AlphaFold3 Structural Model
[0294] Structural models of BioSAS-TEVp and TEVp2M were generated using AlphaFold3 (AF3). For BioSAS-TEVp, the sequence corresponding to the thrombin-cleaved BioSAS-TEVp protein was used as the input sequence. ForTEVp2M, the sequence of the self-cleaved protein was used. AF3 was also used to generate models of complexes between these two proteins and relevant substrates: ENLYFQG (SEQ ID NO: 5) (with glycine as final residue, “G_pep”), ENLYFQS (SEQ ID NO: 4) (with serine as final residue, “S_pep”), as well as a peptide sequence corresponding to that found in the fusion substrate used for in vitro testing (GGGSMSENLYFQGSMG (SEQ ID NO: 37), “substrate_pep”). Structural figures were prepared using PyMOL Molecular Graphics System, version 2.0, Schrodinger, LLC.Molecular dynamics simulations
[0295] Schrodinger (Schrodinger Release 2022-1: Desmond Molecular Dynamics System, D. E. Shaw Research, New York, NY, 2021.) was used for computational modelling of the Fmoc peptide and for molecular dynamics of the systems. To generate the models of BioSAS-TEVp and TEVp2M in complex with the Fmoc peptide, the AF3 models of these proteins in complex with the substrate_pep were used as a template. The build tool in Schrodinger Maestro were used to build in the modified substrate, followed by local minimization of the structure (4 A around the modelled substrate). The Protein Preparation Workflow was then run using default settings (pH 7.4, termini capping on proteins but not peptides, and minimization of the protein-substrate complexes). Protein-substrate complexes were solvated in a Rhombic dodecahedron xy-square box using SPC water molecules and a 14 A buffer around the protein.Counter ions (Na+and / or Cl’) were added to neutralize the systems, and the equivalent of 0.1 M NaCI was added. Simulations were run using the OPLS4 forcefield (J. Chem. Theory. Comput. 13;17(7):4291-4300 (2021)). The default relaxation protocol was performed on random-seed triplicates, followed by 200 ns of production simulation time. Simulations were performed at 300 K. Trajectory analysis was performed in Schrodinger Maestro.100659216572Protein crystallography
[0296] For protein crystallography, a C151A variant comprising residues 8-221 of BioSAS-TEVp was used (BioSAS-TEVp(C151A)core). As with the other sequences, the coding sequence of BioSAS-TEVp(C151A)corewas appended with an amino acid sequence encoding an N-terminal Hise tag and thrombin protease cleavage site (MGSSHHHHHHSSGLVPRGSHM (SEQ ID NO: 36)). The construct was codon-optimized for expression in E. coli, synthesized and cloned between Ndel and Xhol sites in pET-29b(+) vectors by Twist Bioscience. This variant was expressed and purified by IMAC as described above. Thrombin (NEB) was used to cleave the N-terminal His-tag from NTA-purified BioSAS-TEVp(C151A)coreas per the manufacturer’s instructions. The cleaved protein was then run on a HiLoad Superdex 26 / 600200 prep grade column (GE Healthcare), in 2x crystallization buffer (20 mM HEPES, 150 mM NaCI, pH 7.6).Fractions containing the protein were collected and pooled, and purity was confirmed by SDS-PAGE analysis, as described above. The protein sample was diluted 2-fold in water to yield protein in 1x crystallization buffer (10 mM HEPES, 150 mM NaCI, pH 7.6). This protein was concentrated using an Amicon® Ultra-15 10K MWCO Centrifugal Filter Unit (Merck Millipore). The TEVp cleavage peptide H-TENLYFQGT-OH (SEQ ID NO: 43) was obtained from Mimotopes. Protein samples were incubated with a 5-fold molar excess of the peptide at 18 °C for 2 hours prior to screening using commercial spare-matrix screens. Crystals grew in 300 nL sitting drops in condition G4 of the Crystal Screen from Hampton Research: 1.6 M Sodium Citrate tribasic dihydrate, pH 6.5. Data was collected at the MX2 beamline at the Australian Synchrotron. Data was processed using XDS (Kabsch, W. (2010a). XDS. Acta Cryst. D66, 125-132.) and truncated using Aimless (3.08 A) (P.R. Evans and ,G.N. Murshudov “How good are my data and what is the resolution?” Acta Cryst. (2013). D69, 12041214). Molecular replacement was performed using Phaser-MR (J. Appl. Cryst. (2007). 40, 658-674) and an AlphaFold2 model of BioSAS-TEVp(C151A)core. Refinement was performed iteratively using Refmac and Phenix. refine, with manual real-space refinement in Coot.HPLC assessment of enzyme-induced degradation
[0297] Cleavage of SAPs sequence was assessed using HPLC after treatment with BioSAS-TEVp and several previously published TEV protease variants; TEVp2M, His6-MBP-UTEV3 (uTEV3)Click or t here to enter text. (Nat Methods 2020, 17 (2), 167-174), and 10xHis-Super TEV (SuperTEVp) (Purification of 10xHis-SuperTEV.100659216573protocols. io 2023). 25 pL of ERG was settled at the bottom of a microtube and incubated for 1-3 h at 37 °C. 25 pL of each protease variant in PBS at 1 mg mL-1was then added to the prepared ERG and incubated at 37 °C for 24 h. To optimize BioSAS-TEVp reactions with the hydrogel structure and under biological conditions, the same procedure was followed for different concentrations of BioSAS-TEVp (0.25-15 mg mL-1) and different incubation times (1 h-7 d).
[0298] For quenching the reaction at the desired time-point, 950 pL of 70% acetonitrile + 0.1% Trifluoroacetic acid were added and vortexed to complete be dissolved. Each reaction mixture was filtered through an Amicon® Ultra-153K MWCO Centrifugal Filter Unit (Merck Millipore). The flow through was analysed using analytical HPLC. The HPLC was conducted using reverse phase ZORBAX Eclipse Plus C18, 4.6 x 150 mm, 5 pm on Agilent Analytical HPLC (1290 Bioinert HPLC System). The test was running by flowing binary gradient of acetonitrile and water contained 0.1% TFA (Table 2)Table 2. Binary mobile phase gradientTime (min) Water + 0.1% TFA (%) Acetonitrile + 0.1% TFA (%)0 98 25 95 515 5 9519 5 9523 95 524 98 2Mass spectrometer assessment of enzyme-induced degradation product
[0299] To confirm that the cleavage of the peptide sequence occurred at the location that is expected (ENLYFQ / / / SK (in ENLYFQSK, SEQ ID NO: 6)), the fractions100659216574correlated to the reaction products were collected from HPLC and tested using ThermoFisher Scientific Orbitrap Exactive Plus mass spectrometry coupled with Dionex UltiMate® 3000 LC.Material assessment of enzyme-induced degradation
[0300] Disassembling of SAPs was assessed using TEM, AFM, BioSAXs and rheology after treatment with BioSAS-TEVp. 25 pL of ERG was settled at the bottom of a microtube and incubated for 1-3 h at 37 °C. 25 pL of BioSAS-TEVp in PBS at 3 mg mL'1was then added to the prepared ERG and incubated at 37 °C for 24 h. For the negative control, PBS was added in place of BioSAS-TEVp. After 24 h, the samples were collected and assessed using TEM, AFM, BioSAXs and rheology (supra vide).Cytotoxicity assay
[0301] The cytotoxicity of the prepared SAPs, purified TEVp2M and BioSAS-TEVp and the pre- and post-treatment SAP extracts were tested using astrocytes extracted from postnatal (1.5-2 days) Swiss mice pups and primary cortical neutrons extracted from embryonic (E14.5) foetuses of sacrificed pregnant mice.
[0302] To extract primary astrocytes, following dissection, meninges were removed and the forebrain was mechanically dissociated in cold Dulbecco's Modified Eagle Medium (DMEM) to produce a single-cell suspension. The cell suspension was centrifuged at 1000 rpm for 10 minutes, following which the supernatant was removed and the cells were resuspended in maintenance DMEM containing 10% fetal bovine serum (FBS), 10% horse serum (HS) and 1% penicillin / streptomycin (Hyclone). The cells were cultured on a cultured on a poly- D-lysine (PDL)-coated 75 cm2flask and incubated at 37 °C under 5% CO2 for 14 days. Upon confluency, microglia and oligodendrocyte precursor cells were removed by shaking the flask at 230 rpm and 37 °C overnight, followed by three washes with PBS. Purified astrocytes were harvested by treating the cells with trypsin / EDTA for 10 min at 37 °C, followed by resuspension in culture DMEM. Cells were then seeded in PDL-coated 96 well-plates at a density of 1 x 105cells mL-1and incubated at 37 °C under 5% CO2.
[0303] To extract primary cortical neurons, following dissection, meninges were removed and the cortices were collected and dissociated into a single-cell suspension through 20 min trypsinization (digestion in HBSS with 1X 0.25% trypsin (Gibco), 1X100659216575DNAase (Gibco)) and mechanical dissociation in serum-free minimum essential medium (MEM) solution with 10% FBS. Then cells were loaded with desired density into PDL coated culture plates and allowed to attach for 3 hours. Then the medium was replaced with fresh primary neurobasal culture media (neurobasal medium (Gibco) with 2% serum-free B27 supplement (Gibco), 5 mM glutamine (Gibco) and 10 pg mL-1 gentamicin (Sigma)).
[0304] To prepare the pre- and post-treatment SAP extracts, 100 pL of ERG and ERM at 15 mg mL-1were plated at the bottom of a 96-well plate. Then 150 pL of CDMEM containing 5% FBS, 5% HS and 1% penicillin / streptomycin conditioned with either 4 mg mL-1 of BioSAS-TEVp or Dulbecco's Phosphate-Buffered Saline (DPBS) (negative control) was added on top of the SAPs. The plates were incubated at 37 °C with 0.5% CO2 for 24 hours, following which the extracts were collected for cytotoxicity assessment.
[0305] After 3 days of culture, media was removed from the top of the astrocytes seeded in 96-well plates and the astrocytes were treated with the collected SAP extracts for 24 hours at 37 °C under 5% CO2.
[0306] Following treatment, cell viability was assessed using CellTiter 96 Aqueous Non-Radioactive Cell Proliferation Assay (MTS Assay): the media was removed, and cells were washing with PBS before being treated with 100 pL of CellTiter Blue® solution (20% in CDMEM). After incubation at 37 °C for 1-4 hours, fluorescence was measured with an excitation of 590 nm and an emission of 560 nm to determine the number of viable cells.
[0307] Astrocytes and cortical neurons were also treated with diluted (0.5 mg mL-1) SAP solutions before and after treatment with BioSASTEVp. Astrocytes and cortical neurons were seeded at a density of 1 x 105and 4 x 105cells mL-1, respectively, in 24-well plates and cultured for 3 days. After removal of the media, cells were treated with SAPs mixed with either BioSAS-TEVp or DPBS and incubated at 37 °C under 5% CO2 for 24 hours. Following incubation for 3 days, cells were washed with warm DPBS and fixed with 4% paraformaldehyde (PFA) for 20 minutes at room temperature. The cells were then processed for immunocytochemistry. Fixed cells were washed three times with PBS (300-500 pL), following which they were incubated with a primary antibody solution containing goat monoclonal anti-Glial Fibrillary Acidic Protein (GFAP, 1:500,100659216576Abeam, ab53554) for Astrocyte and Mouse monoclonal anti-p tubulin / TUJ1 (1:500, Biolegend, 801201) for neurons prepared in 5% donkey serum (DS) (Merck) and 0.3% Triton-X (Sigma-Aldrich) in DPBS (PBST), at 4 °C for 16 hours. After incubation, cells were stained with secondary antibody (Alexa Fluor-555 and -594 (1 :500, Abeam)) prepared in 2% DS and PBST for 2 h, followed by three PBS washes and incubation with blocking solution containing 10% DS in PBST. The nuclei were stained with Hoechst (1:5000, Life Technologies) for 10 minutes, washed three times with PBS, and stored at 4 °C until imaging.
[0308] To check the cytotoxicity of ERG and its mixture with ECMLRG, the same procedure of the treatment of primary astrocytes with diluted samples (ERG, ECMLRG, co-assembly, and mix) was conducted. Following incubation for 3 days, the cell viability was assessed with a Live and Dead cell staining kit (ab65470), in which cells were washed with warm PBS 3 times then incubated with a staining solution (Live-dye (1:1000), propidium iodide (1:1000) reagents in Binding Buffer) for 15 minutes.Following the incubation, cells were imaged with a Nikon A1R+ Confocal Microscope. Based on the captured images, the number of live cells were counted by Imaged software.
[0309] The attachment of the astrocytes on the SAP hydrogel before and after treatment with BioSASTEVp was also assessed. To do so, 300 pL of hydrogel was settled at the bottom of the 48-well plate overnight. Then, astrocytes were seeded at a density of 1 105on top of the hydrogels and cultured at 37 °C under 5% CO2 for 3 days. Following incubation for 3 days, cells were washed with warm PBS and fixed with 4% paraformaldehyde (PFA) for 40 minutes at room temperature. The cells were then processed for immunocytochemistry. Fixed cells were washed three times with PBS (300-500 pL) following which they were incubated with a primary antibody solution containing goat monoclonal anti-Glial Fibrillary Acidic Protein (GFAP, 1:500, Abeam, ab53554) prepared in 5% donkey serum (DS) (Merck) and 0.3% Triton-X (Sigma-Aldrich) in DPBS (PBST), at 4 °C for 16 hours. After incubation, cells were stained with secondary antibody (Alexa Fluor-555 (1:500, Abeam)) prepared in 2% DS and PBST for 2 h, followed by three PBS washes and incubation with blocking solution containing 10% DS in PBST. The nuclei were stained with Hoechst (1:5000, Life Technologies) for 10 minutes, washed three times with PBS, and stored at 4 °C until imaging.100659216577Assessment of cargo release
[0310] To assess if the disassembling of the SAP nanostructures can cause cargo release and to find the release profile overtime, a specific dialysis cell (Spectra-Por® Float-A-Lyzer® G2) with the cutoff of 100 kDA was used. To conduct the release profile test, 400 pL of the SAP hydrogel loaded with FITC flourophore (FITC-dextran (500 kDA)) was put inside the dialysis bag for 1 hour to settle. Then the surrounding environment was filled with the solution of BioSAS_TEVp (4 mg.mL'1) or PBS. Then the same amount of PBS (400 pL) was placed on top of the hydrogel and the chamber was incubated at 37 °C. The PBS was collected at each timepoint, and the same amount of PBS was replaced for the next time point. The fluorophore content in the collected samples were measured by Tecan Infinite 200 pro with an excitation of 495 nm and an emission of 519 nm to determine the amount of released cargo.
[0311] To prototype the use of the BioSAS-TEVp-SAP hydrogel systems in cell culture conditions before transitioning to in vivo experiments, the inventors developed an experimental framework incorporating the AAV-DJ-gfaABC1D-mCherry (AAV-mCherry) and AAVDJ-CMV-GFP (AAV-GFP) vectors into the SAP systems.
[0312] AAV production was performed at the Vector and Genome Engineering Facility (VGEF) at Children’s Medical Research Institute (CMRI). Briefly, AAV vectors were produced by transient transfection of adherent HEK293 cells (ATCC) using PEI (pol- yethylenimine, PolyPlus, Cat#115-100) with a 1:1:2 M ratio of pRe-p2CapX:pTransgene:pAd5, and purifies purified using standard iodixanol gradient purification. The AAVs, AAVDJ -gfaABCID-mCherry (AAV-mCherry) and AAVDJ-CMV-GFP (AAV-GFP), were harvested from culture media two times and concentrated using two rounds of ultracentrifugation (Amicon Ultra-4 Centrifuge Filter Units with Ultracel-100 kDa membrane, EMD Millipore, Cat# UFC810024) resulting in a high viral titer to use in vitro and in vivo. The produced AAVs were quantified by real-time quantitative PCR master mix (qPCR, Bio-Rad, Cat# 172-5125) using mCherry primers (F: 5'-CACTACGACGCTGAGGTCAA-3' (SEQ ID NO: 44); R: 5'-GTGGGAGGTGATGTCCAACT-3' (SEQ ID NO: 45)) and eGFP primers (F: 5'-TCAAGATCCGCCACAACATC-3' (SEQ ID NO: 46); R: 5'- TTCTCGTTGGGGTCTTTGCT-3' (SEQ ID NO: 47). The inventors have achieved the of 9.6x1012 vg mL“1for AAV-mCherry and 1.77x1013 vg mL“1for AAV-GFP,respectively.100659216578
[0313] AAV-mCherry and AAV-GFP was incorporated into the SAP systems (ERG, ECMRG / ERM) to achieve a multiplicity of transduction (MOT) of 104viral envelopes per cell. 100 pL of each AAV-SAP mixture was then plated into a 96-well plate and incubated at 37 °C for 2 h to allow for hydrogel settling. Following this, 100 pL of BioSAS-TEVp or DPBS (negative control) was gently added on top of each gel. The plates were incubated at 37 °C with 5% CO2 for 24 h. After incubation, the supernatant of each hydrogel, containing released AAV-mCherry and AAV-GFP, was carefully collected and stored at -20 °C until use in the cell transfection assays.
[0314] Astrocytes and primary cortical neurons were isolated from postnatal mouse pups=embryonic (E14.5) foetuses (supra vide) and seeded at a density of 1 x 105and 4 x 105cells mL'1in 24-well plates, respectively. The cells were incubated at 37 °C under 5% CO2for 3 days. After 3 days, the cells were then transfected with the released AAV-mCherry and AAV-GFP samples obtained from the SAP systems treated with BioSAS-TEVp or DPBS (negative control). Transfection was caried out by subsequently incubating the cells with the applied supernatant 37 °C with 5% CO2 for 24 hours.Following transfection, the cells were further cultured for 3 more days.
[0315] To assess the number of transfected cells released by AAV-GFP from the SAP system, following three more days of culturing after treating the cells with the extraction, the cells were assessed by Flow Cytometry. To conduct the flow cytometry analysis, the cells were harvested by treating the cells with trypsin / EDTA for 5-10 min at 37 °C, followed by resuspension in FBS. The cell suspension was filtered through a 40 pm cell strainer. DAPI was added to the cell suspension to discriminated between live and dead cells. This analysis was performed using a CytoFLEX S Flow Cytometer. The gating firstly was performed based on the size (forward scatter, FSC) and the density (side scatter, SSC) of the cells. To discriminate between the single cells and doublets, another gating was performed based on the area to height. Based on the DAPI staining the live cells were gated. Finally, the last gating was performed to isolate the population of interest, which is GFP positive population here.
[0316] Following incubation, cells were washed with warm DPBS and fixed with 4% paraformaldehyde (PFA) for 20 minutes at room temperature. The cells were then processed for immunocytochemistry. Fixed cells were washed three times with PBS (300-500 pL), following which they were incubated with a primary antibody solution goat monoclonal anti-GFAP (GFAP, 1:500, Abeam, ab53554), and chicken polyclonal anti-100659216579mCherry (mCherry, 1:1000, Abeam, ab205402) for Astrocytes, and Mouse monoclonal anti-p tubulin / TUJ1 (1:2000, Biolegend, 801201), and goat monoclonal anti-GFP (GFP, 1:1000, Abeam, ab6673) for Neurons prepared in 5% donkey serum (DS) (Merck) and 0.3% Triton-X (Sigma-Aldrich) in PBS (PBST), at 4 °C for 16 hours. After incubation, cells were stained with secondary antibody (Alexa Fluor-488 / 555 / 647 (1:500, Abeam)) prepared in 2% DS and PBST for 2 h, followed by three PBS washes and incubation with blocking solution containing 10% DS in PBST (300 pL). The nuclei were stained with Hoechst (1:5000, Life Technologies) for 10 minutes, washed three times with PBS, and stored at 4 °C until imaging.
[0317] To assess whether viral vector delivery in ERG and ERM, and subsequent release upon application of BioSAS-TEVp, endowed improved spatial control of subsequent viral vector expression in addition to the temporal control shown in Figure 14, a mouse model was used to assess release localisation with the SAP systems (mix) before and after application of BioSAS-TEVp.
[0318] To run the in vivo assessment, 1pL of mix sample loaded with AAV-mCherry (1:12.5) were delivered into the mice (female, 10 week) brain using stereotaxic injection via 10pL Hamilton syringe. For group with enzyme injection, 1pL of BioSAS-TEVp at 4 mg.mL'1was injected 3 days post-implantation in the same location (AP-1.0 mm, L-2.0 mm, 2.8 mm below the surface of the dura). After 7 days of the mix sample injection, the mice were culled using overdose of sodium pentobarbitone (100 mg / kg) with Tyrode’s buffer transcranial perfusion followed by 4% PFA. Then brains were collected and fixed in 4% PFA for 2 hours and stored at 20% sucrose in PBS before cryosectioning. Brain sections were stored at -20 in antifreeze solution.
[0319] For immunohistochemistry of brain sections, after rinsing in PBS 3 times for 5 minutes, they were soaked in a blocking solution (0.3% PBST, 0.02% sodium azide, and 5% DS) for 1 hour at room temperature. Then, they were soaked in primary solution containing (0.3% PBST, 0.02% sodium azide, 5% DS, goat anti-GFAP (GFAP, 1:500, Abeam, ab53554, astrocyte marker), chicken anti-mCherry (mCherry, 1:1000, Abeam, ab205402), and rabbit anti-iba1 (1:1000, WAKO, 019-19741, microglial marker) overnight followed by 3 times wash with PBS. After that the brain sections were blocked with the same blocking solution for 1 hour at room temperature. Then they were soaked in secondary antibody solution (0.3% PBST, 0.02% sodium azide, 5% DS, Alexa Fluor-488, 555, and 674 conjugated donkey anti-rabbit / goat / chicken at a dilution of 1:200 for 2100659216580hours on the shaker at room temperature. After that the brain sections were washed with PBS for 3 times followed by soaking at Hoechst nuclear marker counter-staining (1 :5000) in PBS / sodium azide for 10 minutes and washing with PBS (X3) after that.
[0320] For imaging, the brain sections were mounted on gelatine coated coverslip using DAKO fluorescent mounting medium (Agilent). Both cells and brain sections were imaged using Nikon A1R+ Confocal Microscope.Example 2 - Development of ERG and ERM, SAP hydrogels that contain the TEV protease cleavage site
[0321] An SAP hydrogel that responds to the application of TEV protease would require inclusion of its protease cleavage site, ENLYFQS (SEQ ID NO: 4) or ENLYFQG (SEQ ID NO: 5), in the peptide sequence, in addition to being capable of self-assembly to form a hydrogel nanostructure and possessing biocompatible material properties. Two approaches to forming such SAPs were investigated, using (i) a palmitoyl peptide amphiphile, whose amphiphilic properties should drive self-assembly in aqueous environments; and (ii) an Fmoc peptide, which should self-assemble via intermolecular pi-stacking of the Fmoc moiety. Sequences relevant to each SAP class were successfully synthesised, an amphiphilic palmitoyl-AAAGGGENLYFQSK-amide peptide (SEQ ID NO: 33) (ERM) and the peptide Fmoc-ENLYFQSK (SEQ ID NO: 34) (ERG). Both peptides are able to form nanostructures with desired properties under aqueous conditions at pH 7.4.
[0322] For designing the ERM sequence, in addition to palmitoyl moiety, a B-sheet forming group (AAAGGG (SEQ ID NO: 48)) was added to further reinforce the selfassembly of the nanostructures. A lysine (K) residue and the amination at the C-terminal provide the positive charge of the nanostructures for either attracting the therapeutic agents with negative charge (eg viral vectors) or interacting better with cells (Figure 1a). Given that ERM cannot form a self-supportive hydrogel; to keep it in the target tissue, the mixture of ERM and a representative therapeutic agent (AAV) in a biocompatible Fmoc-SAPs (ECMRG) was encapsulated.
[0323] To achieve a stable nanofibrous network at physiological pH and fabricate a hydrogel for ERG, a K residue was added at the C-terminal of the sequence to adjust its pKathat plays an important role in self-assembly (Figure 1b).100659216581
[0324] All SAP system can form self-supportive structure (Figure 2a). The formation and properties of the secondary structures in ERG and ERM were studied using Fourier-transform infrared spectroscopy (FTIR), circular dichroism (CD). Electrophoretic light scattering (ELS) was conducted to measure the surface d potential of the assembled nanostructures. FTIR spectra of both ERM and ERG samples showed a major peak within the 1600-1640 cm-1and a minor peak within 1650-1690 cm-1ranges (Figure 2 b, c, d), consistent with the characteristic peaks of antiparallel p-sheet formation. CD spectra corroborated the formation of antiparallel p-sheet based on the observation of a distinct n-TT* transition from 190-220 nm (Figure 2 b’, c’, d’). ELS was then used to analyse the surface charge of the nanostructures - the positive surface zeta potential of ERM (+22 mV) corresponds to the terminal amine of its peptide sequence, and the negative surface charge of ERG (-35 mV) corresponds to its terminal carboxylic acid. This confirms that the mechanism of peptide self-assembly is a hydrophobic-hydrophilic interaction through the amphiphilic structure in ERM and TT-TT stacking through Fmoc-group in ERG. These results confirm the nanostructures are antiparallel p-sheets that self-assemble as intended.
[0325] The rheological properties of the SAP hydrogels were assessed using an oscillatory rheometer. ERG was studied both as a pure SAP hydrogel and in a combination with a previously developed Fmoc-DDIKVAV (SEQ ID NO: 40) as ECM laminine resembling gel (ECMLRG) with two different methods of blending (before gelation (co-assembly) / after gelation (mix)). However, as ERM could not create self-supportive hydrogel, it was studied just as an additive to SAP hydrogels composed of a previously developed Fmoc-DIKVAVD (SEQ ID NO: 39) as ECM resembling gel (ECMRG) at two different concentrations (1 mg mL-1and 5 mg mL-1), to assure the addition of ERM to the hydrogel did not adversely affect its mechanical properties. As shown in (Figure 3a, c), all SAP hydrogels displayed viscoelastic behaviour with a storage modulus (G’) greater than the loss modulus (G”), consistent with the formation of a stable hydrogel network. The addition of ERM at various concentrations to ECMRG hydrogels did not affect its viscoelastic behaviour (Figure 3c), confirming both ratios are suitable mixtures for the delivery of ERM. The addition of ERG in both condition (Coassembly and Mix) to ECMLRG hydrogel did not affect its viscoelastic behaviour as well and mix sample shows the most similar mechanical properties to the brain tissues (Figure 3a). Shear-thinning behaviour was confirmed using continuous step-strain measurements (Figure 3b, d) and demonstrated that all tested hydrogels rapidly100659216582recover the gel state, consistent with injectable properties suitable for minimally invasive administration. These results collectively confirm that ERG / ERG-based and ERM-based biomaterials have properties consistent with low invasive drug delivery materials.
[0326] The morphological properties of the SAP hydrogels were assessed using transmission electron microscopy (TEM), cryo-TEM and atomic force microscopy (AFM). TEM shows ERG and ERM formed distinct nanostructures - ERG consists of nanofibrillar structures whereas ERM formed nanocylindrical micelles (Figure 4). To confirm these structures are not artefacts of the drying process during TEM sample preparation, cryo-TEM and AFM were also performed under wet conditions. As expected, the formation of the stable and fine nanofibers in ERG was also observed in aqueous environments (Figure 5b, g). The Cryo-TEM and AFM images of ERM (Figure 5f, h) show that ERM forms a network of weak nanocylinders that become truncated after attaching to an oppositely charged surface e.g., the carbon film on a TEM grid or negatively charged AFM silicon wafer. As a result, shortened noncylindrical micelles (relative to the truncated nanocylinders) can be seen in TEM and atomic force microscopic (AFM) images in these samples.
[0327] Both ERM and ERG (i) can self-assemble to form the desired nanostructure in aqueous environments and (ii) contain the TEV protease cleavage site ENLYFQS (SEQ ID NO: 4).Example 3 - BioSAS-TEVp is a stable and functional variant of TEV protease
[0328] The wild-type and current engineered variants of TEV protease, whose target cleavage sequence was included in both ERM and ERG, is not compatible with robust drug delivery systems due to (i) poor expression and solubility, (ii) lack of stability over time, and (iii) a general requirement for reducing conditions (dithiothreitol, which is toxic for living systems) due to the active site cysteine.
[0329] To address (i) and (ii), it was posited that ProteinMPNN could yield a variant with significant improvements in stability and soluble expression, and that (iii) may be indirectly addressed in the design. The chymotrypsin-like fold core of the published 1.8 A co-crystal structure of the catalytically-active TEVpS219D (PDB 1LVM, residues IQ-236) bound to a product peptide was used as an input for ProteinMPNN. In an effort to retain TEVp activity, all residues at the interface with the peptide product in the crystal100659216583structure were held constant. This yielded a sequence, BioSAS-TEVp, that was predicted to fold into the TEVp structure and express well in Escherichia coli. To compare the properties of BioSAS-TEVp to previously developed TEVp variants, it was elected to use TEVp2M (Protein Sci., 16(11): 2360-2367 (2007)) as a benchmark because it is minimally mutated and compatible with heterologous expression in E. coli.
[0330] Hise-tagged BioSAS-TEVp was expressed in the cytosol of E. coli BL21 (DE3) cells using autoinduction media. BioSAS-TEVp exhibited improved soluble expression in E. coli BL21(DE3) cells compared to other previously reported TEVp variants, despite lacking solubility tags (Figure 25). Expression of BioSAS-TEVp from small-scale pilot cultures of E. coli in autoinduction media followed by a single-step IMAC procedure yields the equivalent of 185 mg of pure protein per litre of culture (Figure 6b), a substantial (approx. 40-fold) improvement over the 4.5 mg yields the inventors typically obtained with TEVp2M under the same conditions. When purified by size-exclusion chromatography, BioSAS-TEVp elutes cleanly as a single peak, with no high-molecular weight peaks in the chromatogram that are typically associated with inactive aggregated protein (Figure 26). BioSAS-TEVp also displayed high thermal stability, with little to no signs of loss of secondary structure at 95 °C, in contrast to TEVp2M, which has a predicted melting temperature (Tm) of 49 °C (Figure 6c). BioSAS-TEVp also shows high solubility, with no signs of precipitation at concentrations as high as 260 mg mL-1and remains folded after lyophilisation at concentrations as high as 180 mg mL-1(Figure 27). Again, this was a significant improvement over TEVp2M, where there is commonly observed precipitation of the self-cleaved protein at concentrations above 2 mg mL-1. Finally, purified BioSAS-TEVp retained cleavage activity against a TEVp-cut site-containing fusion substrate in vitro (Figure 6d,e), including in the absence of the reducing agent dithiothreitol (Figure 28). These results suggest reduced catalytic efficiency of BioSAS-TEVp, ■ compared with TEVp2M.
[0331] To gain a better understanding of how BioSAS-TEVp interacts with substrates, the inventors obtained a 3.08 A crystal structure of a catalytically inactive (C151A) variant of BioSAS-TEVp bound to a TEVp recognition peptide (H-TENLYFQ\GT-OH in TENLYFQGT (SEQ ID NO: 43)). In this structure, BioSAS-TEVp (C151A) adopts the canonical chymotrypsin fold of TEVp, with a backbone RMSD of 0.7 A when aligned with 1LVM (over 187 residues, Figure 7a). Clear electron density (3 s) from a Polder OMIT map within the canonical TEVp peptide-binding site confirmed binding of the100659216584TEVp recognition peptide (Figure 7b), with the peptide binding in the same position and with the same key protein-ligand interactions observed in the crystal structure of TEVpS219D (Figure 7c, Figure 29). This is consistent with the observed activity on the TEVp recognition sequence. No electron density was observed for the residues after the cleavage site in the substrate, indicating the peptide autocleaved during crystallization. The structure confirmed that all of the BioSAS-TEVp residues that form direct interactions with substrate were those that were retained during the design process (Figure 7c, d, Figure 30). Molecular dynamics (MD) simulations of BioSAS-TEVp and TEVp2M in complex with the peptide sequence found in the substrate used for in vitro assays (GGGSMSENLYFQGSMG (SEQ ID NO: 37)) and the Fmoc-ENLYFQSK peptide (SEQ ID NO: 34) used in the ERG hydrogel, confirmed BioSAS-TEVp binds target peptides in catalytically-competent positions, with distances between the catalytic cysteine and the reactive carbonyl of the substrate remaining stable over the triplicate 200 ns simulations (Figure 7d,e, Figure 31, Figure 32). These results confirmed that the N- and C-terminal modifications of ERG will not significantly affect binding to the active site of BioSAS-TEVp.
[0332] In addition to the full length BioSAS-TEVp construct, several other constructs were generated, comprising truncations of N- and / or C-terminal residues of BioSAS-TEVp (Table 3). Additional constructs encoding the core BioSAS-TEVp sequence (residues 8 to 220) were also expressed as a fusion with maltose-binding protein (MBP) solubility tag (His7-MBP-BioSAS-TEVp -core) or with an auto-cleavable MBP partner with TEVp cut-site (cs) (MBP-cs-His7-BioSAS-TEVp-core). An inactive C151A mutant of BioSAS-TEVp-core was also generated. Genes encoding these proteins were codon optimised for expression in E. coli, synthetised and cloned into pET28a(+) vectors by Twist Bioscience. All variants were overexpressed as soluble proteins in E. coli BL21 cells (Figure 33). Table 3 demonstrates that all truncation variants of BioSAS-TEVp, including with no flanks, retained cleavage activity, except for the catalytic residue mutant BioSAS-TEVp-core(C151A) which is catalytically inactive. Aside from this mutant, all variants (full or truncated) retained the ability to cleave TEVp substrates in overnight reactions (Table 3 and Figure 33).100659216585Table 3. Cleavage activity of full length and truncated variants of BioSAS-TEVpName Residues of BioSAS- Cleavage Activity**TEVpAN-BioSAS-TEVp 8-236 (SEQ ID NO: 10) +BioSAS-TEVp-A219 1-218 (SEQ ID NO: 12) +BioSAS-TEVp-A220 1-219 (SEQ ID NO: 14) +BioSAS-TEVp-A221 1-220 (SEQ ID NO: 16) +BioSAS-TEVp-A222 1-221 (SEQ ID NO: 18) +BioSAS-TEVp-core 8-220 (SEQ ID NO: 20) +BioSAS-TEVp (C151A)-core 8-220 (SEQ ID NO: 30) - MBP-cs-His7-BioSAS-TEVp- 8-220 (SEQ ID NO: 31) +coreHis7-MBP-BioSAS-TEVp - 8-220 (SEQ ID NO: 32) +core** (+) indicates cleavage of TEVp substrate in vitro in an overnight cleavage reaction. (-) indicates no observable cleavage of TEVp substrate in vitro in an overnight cleavage reaction.Example 4 - ERM- and ERG-based materials respond to the application of BioSAS-TEVp as a stimulus.
[0333] An SAP hydrogel that responds appropriately to the application of BioSAS-TEVp would need to (i) have its substituent peptides be cleaved at the TEV cleavage site embedded in its sequence (ii) demonstrate an alteration of the material and morphological properties demonstrated in Figures 2-5, which would result in cargo release in a therapeutic-imbibed hydrogel system.
[0334] To assure that the BioSAS-TEVp can only detect_the cleavable sequence from the desired location in assembly condition in both ERM and ERG and does not have100659216586any impact on the other sequences, HPLC was conducted on ERG, ERM, ECMRG and ECMLRG (alone and with ERG) after treating with BioSAS-TEVp for 24 h. It was observed that in ERG and ERM, both area and height of the peak correlated with the intact sequence after treating with BioSAS-TEVp decreased and another peak came up (Figure 8a, f). However, no changes can be seen on peaks correlated with ECMLRG (Figure 8b) and ECMRG (Figure 8e) after treating with BioSAS-TEVp. When it comes to the co-assembly and mix samples (Figure 8b), it can be seen that no changes were observed for the peak related to the ECMLRG, but the height and area of ERG peak decreased, and another peak came up. To confirm that the other peak is related to the cleavage product of the ERG and ERM sequence, the fractions of each peak were collected and tested by mass spectrometetry. Based on the mass spectrometer results (Figure 8b, g), the masses that were detected with mass spectrometer, are aligned with the expected masses for cleavage products (Fmoc-ENLYFQ (SEQ ID NO: 49):1035.43 / SK: 234.26 / Pal-AAAGGGENLYFQ (SEQ ID NO: 50): 1435.77 / 2=717.88).
[0335] It was also investigated whether BioSAS-TEVp and several other engineered TEV protease sequences were able to specifically cleave the sequence of ERG, in hydrogel form, using HPLC, which allowed for observation of both cleaved and uncleaved substituent peptides after quenching the reaction. In addition to BioSAS-TEVp and TEVp2M, uTEV3 (Nature Methods, 17, pages167-174 (2020)) and SuperTEV (Lau et al. Purification of 10xHis-SuperTEV, protocol. io, 10 February 2023) were also included in these experiments.
[0336] It was observed that, after a 24-hour incubation time, BioSAS-TEVp (at the concentration of 1 mg / mL-1) demonstrates 44% cleavage of ERG, greater than the 35% cleavage observed for the second-best performing variant, Super TEVp2M (Figure 9a).Although, these results are not in a good agreement with the rates of cleavage observed in Figure 6b, it does suggest that BioSAS-TEVp is more suited to cleavage of biomaterial peptide substrates. This could be attributed to the improved stability and exceptional solubility endowed by the ProteinMPNN design - it is likely that this improves the fidelity of the SAP-hydrogel interaction and thus facilitates improved cleavage in comparison to the other variants with empirically poor solubility. These results indicate that the substituent peptides of ERG can be degraded by TEV proteases, and that the BioSAS-TEVp design is a suitable protease variant for this activity.100659216587
[0337] Having established that BioSAS-TEVp is suitable for cleavage of the substituent peptides of ERG, the optimal conditions for this activity, considering the hydrogel environment, using the same HPLC assay were investigated. It was identified that an applied ratio of BioSAS-TEVp: ERG at 1:7.5-1:3.75 had high cleavage efficiency after 24 hours (-60%), with no improvements in activity above this concentration (Figure 9b). A time-course HPLC experiment was used to identify that the cleavage rate is maximal between 0 to 15 hours but continues until 24 hours, beyond which no more cleavage is observed (Figure 9c). The maximal cleavage activity being observed soon after protease application is consistent with the intended use of BioSAS-TEVp for initiating temporally controlled biomaterial degradation with the stimulus. Importantly, all HPLC experiments show BioSAS-TEVp induced highly specific cleavage of ERG at the included TEV protease cleavage site, which further corroborates the compatibility of ERG and BioSAS-TEVp.
[0338] An important consideration for the delivery mechanism of the stimulus, BioSAS-TEVp, in in vitro and in vivo conditions is whether topical application is sufficient to initiate strong biomaterial degradation. To assess whether topical application is sufficient or if mixing improves the degradation rate, cleavage was assessed using HPLC after applying BioSAS-TEVp to several samples (ERG, co-assembly, and mix) with (i) topically or (ii) by vortexing. While hydrogel cleavage is observed using both application procedures, BioSAS-TEVp cleavage was improved when delivered with vortexing especially in ERG samples (Figure 9d). This is likely due to diffuse substrate access throughout the material, whereas topical application only permits cleavage activity at the surface. However, this difference is much less in co-assembly and Mix samples, which may confirm that the enzyme can better integrate into these samples and vortexing the enzyme does not have much of an effect on the cleavage rate. It is also obvious that the cleavage rate is less in co-assembly samples, likely due to the non-homogenous fibre structure in the samples, which may limit high-fidelity temporal control of cleavage in vitro and in vivo for mixtures. However, given that HPLC shows both BioSAS-TEVp application procedures degrade all tested SAPs that contain a TEVp target sequence, they should both be tested as methods for BioSAS-TEVp application in vitro and in vitro. Topical application is likely a less invasive delivery procedure in vivo from the perspective of viable cargo delivery.100659216588
[0339] Having confirmed that BioSAS-TEV can cleave SAP hydrogels that contain the TEVp target sequence, it was next important to assess whether this induced nanostructural deformations in the materials that changed their physicochemical behaviour. It was the expectation that cleavage of the peptide sequence should interfere with self-assembly and cause an alteration of the properties of ERG and ERM shown in Figure 1.
[0340] Small angle X-ray scattering (SAXS) was initially conducted on the ERM, ERG and ECMRG / ERM to confirm both the interaction of the enzyme with the peptide nanostructures and changes that can happen for the nanostructures’ morphology after BioSAS-TEVp treatment. P(r) inversion analysis was used to estimate the average radius of the nanostructures within the samples, with notable differences observed in samples with detectable sequences between control samples and samples treated with BioSAS-TEVp. The peak radius value for ERG without enzyme was 4.6 nm whereas with enzyme the peak radius value increased to 7.8 nm. The increase in radius is similar to the radius of the enzyme (2.4 nm), this observation suggests that BioSAS-TEVp was binding to the surface of the nanofibres (Figure 10b). However, the radius values of the anionic ECMRG fibres remained constant with and without the enzyme (Figure 10e). Interestingly the radius values of ERM slightly increased but not as much as the size of the enzyme despite the expectation that cationic surface charge and active site affinity of the peptide would result in binding of the enzyme. However, because of the changes that may happen for the nanostructures after BioSAS-TEVp treatment, this binding can be masked with the morphological changes of the nanostructures. The peak radius value for the control ECMRG / ERM hydrogel was closer to ERM indicating that the observed radius value of this sample is determined by the ERM component. However, with the addition of the enzyme, after 24 h, the radius of the ECMRG / ERM fibres had decreased to 7.5 nm, indicating that the enzyme had partially degraded the ERM component, and the sample composition was transitioning to ECMRG dominant structures (Figure 10).
[0341] The expectation related to the effect of the peptide sequence cleavage on the self-assembly that causes a loss of the properties of ERG and ERM shown in Figure 11, was investigated by conducting TEM on ERG and ERM and the combination of these two with ECMLRG and ECMRG, respectively, using an ECMLRG and ECMRG peptide alone (which does not contain the TEVp target sequence) as a negative control.100659216589No change in the nanostructure of ECMLRG (Figure 11a) and ECMRG (Figure 11f) was observed after application of BioSAS-TEVp, but application of BioSAS-TEVp to ERG (including the co-assembly and mix (Figure 11b-d)) and ERM (Figure 11e) for 24 hours caused an observable loss in the nanofibri liar network and nanocrystalline micelles, with the retention of only small pieces of nanofibre and nanodots, respectively. Based on the fiber diameter assessment of SAP system before and after BioSAS-TEVp application, SAP systems containing detectable sequence for BioSAS-TEVp have undergone significant fiber diameter change after enzyme incubation because of thew peptide disassembling (Figure 11g).
[0342] The results of TEM are in a good agreement with the results of AFM and Cryo-TEM (Figure 12) which were conducted in wet conditions by observing the reduction in nanofibers loading (considering that the same concentration was used) in ERG and its combination with ECMLRG (Figure 12b-d) and nanodots instead of nanocylindrical micelles in ERM (especially on the positive substrate (Figure 12g) and no changes for ECMRG and ECMLRG (Figure 12a, e), respectively.
[0343] Consistent with these results, rheology showed that BioSAS-TEVp application causes a reduction in the loss and storage modulus of ERG hydrogels and its combination with ECMLRG (Figure 13), whereas ECMRG and ECMLRG alone exhibit almost the same rheological properties before and after treatment. However, a slight reduction can be seen in the distance of the G’ and G”, which is because of the integration of the enzyme into its nanofibrillar network. It is also worth mentioning that in ECMRG / ERM, this alteration decreases which may be because of the binding of BioSAS-TEVp to ERM. A greater reduction in G’ and G” are observed after cleavage of ERG compared to the ECMRG / ERM samples, likely because the latter has a heterogenous structure - the ECMRG components of these samples will remain intact and prevent complete nanofibre collapse that is observed for ERG. It is also worth mentioning that the reduction of G’ and G” after BioSAS-TEVp treatment is more obvious in co-assembly in comparison with mix sample because of the heterogenous nature of the nanofibers in this sample. So, by cleavage of the detectable sequences in this sample, the whole structure of the nanofibers collapsed that results in more failure in the structure.
[0344] To assess if these nanostructural alteration can cause the cargo release, a FITC-Dextran dye was used as a cargo for measuring the amount of released cargo from the100659216590system in the presence of the BioSAS-TEVp. Considering the importance of the cargo surface charge in assessing the release profile of samples including ERM, and the importance of protein corona formation on the cargo surface and its impact on the interaction of ERM and cargo, no suitable fluorescent nanoparticle can be found to run this test. So, this test only has been done on sample including ERG. As can be seen in Figure 14, applying BioSAS-TEVp activates the release of the cargo in responsive systems (ERG, co-assembly, and mix) in 48 h at different time scale based on their nanostructure heterogeneity, however in negative control sample (ECMLRG) no change can be seen in passive diffusion after applying BioSAS-TEVp.
[0345] Taken together, data presented in Figure 8-14 demonstrate that the application of BioSAS-TEVp to several formulations of ERG and ERM result in both chemical alterations to the substituent peptides and nanostructural alterations to the bulk hydrogel material. Most importantly, it was demonstrated that this activity is specific to SAP hydrogels that contain a TEVp target cleavage site. Having established and optimised stimulus-responsive materials in vitro, it is next important to consider the cellular effects of these systems, particularly their biocompatibility, prior to delivering therapeutic cargo.Example 5 - ERG, ERM and BioSAS-TEVp are biocompatible independently and as formulations.
[0346] To assess the cytotoxicity of BioSAS-TEVp and various combinations of the hydrogel materials, a-CellTiter-Blue® Cell Viability assay on murine primary astrocytes derived from postnatal Swiss pups and SH-SY5Y cell lines was conducted. Cell viability was determined following treatment with a range of BioSAS-TEVp concentrations and SAP system. A previously reported TEVp2M was used as a control protease to assess the relative cytotoxicity of the design (Figure 15a). The ERG ± BioSAS-TEVp exhibited viabilities close to the control (approximately 100%), indicating this peptide do not significantly impact cell viability under the tested conditions. As seen in (Figure 15b), samples conditioned with ERM before and after adding BioSAS-TEVp, exhibited increased cell viability, surpassing the control at approximately 120% and 105%, respectively, which might be attributed to the positive surface charge of NH2 at the C-terminal, which is more favourable for the cells.100659216591
[0347] BioSAS-TEVp alone, tested at concentrations ranging from 4 mg mL-1to 1 mg mL'1, retained viability near or above 90% at all concentrations tested, indicating no significant cytotoxicity profile across the tested range. In contrast, TEVp2M displayed a more pronounced concentration-dependent reduction in viability - at the highest concentration of 4 mg mL-1, cell viability decreased to approximately 40% (Figure 15a) or 60% (Figure 15b), indicating significant cytotoxicity at this dose. Lower doses demonstrated a progressive increase in viability, yet remained below the baseline control, indicating that TEVp2M exerts a dose-dependent cytotoxic effect on astrocytes that is not observed for BioSAS-TEVp. Taken together, these results demonstrate that not only are ERG and ERM cytocompatible, but BioSAS-TEVp is markedly more suitable than TEVp2M for cytocompatible degradation of both materials.
[0348] Immunocytochemistry was also then used to assess the impact of using BioSAS-TEVp and SAP hydrogels on primary astrocytes and primary cortical neurons morphological changes. To do so, after treating cells with ERG, ERM and their combination with ECMRG and ECMLRG (0.5 mg mL-1) with or without BioSAS-TEVp (4 mg / ml) for 24 h, cells were fixed and immunostained for astrocyte marker (glial fibrillary acidic protein (GFAP)) and neuronal marker (B-tubulin). Staining with GFAP showed no changes relative to the control, maintaining typical stellate morphology, after application of ERG, ERM, and their combination with ECMRG, and ECMLRG with or without coadministration of BioSAS-TEVp (Figure 16b-d’). This is consistent with the retention of astrocyte-like protein expression profiles stellate morphology in the treated cells.Interestingly, it can be seen than the cells make networking structures rather than small clusters in contact with ERM before and after treatment (Figure 16d, d’), which can be corelated with the higher number of cells in these two samples which is aligned with the previous cytotoxicity results (Figure 15). Regarding the immunostaining with B-tubullin (Figure 16f-h’), cells in all conditions attached and expanded with healthy axons and dendrites like the control sample (Figure 16e,e’) that does not contain SAP or BioSAS-TEVp.
[0349] To detect the cell behaviour in direct contact with SAP system with or without BioSAS-TEVp, SAP systems in cell culture media were also stained with Thioflavin T, which can stain B-sheet-rich structures. As can be seen in Figure 17, the cells in contact with ECMRG, which has IKVAV (SEQ ID NO: 51) (functional epitope of Laminin) in its structures, started to create some more new dendrites and growing inside its100659216592nanofibrous structures. Interestingly, this phenomenon can also be seen in ERM nanostructure before enzyme administration which can be because of the positive surface charge that serves as anchor site to attract cells. It is also obvious that ERM structures tend to attach to the cells’ membrane because of this positive surface charge. These results suggest that ERM nanostructures, by their own, can play as a transporter of viral vectors to the cells by increasing the time of the connection between viral vectors and the cells.
[0350] In addition to cytotoxicity test, the inventors also examined the impact of morphological change of SAP system containing detectable sequence as part of the hydrogel structure, by BioSAS-TEVp on the morphology of primary astrocytes and primary cortical neurons. To do so, primary astrocytes were cultured on top of ERG and its combination with ECMLRG (co-assembly and Mix) samples, and after 3 days of culturing, cells were fixed and immunostained for astrocyte marker (glial fibrillary acidic protein (GFAP)). GelMa at the concentration of 8% was used as negative control.Based on the results (Figure 18), cells attached on the SAP hydrogels very well, but on the surface of gelatine methacrylate (GelMa) they prefer to attach to each other to survive rather than attaching on the surface. In comparison, in SAPs before BioSAS-TEVp treatment, it is obvious that cells attached better on the samples that have IK AV (SEQ ID NO: 51) in their structures (ECMLRG, co-assembly and mix). After BioSAS-TEVp treatment, the cells still attached very well on the surface, but the number of the cells on the co-assembly reduced significantly because of the higher disassembling ratio of this sample. It is also worth noting that after BioSAS-TEVp treatment, because of the disassembling of the structures in SAPs with detectable sequence (ERG, Coassembly, and mix) resulting in larger porosity, cells propagated well inside the nanofibrous structure. Although cells attached very well on the surface of ECMLRG, because of the weaker mechanical properties of this SAP, it washed away during the media change procedure.
[0351] Having established that the BioSAS-TEVp, ERG and ERM are cytocompatible independently and as formulations, it is next important to consider whether BioSAS-TEVp application facilitates improved temporal control of therapeutic delivery by ERG and ERM.100659216593Example 6 - Viral vector release from ERG and ERM upon application of BioSAS-TEVp
[0352] To prototype the use of the BioSAS-TEVp-SAP hydrogel systems in cell culture conditions before transitioning to in vivo experiments, an experimental framework was developed incorporating the AAV-DJ-gfaABC1D-mCherry (AAV-mCherry) and AAVDJ-CMV-GFP (AAV-GFP) vector into SAP hydrogels. Following gel formation, either BioSAS-TEVp or DPBS (negative control) was applied to the surface of the gel, and the system was incubated for 24-48 hours. This application procedure reflects the topical application procedure. The supernatant, containing AAV-mCherry and AAV-GFP released proportionally to amount of effective SAP cleavage by the applied BioSAS-TEVp, was then collected and used to transfect primary astrocytes and cortical neurons respectively. The subsequent expression of mCherry in the astrocytes, and GFP in neural cells reflecting the amount of AAV - successfully released from the disassembled SAP and diffused into the supernatant, was assessed through immunocytochemistry and quantified by flow cytometry. This process mirrored the cytotoxicity assay but included an additional antibody for mCherry and GFP to show transgene expression.
[0353] mCherry and GFP fluorescence in each immunofluorescence scan is indicative of AAV-mCherry and AAV-GFP released from the relevant hydrogel in vitro, respectively. The higher number of cell transduction in the cells treated with BioSAS-TEVp (as confirmed with mCherry / GFP markers) (Figure 19) can be attributed to the SAP disassembling, based on evidence presented in Figures 8-13, in addition to passive diffusion. While, in the negative control samples (treated with DPBS), the presence of mCherry / GFP fluorescence can be attributed to passive diffusion of AAVs from the hydrogel.
[0354] By comparing the control condition (loading AAV directly) with SAP delivery systems, all hydrogels have the ability to retain the viral vectors in their structures for a longer time that can increase the functionality of the therapeutic agents with using these materials, which is aligned with previous studies on using SAP hydrogel for delivering different types of therapeutic agents. In comparison, application of BioSAS-TEVp to the ERG nanostructure produced supernatants that yielded a significant increase in mCherry / GFP fluorescence compared to DPBS application, indicating that BioSAS-TEVp-induced degradation of the ERG nanostructure increased the release of imbibed100659216594AAV and yielded an increase in transfection rate (Figure 19 c-d’, and 20 c-d’). This confirmed the intended activity of the BioSAS-TEVp-ERG drug delivery system in vitro.
[0355] In the case of ERG and its mixture with ECMLRG, as can be seen in Figure 19b, b’ and 20 b, b’, applying BioSAS-TEVp activates the release of the cargo in responsive systems (ERG, co-assembly, and mix) in 48 h, however in negative control sample (ECMRG) condition, in which no cleavage of the nanostructure should occur after BioSAS-TEVp application - all mCherry and GFP fluorescence can be attributed to passive diffusion from the nanostructure (Figure 19b, b’, and 20b, b’).
[0356] The ECMRG-ERM hydrogels also showed increases in mCherry / GFP immunofluorescence upon BioSAS-TEVp application relative to DPBS (Figure 20 e-f’).Although, in the case of mCherry (Figure 19 e-f’), it is slightly confounded by increased leaching in the DPBS condition, in primary cortical cells it is obvious that more AAV-GFP released from the responsive systems after BioSAS-TEVp treatment that results in more cell to be transfected.
[0357] Considering the better cell attachment on the mix sample, release of AAV-GFP was also investigated from mix sample at different MOT (101, 102, 103, and 104). Based on the immunofluorescence images, it is obvious that more cells transfected by AAV-GFP after application of BioSAS-TEVp (Figure 21).
[0358] Based on the flow cytometry results, the control transduced with different multiplicity of transduction (MOT= 101, 102, 103, and 104) shows no significant difference in GFP fluorescence in the DPBS and BioSAS-TEVp control, confirming that viral vector transduction is effective in this experimental system without any negative impact from BioSAS-TEVp (Figure 22).
[0359] Based on the percentage of GFP positive cells in Figure 23, it can be seen that applying BioSAS-TEVp to SAP system with detectable sequences results in a significant increase in the number GFP positive cells in comparison with the negative controls (treated with DPBS), in which the release happens through diffusion.
[0360] However, applying BioSAS-TEVp to the control SAP (ECMRG) does not affect the diffusion rate of AAV from the structure (Figure 23a, a’)100659216595
[0361] Taken together, these results indicate that the application of BioSAS-TEVp to all three biomaterials with detectable sequence in vitro significantly increases the release of an imbibed viral vector. Having shown that ERG and ERM embedded in ECMRG can provide the spatial control and BioSAS-TEVp application endows temporal control.Example 7 - ERG, ERM and BioSAS-TEVp endow spatial control of AAV delivery in mouse models
[0362] To assess whether viral vector delivery in ERG and ERM, and subsequent release upon application of BioSAS-TEVp, endowed improved spatial control of subsequent viral vector expression in addition to the temporal control shown in Figures 19-23, a mouse model was used to assess release localisation with mix systems, which showed cytocompatibility before and after application of BioSAS-TEVp.
[0363] Based on the immunohistochemistry images of brain sections, release of AAV-mcherry from mix hydrogel increased after administration of BioSAS-TEVp (Figure 24a, b). As shown in Figure 24 c,d, the leakage of AAV-mCherry without BioSAS-TEVp injection is in two sections (80 pm), but with BioSAS-TEVp, the AAV-mCherry vectors were leaked in 4 sections (160 pm). In the case of inflammatory response activation, based on the Figure 24e, f after enzyme administration, less GFAP and I ba- 1 positive cells can be seen around injection site, which can be because of the degradation of the structure that results in more similar mechanical properties of hydrogel to the brain tissue. In addition, since the BioSAS-TEVp cleave the SK residue from ERG, the cleavage of positively charge residue (K) can cause the reduction of inflammatory response.
[0364] Therapeutic delivery must provide targeted site-specific delivery, temporally controllable release profiles and protection from degradation. Current systems that meet these requirements are limited by invasive delivery procedures and non-controllable release profiles via mechanisms such as passive diffusion. Here the inventors engineer several self-assembling peptide (SAP) hydrogel systems with a biocatalytic specific peptide based on Fmoc and palmitoyl moieties, that facilitate stimulus-responsive release of active agents. These systems consist of SAP hydrogels that contain the target cleavage site of a stimulus protease called Tobacco Etch Virus protease (TEVp). To enhance the biocompatiblity, stability, activity and solubility (BioSAS) of this protease100659216596a machine learning tools called ProteinMPNN was used to produce a new variant of TEVp, named BioSAS-TEVp. The inventors show these paired SAP-protease systems are cytocompatibile and provide controllable, biocompatible, release of adeno-associated viruses to mouse primary astrocytes and cortical neurons compared to conventional engineered systems that rely on passive diffusion mechanisms. This approach could result in improved, minimally-invasive, spatiotemporally controlled, methods for the delivery of active agents to difficult-to-access targets, particularly across the blood-brain barrier.
[0365] It will be understood that the invention disclosed and defined in this specification extends to all alternative combinations of two or more of the individual features mentioned or evident from the text or drawings. All of these different combinations constitute various alternative aspects of the invention.
Claims
100659216597CLAIMS1. A compound capable of self-assembly comprising, consisting essentially of or consists of a tobacco etch virus (TEV) protease cleavable peptide and a moiety that facilitates or promotes self-assembly.
2. The compound of claim 1, wherein the only amino acids present in the compound are those of the TEV protease cleavable peptide and equal to, or less than, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 additional amino acid(s) N and / or C terminal to the TEV protease cleavable peptide.
3. The compound of claim 1 or 2, wherein the TEV protease cleavable peptide is from 7 to 20, 7 to 19, 7 to 18, 7 to 17, 7 to 16, 7 to 15, 7 to 14, 7 to 13, 7 to 12, 7 to 11, 7 to 10, 7 to 9, or 7 to 8 amino acids in length.4 The compound of claim 1 or 2, wherein the TEV protease cleavable peptide is about 7, about 8, about 9, about 10, about 11 , about 12, about 13, about 14, about 15, about 16, about 17, about 18, about 19 or about 20 amino acids in length.
5. The compound of claim 1 or 2, wherein the TEV protease cleavable peptide is 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 amino acids in length.
6. The compound of any one of claims 1 to 5, wherein the TEV protease cleavable peptide is cleavable by any TEV protease described herein, including those comprising the amino acid sequences shown in Table 1.
7. The compound of any one of claims 1 to 6, wherein the TEV protease cleavable peptide comprises, consists essentially of or consists of ENLYFQX (SEQ ID NO: 3) wherein X is any amino acid, preferably any naturally occurring amino acid. Typically, X is serine (S) or glycine (G).
8. The compound of any one of claims 1 to 7, wherein the compound comprises a TEV protease cleavable peptide of ENLYFQS (SEQ ID NO: 4) or ENLYFQG (SEQ ID NO: 5) with an additional amino acid at the C-terminus.
9. The compound of any one of claims 1 to 8, wherein the additional amino acid is a lysine (K) an arginine (R) or a histidine (H), preferably a lysine (K).10065921659810. The compound of any one of claims 1 to 9, wherein the compound comprises comprise the amino acid sequence ENLYFQSK (SEQ ID NO: 6) or ENLYFQGK (SEQ ID NO: 7).
11. The compound of any one of claims 1 to 10, wherein the only amino acids present in the compound is ENLYFQX1X2 (SEQ ID NO: 38), wherein Xi and X2 are any amino acid, preferably any naturally occurring amino acid, preferably Xi is S or G, preferably, X2 is K.
12. The compound of any one of claims 1 to 11 , wherein the TEV protease cleavable peptide is not significantly degradable by biological and metabolic activity of cells and tissues.
13. The compound of any one of claims 1 to 12, wherein the compound is not degradable by biological and metabolic activity of cells and tissues.
14. The compound of any one of claims 1 to 13, wherein the compound is capable of self-assembly in an aqueous environment.
15. The compound of any one of claims 1 to 14, wherein the moiety that facilitates or promotes self-assembly initiates self-assembly.
16. The compound of any one of claims 1 to 15, wherein the moiety that facilitates or promotes self-assembly does so by hydrophobic-hydrophilic interactions.
17. The compound of any one of claims 1 to 15, wherein the moiety that facilitates or promotes self-assembly is an amphiphile.
18. The compound of claim 17, wherein the amphiphile contains a hydrophilic portion and a lipophilic portion.
19. The compound of claim 18, wherein the hydrophilic portion is a peptide.
20. The compound of claim 18 or 19, wherein the lipophilic portion is an aliphatic chain, which is either saturated or unsaturated.
21. The compound of claim 20, wherein the aliphatic chain is palmitoyl, myristoyl, stearoyl, lauroyl, octanoyl ordecanoyl, preferably palmitoyl.10065921659922. The compound of any one of claims 1 to 21 , wherein the compound comprises, consists essentially of or consists of a palmitoyl group linked to a TEV protease cleavable peptide linked to an amide group.
23. The compound of any one of claims 1 to 21 , wherein the compound comprises, consists essentially of or consists of palmitoyl-AAAGGGENLYFQSK-amide (SEQ ID NO: 33).
24. The compound of any one of claims 1 to 15, wherein the moiety that facilitates or promotes self-assembly does so by TT-TT stacking.
25. The compound of claim 24, wherein the moiety is fluorenyl methoxycarbonyl (Fmoc).
26. The compound of any one of claims 1 to 15, wherein the compound comprises, consists essentially of or consists of an Fmoc group linked to a TEV protease cleavable peptide.
27. The compound of any one of claims 1 to 15, wherein the compound comprises, consists essentially of or consists of Fmoc-ENLYFQSK (SEQ ID NO: 34).
28. A protease comprising, consisting essentially of or consisting of an amino acid sequence of any one of SEQ ID NO: 8 to 21 , 52 or 53, or an amino acid sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to an amino acid sequence of any one of SEQ I D NO: 8 to 21 , 52 or 53.
29. The protease of claim 28, wherein the protease is capable of cleaving a peptide that comprises, consists essentially of or consists of:- ENLYFQX (SEQ ID NO: 3) wherein X is any amino acid, preferably any naturally occurring amino acid;- ENLYFQS (SEQ ID NO: 4);- ENLYFQG (SEQ ID NO: 5);ENLYFQSK (SEQ ID NO: 6); and / or1006592165100ENLYFQGK (SEQ ID NO: 7).
30. The protease of claim 28 or 29, wherein the protease is capable of cleaving a compound of any one of claims 1 to 27.
31. The protease of any one of claims 28 to 31 , wherein the protease of the disclosure has negligible activity on mammalian proteomes.
32. The protease of any one of claims 28 to 31 , wherein the protease does not significantly affect cell viability at concentrations of 1 mg / ml, 5mg / ml, about 1mg / ml, about 5mg / ml, or from 1 mg / ml to 5mg / ml or about 1 mg / ml to about 5mg / ml.
33. The protease of claim 32, wherein the cell is an astrocyte.
34. The protease of claim 32 or 33, wherein cell viability is determined using a cytotoxicity assay, preferably an MTS assay.
35. The protease of any one of claims 28 to 34, wherein the protease exhibits protease activity in the absence of reductant.
36. The protease of claim 35, wherein the protease activity of the protease in absence of reductant may be at least 75%, 80%, 85%, 90%, 95% or 100% of the protease activity of the protease when reductant is present.
37. A nucleic acid comprising, consisting essentially of, or consisting of a nucleotide sequence encoding a protease of any one of claims 28 to 36.
38. A vector comprising a nucleic acid of claim 37.
39. A cell comprising a nucleic acid of claim 37 or vector of claim 38.
40. A hydrogel comprising a compound of any one of claims 1 to 27.
41. The hydrogel of claim 40, wherein the hydrogel comprises 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% w / w of compounds of the present disclosure as described herein.
42. The hydrogel of claim 40, wherein the hydrogel comprises 1, 5, 10, 12.5, 15, 16, 17, 18, 19 or 20 mg.mL-1of compounds of the present disclosure as described herein.100659216510143. The hydrogel of any one of claims 40 to 42, wherein one or more further compounds capable of self-assembly.
44. The hydrogel of claim 43, wherein the one or more further compounds capable of self-assembly are not cleavable by a TEV protease, or not cleavable by a TEV protease of any one of claims 28 to 36.
45. The hydrogel of any one of claims 40 to 44, wherein the hydrogel further comprises one or more active agents.
46. The hydrogel of any one of claims 40 to 45, wherein the hydrogel is injectable.
47. The hydrogel of any one of claims 40 to 46, wherein the hydrogel is biocompatible with native tissue at physiological conditions.
48. The hydrogel of any one of claims 40 to 47, wherein the hydrogel shows viscoelastic behaviour with a storage modulus (G’) greater than the loss modulus (G”) independent of frequency.
49. The hydrogel of any one of claims 40 to 48, wherein the hydrogel decreases in viscosity under shear strain (ie shear-thinning behaviour).
50. The hydrogel of any one of claims 40 to 49, wherein the hydrogel is formed of nanofibrillar structures or nano-cylindrical micelles.
51. The hydrogel of any one of claims 40 to 45, wherein the hydrogel is does not significantly affect cell viability.
52. The hydrogel of claim 51 , wherein the cell is an astrocyte.
53. The hydrogel of claim 51 or 52, wherein cell viability is determined using a cytotoxicity assay, preferably an MTS assay.
54. A method of releasing an active agent comprising contacting a hydrogel of any one of claims 40 to 53, with a protease of any one of claims 28 to 36, thereby releasing the active agent.
55. A method of releasing an active agent in an individual, the method comprising:1006592165102administering a hydrogel of any one of claims 40 to 53 comprising an active agent to the individual; and subsequently- administering a protease of any one of claims 28 to 36 to the individual, thereby releasing an active agent in the individual.
56. A method of delivering an active agent in an individual, the method comprising:- administering a hydrogel of any one of claims 40 to 53 comprising an active agent to the individual; and subsequently- administering a protease of any one of claims 28 to 36 to the individual, thereby releasing an active agent in the individual.
57. A method of treating or preventing a disease or condition in an individual, the method comprising:- administering a hydrogel of any one of claims 40 to 53 comprising an active agent for treating or preventing the disease or condition to the individual; and subsequently- administering a protease of any one of claims 28 to 36 to the individual, thereby treating or preventing the disease or condition in the individual.
58. The method of claim 57, wherein the disease or condition is caused by, or associated with, protein dysfunction or dysregulation.
59. Use of a compound of any one of claims 1 to 27 or a hydrogel of any one of claims 40 to 53, in the manufacture of a medicament for:- releasing an active agent in an individual, or- treating or preventing the disease or condition to the individual.
60. A compound of any one of claims 1 to 27 or a hydrogel of any one of claims 40 to 53, for use in treating or preventing the disease or condition in the individual.
